


The Journal of the American Diabetes Association

diabetes

Volume 14 • 1965

INDEX

By Subject and Author



140349

Copyright 1966, by American Diabetes Association, Inc.

SUBJECT INDEX 1965

This index covers all reading matter in Volume 14 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index appears on page 35.

A

ABDOMEN
and pancreas autograft in dogs, 689-695

ABORTIONS, 573, 575
and chromosome abnormalities, 340, 367
and diabetic pregnancy, 175, 371
and hyperthyroidism and diabetes study, 741
and triamcinolone-glucose tolerance test, 482

ACETALDEHYDE, 18

ACETATE
oxidation rate, *50
thiokinase and carbohydrate metabolism, *683-684
and urate excretion, 787, 804

ACETATE I-C-14
incorporation into fatty acids, 709-715, *747
incorporation into lipids, 584

ACETOACETATES, 498
and diabetic acidosis, 370
and myocardial metabolism, *531

ACETOHEXAMIDE, *114, *382
metabolism, *456
in serum and urine, 362-367

ACETONE
in arterial blood, 663-665
and fasting, *381
and plasma corticoid elevation, 745
tests for juvenile diabetic campers, 678

ACETONURIA, *464
and juvenile diabetes, *531

p-ACETYL BENZENESULFONYL-UREAS, *382

ACETYL CARBOXYLASE, 662

N-ACETYL-DL-HOMOCYSTEINE THIO LACTONE, *236

ACHILLES REFLEX, *380, 427

ACHRESTIC DIABETES, 718

ACIDOSIS
and fatty acid metabolism, 713

and infants, 160
and juvenile diabetes, *317-318
and sulfated insulin, *440

ACIDOSIS, DIABETIC, *609
and acute renal insufficiency, 36-37
and bicarbonate therapy, *113
biochemical factors, 370
and diabetes control study, *469
in induced pancreatitis in rats, 637
in juvenile diabetes study, 242, 247-249
and lactate metabolism, *440
and pancreatic diabetes, 95
and reduced hyperglycemic response, 104
and steroid therapy, *114

ACIDOSIS, LACTIC
and fasting, *532
and nonketoacidotic coma, 162
and phenformin, *464-465

ACIDOSIS, METABOLIC
and hyperosmolality, 164
in hypophysectomized diabetics, 43

ACIDS
arachidonic, 105
and glucagon and epinephrine, *681
ascorbic
and alloxan diabetes, 312
and diazoxide, 592
and glucose oxidase, 224, 225
benzoic
insulin-like activity, *681
dehydroascorbic
and alloxan, 289-290
glucuronic, 311-312
and glucose metabolism, 311-312
glutamic
and respiration, *685
5-hydroxyindolacetic, *53
hydroxy-, and muscle metabolism, 82
lactic
and 3,5-dimethylpyrazole, 508, 514
and free fatty acids, *534
in leucocytes of diabetics, 584, 587
and nonketoacidotic coma, 162, 164
3-methoxy-4-hydroxymandelic, 78, *233
nalidixic
and convulsions, hyperglycemia, and glycosuria, *683
nicotinic
and free fatty acid, *532
and protein synthesis, *534

oleic, 662
palmitic, *535
and radioactivity incorporation, 712-713
palmitoleic, 105
6-phosphogluconic, 147, 148
pyruvic
and diabetic neuropathy, 4
and sulfonylureas, 211
pyruvic C-14
and glucose production, 355
tricarboxylic
cycle and enzymes, *377
trichloroacetic
and insulin, 89

ACROMEGALY
and diabetes, 43
and glucose loading, 27, 28
and growth hormone, 374
and insulin, *167
and insulin dosage, *117
and insulin resistance, 556
and retinopathy, 558
and serum insulin response, *532-533

ACTINOMYCIN D
and glycogen synthesis, *236

ACTH. See Adrenocorticotrophic hormone

ACTINOMYCIN D
and insulin, 633, 662

ADDISON'S DISEASE, 562
and diabetes, 300-301
and myxedema, *317
and thyroid insufficiency, *48

ADENOHYPOPHYSES
and alloxan diabetic rats, *50

3,5-ADENOSINE MONOPHOSPHATE
and phosphorylase activity, *534

ADENOSINE TRIPHOSPHATASE
and glucocorticoids, 484

ADENOSINE-PHOSPHATE, *235

ADRENAL GLANDS
Addison's disease
and diabetes, *48
of alloxan-diabetic rats, 502
androgens and obesity, 791
catecholamines, *532
cortex hypertrophy, 95

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

- corticosterone
and gravity changes, *535
and cortisol, 195
and diabetes, *169, 300-303
and diazoxide hyperglycemia, 591,
593-594
hemorrhage and infant hypoglycemia,
*815
hyperplasia
and alloxan diabetic pregnancy, 727
in diabetic-lathyrus rats, *613
and hypoglycemia, 249
hypophyseal function and diabetic an-
giopathy, *53
insufficiency and diabetes, *317
and insulin-induced hypoglycemia,
*169
and leukemic mice, 325, 328
and thyroid deficiency, 300-303
- ADRENALECTOMY, *684**
and adrenocorticotrophic hormone ef-
fect, *748
and amino acid incorporation, *115
and diazoxide hyperglycemia study,
591, 592
and 3,5-dimethylpyrazole, 508
- ADRENALIN**
and glycogenolysis, 345
and hypoglycemic convulsions, *49
and insulin release, *232
- ADRENOCORTICOSTEROIDS**
and insulin activity, 135
- ADRENOCORTICOTROPHIC HORMONE, *534, 562, 563**
and adrenalectomized rats, *748
and corticosteroid production, 334
and Cushing's syndrome, *684
and diabetes, 550, 552
and free fatty acids, 87
and hypoglycemic infants, 333
and infant hypoglycemia, *815
and insulin and glucose, *748
and insulin resistance, *818
and lipolysis and lipogenesis, 369
- AGE**
and asteroid hyalitis, *171
and blood glucose levels, 415-422
and blood saccharoid content, 721, 722
and diabetes incidence, 213, 216-218,
222
and diabetic acidosis, 248, 249
and diabetic neuropathy, 4, 428, 520
and diabetic retinopathy, 264
and exercise, *533
and facial redness, 207-208
and fasting serum L-xylulose, 311
and galactose and fructose removal,
156
and glomerulosclerosis, 265
- and glucose tolerance, 474, 475, 477,
579-583
and hypertension and diabetes, *749
of Indians at diabetes onset, 405-406,
409
and insulin
dosage, 246
resistance, 433
of juvenile diabetics
in camping program, 677
in survey, 106
and ketosis-resistant diabetes, *814
and leukemic mice, 326-327
and lipid concentration, 250
and liver function, 253
in mass screening for diabetes, 298,
299
of menarchial onset and diabetes, 788-
791
and nonketacidotic coma, 162
old
and cerebrovascular and pancreatic
insular amyloid, *612
and diabetes survey, *47
and diabetic pruritis, *168
and pancreatic exocrine function, *53
of patients
in bone study of diabetics, 142
with ischemic leg ulcers, *318
in juvenile diabetes study, 241-242
in myocardial infarction study, 84,
85
and phenformin hydrochloride study,
*465
and pyruvate excretion study, *231
of subjects
in chronic hypoxia study, 100
in new glucose tolerance test, 97
in RH negative pregnancy study,
*460
in skinfold thickness study, *314
and sulfonylureas, 63, 64, 655
and triglyceride level, 251
and weight and calorie intake, 245
- ALANINE**
and insulin activity, 698
- ALANINE-C-14, 355, 359**
- L-ALANINE**
and liver carbohydrate synthesis, *378
- ALBUMIN**
and diabetes, *234
-globulin ratio and exercise, *317
and glomerulosclerosis study, 755-770
and insulin, *456-457
antagonism, 82, 86, 566-567
inhibition, *608
and insulin I-131, 27, 31
in juvenile diabetes study, 251
radioimmunoassay, *234
urine test for, 59
- ALBUMINURIA**
and prednisolone-fed rabbits, 595-596
- ALCOHOL**
hypoglycemia, 350-360
ingestion
and hemochromatosis and siderosis,
699, 708
and sulfonylureas, *114
- ALCOHOLISM**
and diabetes, 259
and hypoglycemia, *234
and neuropathy, 2, 4, 8
and nonketacidotic coma, 162
and tolbutamide, *233
- ALKALINE PHOSPHATASE, 126, 654**
- ALLERGIES**
and glomerulosclerosis, 755
and induced pancreatitis, 640-642
and insulin resistance, *818
and insulin tests, *457
and neuropathy, 516
in sulfonylurea therapy, 59, 60
- ALLOSE G-PHOSPHATE, *52**
- ALLOXAN, 373**
and beta-cell changes, 289
and diabetes production, 306
distribution, *383
and glucose oxidation, *48
injections in male rats, 179-184
and insulin level immunoassay, 669-
671
and obesity, *169
and pancreas islet tissue, *383
- ALLOXAN-C-14, *532**
- ALLOXAN DIABETES, 137**
and adenosine phosphate synthesis,
*684
and adipose tissue metabolism changes,
179-185
and ascorbic acid synthesis, 312
and diazoxide, *469
and ethanol disappearance, 14, 16, 17,
18
and fat metabolism, *232, *235, 633,
662, 713
and growth hormone, *50
and hormones, 368
and hyperlipemia, 666-668
and insulin requirements, 373
and ketoacidosis, 289-294
and leukemic mice, 325-332
and lipids
in incubated sciatic nerve, *447
in newborn rats, 724-728
and nerve conduction, *232
in pregnant ewes, *235
and rabbits, 792
and retinopathy, 705
and sex hormones, 501-505
- ALPHA-GLOBULINS**
and insulin-like activity, 71-76

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

ALPHAMETHYLBENZALHYDRAZINE
and diazoxide-induced hyperglycemia,
*469

ALVEOLAR GAS
and acetone determinations, 663-665

AMERICAN DIABETES ASSOCIATION
Affiliate Associations, 57-58, 120, 174,
324, 386, 548, 616-617, 688,
753, 822-823

and American College of Physicians,
618

annual meetings

Twenty-fifth, 54, 118, 237, 471, 319-
323, 537-545
business, 541

Twenty-sixth, 384, 471, 547, 616,
752, 819

awards

Banting Medals, 538

Banting Memorial, 538-539

Lilly, 472, 541, 547, 616, 687, 753

Outstanding Layman, 541

Board of Directors, 54, 820

Committee of State Coordinators, 56-
57, 821-822

Committee on Affiliate Associations,
56, 821

Committee on Bequests, 56, 821, 822

Committee on Emergency Medical
Care, 56, 821

Committee on Employment, 56, 821

Committee on Food and Nutrition, 55,
820

Committee on Information for Diabet-
ics, 56, 821

Committee on Policies, 56, 821

Committee on Professional Education,
55, 820

Committee on Public Education and
Detection, 56, 821

Committee on Research, 56, 821

Committee on Scientific Awards, 55,
821

Committee on Scientific Programs, 56,
820

Committee on Scientific Publications,
56, 820

Committee on Statistics, 56, 820

Committee to Study the Functions and
Structure of the American
Diabetes Association, 56, 821

Constitutional Committees, 820

Diabetes Week, 238, 324, 386, 472,
547, 616

diagnostic criteria, 478-479

dues increase for overseas members,
820

Executive Committee, 55

FORECAST

"Diabetes: Past, Present, and Fu-
ture," 238

"Job Guidelines for People with
Diabetes," 174

fourth research symposium, 324, 384,
472, 545-546

index, diabetes-related literature, 19-
62, 237

International Congress of Gerontology,
386

Journal

index, 55

volume changes, 55

necrology, 58, 174, 386, 618, 754, 824

new members, 57, 119, 323, 384, 547-
548, 616, 687-688, 753

New Patient Study, 617

News notes, 58, 120, 174, 238, 324,
386, 472, 548, 617, 688, 753-
754, 823

Nominating Committee, 55

officers, 54

personals, 58, 120, 238, 324, 386, 472,
548, 618, 688, 754, 824

postgraduate courses, 385, 471, 547-
548, 614, 617, 686, 750, 819

Research and Development Award
Program, 546-547, 615, 687

Research and Essay Contests, 54-55,
119, 173-174, 615, 686-687,
822

research fellowships, 324

research support program, 472

research symposium

future meetings, 2, 820

sabbatical leave, 55

Silver Anniversary Meeting, 173

submission of abstracts, 54

symposium on automation, 472

AMINO ACIDS

and cortisol and insulin, *115

and glucose production, *235

and growth hormone, 374

incorporation into protein, 305, 306

and insulin, 529, *815

and milk diet, 335

nitrogen

and carbohydrate utilization, *448

and sulfonylureas, 209-211

AMINOACIDURIA, 335

AMMONIUM SULPHATE, 71, 72

AMPUTATIONS

for gangrene, 7

AMYLASE, 132, 135

and diagnosing fibrocystic disease,
*117

AMYLO-1,6-GLUCOSIDASE, 337

AMYLOGLUCOSIDASE

and glycogen content, *232

AMYLOIDOSIS

and old age, *612

AMYOTROPHY, DIABETIC, 1, 427,

428, 520

ANAEROBIOSIS

and adipose water and glucose up-
take, *379

and glucose uptake, 128-131

and glycogen, 749

ANAPHYLAXIS, *116

ANDROGENS

and diabetes, 368

ANDROSTERONE

and chlorophenoxyisobutyrate, *814

ANEMIA, 201

and blood sugar determinations, 673-
674

and plasma sugar, 165

ANGINA PECTORIS

in diabetic neuropathy, 2, 7

ANGIOPATHY

and antigen-antibody reaction, 110

and diabetes duration, 370

and diabetic neuropathy and nephro-
pathy, 517

and heredity, 518

and hypophyseo-adrenal function, *53

and muscular atrophy, 426

ocular, 43

symposium, 309-310

ANOREXIA

and alloxanization, 291

and diabetic neuropathy, 427

induced, *52

ANTABUSE, *114

ANTAGONISTS. See also Antibodies

to insulin

albumin, 356-357

ANTIBIOTICS

aureomycin, 194

and diarrhea, 371

and hypophysectomized dogs, 659

and infants of diabetic mothers, 160

and pancreatectomized dogs, 731

penicillin, 93, 696

streptomycin, 93

ANTIBODIES

to adrenals, *317

antithyroid, 743

binding capacity

and insulin, *815-816

and disc electrophoresis separation,
*50-51

to glucagon, *450

to growth hormone, 44

to insulin, *51, *170, *449, 551, 552,
564

and alloxan-diabetic rats, 183

and diabetic glomerulosclerosis, 755

and diabetic kidney tissue, 277-278

in diabetics and nondiabetics, *531

and heterologous and homologous

insulin, *747-748

and induced diabetes, 369

and insulin, 771-772

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58

February, 59-120

March, 121-174

April, 175-238

May, 239-324

June, 325-386

July, 387-472

August, 473-548

September, 549-618

October, 619-688

November, 689-754

December, 755-824

SUBJECT INDEX 1965

- and insulin-binding, 27-31, 235, 396-402
and insulin and I-125 insulin, *449
and insulin-like activity, 805
and insulin resistance, 309, 432-434, 716
and pancreas islet studies, *449-450
and pancreatic changes, 493-500
and pregnancy, 577
and Regular Insulin, *316
pancreatic, 226-227
in Schmidt's Syndrome, *48
- ANTIGEN**, 226-227
- ANTIHISTAMINES**, 60
- ANTISERUM**
electrophoresis, *50-51
and induced diabetes, *52
insulin, 756
and radioimmunoassay, 772
and tissue electrical potential, 529
and study of renal lesions, 755-756
- AORTIC SCLEROSIS**
and diabetic neuropathy, 1-3
- L-ARABINOSE**, *48
- ARGYLL-ROBERTSON PUPIL**, 5, 428
- ARTERIOULAR NEPHROSCLEROSIS**
and diabetics and nondiabetics, 110
- ARTERIOSCLEROSIS**, 761
and diabetes, 84-86, 110, 550
and diabetic neuropathy, 428, 516-517
peripheral ischemic, 1
- ARTERIOSCLEROSIS OBLITERANS**
and diabetic neuropathy, 7
- ARTHRITIS, GOUTY**
and diabetes, *116
- ARTHRITIS, RHEUMATOID**
and ischemic leg ulcers, *318
and phenformin, *532
- ASHKENAZI**
and study of diabetes and face color, 201-208
- ASPARAGINE**
and insulin activity, 698
- ASTEROID HYALITIS**
and diabetes, *171-172
- ATHEROGENESIS**
and hyperglyceridemia, *458
- ATHEROMATOSIS**
and diabetic neuropathy, 517
- ATHEROSCLEROSIS**
and cholesterol, 369
and diabetes potential, 489-491
and diabetic lesions, 110
and dietary control, 307
and glucosamine, *380
and hypertension and diabetes, *749
and hypertriglyceridemia, 251
premature
and diabetes, 41
and race, *470
and serum beta-glucuronidase and glucose tolerance, *682
and sulfonylureas, *377
- ATHEROSCLEROSIS OBLITERANS**
and glycoproteins, *168
- ATROPHY**
and diabetic neuropathy, *454
muscular
and glucocorticoids, 484
- ATROPINE TEST**, *747
- AUTOANALYZER TEST**, 78, 93, 97, 165, 166, *170, 186, 187-188, 192, 193, *232, 296, *452, *453, *458, 494, 507, 580, 591, 672
- AZAMETHONIUM**
and free fatty acids, *532
- AZOTEMIA**
and diabetic nephropathy, 2
and insulin response to glucose, *459
in juvenile diabetes study, 265
- ## B
- BALANITIS**, 60
- BALLISTOCARDIOGRAMS**
in juvenile diabetes study, 267
- BANTING, FREDERICK**, 37-42
- BANTING MEMORIAL LECTURE**, 549-568
- BANTUS**
and idiopathic hemochromatosis and siderosis, 699, 708
- BARBITURATES**
and nonketoacidotic coma, 162
- BASEMENT MEMBRANE**
changes
and diabetes, 517
in prednisolone-induced nephropathy in rabbits, 600-601
thickening
and diabetes, *47, 110, 550, 702-706
and diabetic glomerulosclerosis, *377
and fatty acids, 370
and glomerulosclerosis, 759
- BENEDICT'S TEST**
and false negative reactions, 224-225
- BENSON'S DISEASE**. *See* Asteroid hyalitis
- BEST, CHARLES**, 37-42
- BIBLIOGRAPHY OF MEDICAL TRANSLATIONS**, 657
- BICARBONATE**
duodenal, *53
and nonketoacidotic coma, 162-164
- BIGUANIDES**
and juvenile diabetes, 531
statistics on, 61
- BILIRUBIN**
in juvenile diabetes study, 253
- BLADDER**
atonic
and diabetic neuropathy, 427, 428
and diabetic neuropathy, 370, *455
dystonia, *47
infections
in juvenile diabetics, 256
paralysis, 5, 7
- BLOOD**
acetate, *235
acetone determination, 663-665
antibody content, 28
cholesterol, 1
and diabetic neuropathy, 4
clotting and lesions, 604
corticosterone and gravity changes, *535
count in sulfonylurea therapy, 59, 60
drug levels and sulfonylurea therapy, 653-654, 655-656
dyscrasias in sulfonylurea therapy, 67
ethanol in experimental dogs, 15-18
fatty acids, 395
flow
and diabetic neuropathy, 517
and Kreb's intermediate metabolites, *532
splanchnic and glucose production, 355
and free and bound insulin, *608
and free fatty acids, 87
fructose
and hypoglycemic convulsions, *49
and galactosemia, 335
glutathione, 132, 135, 136
and growth hormone determination, 43
hematocrit
and blood sugar determination, 672-674
and hemoglobin in leukemia, 326-327
hematological indices and growth hormone, *50
hemoglobin
in juvenile diabetes study, 253
and insulin-inhibitors and binders, *234
in insulin resistance study, 432-434

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

in juvenile diabetic, 121
ketones
and ketosis, 744-745
and labile diabetes study, 286, 287
lactate
and free fatty acids, *611
in newborn calves, *49
and urate excretion, 739
levels
and acetohexamide, *456
of lipid-infused pancreatectomized dogs, 33-35
lipids
and diet, *611, *816
and phenformin and tolbutamide, *456
and radioactivity, 709-715
pancreaticoduodenal venous insulin tests, 393-394
peripheral venous insulin, 387
portal
and plasma insulin, *439
pressure
and glomerulosclerosis, 457, 459, 461
pyruvate, *231
pyruvic acid
and diabetic neuropathy, 4
and radioactivity incorporation into lipid, *747
red cells
and alloxan distribution, *383
and I-C-14 glucose and 6-C-14 glucose metabolism, *747
saccharoid
and mental illness, 719-722
samples
and acetone determinations, 664-665
in adrenal steroid study, 730
and alloxanized rats, 669
in free fatty acid study, 78
in glucose disposal-rate study of elderly, 580
in glucose tolerance test study, 474
from growth-hormone-injected dogs, *444
of guinea pigs in cortisol study, 195
from hypophysectomized dogs, 659
in insulin-like activity study, 71
in juvenile diabetes study, 241
and lactic acidosis, *465
in new glucose tolerance test, 97
new technic, 186-193
of pancreatectomized dogs, 690
and pentosuria study, 311
and plasma samples compared, 165-166
from premature infants, 127
from siblings of juvenile diabetics, *438
of umbilical arterial blood, 160
tests
in lactose- or galactose-induced hypoglycemia, *682
and multiple sclerosis, *464

triglyceride removal, *536
urea nitrogen content, 36
volume
respiratory distress syndrome, 436

BLOOD GLUCOSE. *See also* Blood sugar

and actinomycin D, 633
and adrenalectomized rat, *748
and adrenalin, *49
and age, sex, and diet, 413-422
and alloxan, 291, 669-671
anomers
measurement method, *747
and anti-insulin serum, 15
and autoclaved carbohydrate solutions, *168
and azotemia, *459
and carbohydrate tolerance tests, *315-316
and chlorothiazide, *609
and chronic hypoxia, 100-104
and coronary heart disease, *116
and cortisol, *113, 194
and diabetes diagnosis, 176
disappearance rate
and obesity, *467
fasting
and diabetes detection, *685
and insulin-like activity, 10, 11
fetal, 577
finger
and diabetes detection, 295-299
and glucose loading, 84-86
and hypnotically induced emotional stress, *467-468
of immunized guinea pigs, *52
and insulin, *169, *684-785
hypoglycemia, *536
intestinal, 697-698
intraperitoneal, 23
-like activity in juvenile diabetics, *49
and tolbutamide, *114
and islet cell tumors, *49
and labile diabetes study, 283-285, 287
and lactose-induced hypoglycemia, *682
and liver perfusion system, *235
in newborn infants, 127, 156
after pancreatectomy, 14
and placenta, *172
and pregnant women, 578
regulation
and insulin, 308
and secretin, *167
and serum insulin, *458
and siblings of diabetics, *438
and single injection of anti-insulin serum, *49
and stress, *382
and sulfated insulin, *440
and sulfonylurea therapy, *463
tests, 2, 59, *232, *315
in alloxan diabetic rats, 180, 181, 182, 184

AutoAnalyzer, 78, 93, 97, 165, 166, *170, 186-188, 192, 193, *232, 296, *452, *453, *458, 494, 507, 580, 591, 672
Clinistix, 224-225, 247, *746, *816
Combistix, 224-225
compared, *452
Dextrostix, *170, *232, *381, *383, *611, *817
Folin-Wu, 247, 651, 690, 720-722
Hagedorn-Jensen, 59
Nelson-Somogyi, 591
new technic, 186-193
and postgastrectomy hypoglycemia, 526-528
Schaffer-Hartmann, 2
Somogyi-Nelson, 33, 78, *116, 165, 202, 363, 388, 420, 526, 586, 651, 720, 722
in tolbutamide study, 392-394
and triglyceride-induced hyperketonemia, *448
and thiazide injections, *115
and thyroid administration tests, *49
and tolbutamide
in ulcer patients, *814

BLOOD PRESSURE

and glucose tolerance tests, *116
of juvenile diabetics, 121, 126
and phenformin overdose, 811
and tubular necrosis, 36

BLOOD SUGAR. *See also* Blood glucose

and alcohol ingestion, 350-360
and alloxan diabetic rats, 137-138
and amino acid nitrogen, *448
and antihypertensive drugs, *377
assays, 87, 88
and blood saccharoid content, 719-722
and caffeine and coffee, *169
and chlorpropamide and tolbutamide, 650-656
control
and M-value, *612
and cortisol study, 195, 198
of cortisone-alloxanized rabbits, 793
and diabetes
classification, *234
control study, *469
detection, *461
neonatal, *233
severity, 60
of diabetic children, *460
and diabetic neuropathy, *114
and 3,5-dimethylpyrazole, 507-514
enzyme-strip determination, *170
and ethanol ingestion, *52, *171
fasting, *53
and diabetes diagnosis in dogs, 700
and diabetic neuropathy, 428
and glucose-6-phosphatase, 146
and leukemic mice, 325-331
and L-xylulose levels, 311
and oral hypoglycemics, 405
and phenformin hydrochloride, *463-466

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

- and phenformin and tolbutamide, *456
 - and prediabetes, 175
 - and fetuses, *235, 371
 - and free fatty acids, 369
 - and gastric secretory response, *532
 - and growth hormone, 43
 - and hematocrit, 672-674
 - and hormones, *231, 333-338
 - and hyperglycemia, 792
 - and hypernatremia, 164
 - and hypoglycemia, 606-608
 - and insulin
 - antibodies, 396
 - distribution, 345
 - Rapitard, *685
 - response, *462
 - in juvenile diabetes study, 247, 250
 - lability, *168
 - and L-leucine, *47
 - and newborn infants, *815
 - and oral insulin, *117
 - and oscillatory motion, *317
 - in pancreatectomized and normal dogs, 34
 - of patients in bone study of diabetics, 142
 - and phenformin, *52, 811
 - and plasma sugar determinations compared, 165-166
 - postprandial
 - among Pima Indians, *439
 - and prediabetes, 371-372
 - and pruritis, *168
 - and pyruvate levels, *231
 - and skinfold thickness and serum lipids, *314
 - and stress, 518
 - and sulfation factor, *172
 - and sulfonylureas, 362-367
 - tests
 - and diazoxide hyperglycemia study, 591-594
 - glucose oxidase method, *458
 - Hagedorn and Jensen method, 195
 - and insulin study, *457
 - and juvenile diabetes, 121, *317
 - in thiazide therapy, 136
 - and tolbutamide, *470
 - in tubular necrosis case, 36
- BLOOD VESSELS**
- calcification
 - in juvenile diabetes study, 266
 - capillaries
 - in South African diabetics, *469-470
 - and diabetes, 310
 - retinal
 - reversal of diabetic changes, 121-127
 - spinal cord
 - in diabetic myelopathy, 426
- BODY**
- face
 - color in diabetes, 201-208
 - finger
 - glucose test, 295-299
 - growth
 - and alloxan-diabetic rats, 502
 - of juvenile diabetics, 253-254
 - hands and feet
 - color in diabetes, 201
 - limbs
 - and glucose uptake, *383
 - lower extremities
 - diabetic foot, *172
 - and diabetic neuropathy, 2, 8, 427, 520
 - ischemic leg ulcers, *318
 - skin lesion, *817
 - ulcers, *115-116
 - rib
 - cortical area, *316
 - toes
 - diabetic microangiopathy, *47
 - upper extremities
 - and diabetic neuropathy, *454
 - metabolism studies, *117
 - "thick hand syndrome," *454
 - upper and lower extremities
 - and ulcers, *684
- BONES**
- from diabetics, 142-145, 375
 - fractured and immobilized
 - glucose uptake, *383
 - growth
 - and Vitamin B₆ deficiency, 515
 - metabolism
 - and diabetes mellitus, *455
 - spontaneous fracture, *683
- BOOK REVIEWS**
- Annual Review of Biochemistry, edited by E. E. Snell, J. M. Luck, P. D. Boyer, and G. MacKinney, 46
 - On Diabetes Mellitus, Selected Topics for Students and Clinicians, by Charles C Thomas, 376
 - Diseases of Metabolism, edited by Garfield G. Duncan, 46
 - Etiology of Diabetes Mellitus and Its Complications, edited by Cameron and O'Connor, 674-675
 - Fat as a Tissue, edited by Kaare Rodahl and Bela Issekutz, Jr., 313
 - A Handbook for the Young Diabetic, by Alfred E. Fischer and Dorothea L. Horstmann, 813
 - How Diabetics Can Eat Wisely, by Dorothy Tomkins Revell, 313
 - Juvenile Diabetes: Adjustment and Emotional Problems, by U.S. Public Health Service, Diabetes and Arthritis Program; National Institute of Arthritis and Metabolic Diseases; Child Guidance Center of Mercer County; and New Jersey State Dept. of Health, 111-112
 - del Paciente Diabetico, by Rafael Rodriguez, 112-113
 - Manual del Enfermo Diabetico, by staff of Diabetes and Obesity Clinic of Hospital of Diseases of Nutrition, 112-113
 - Modern Nutrition in Health and Disease, by Wohl and Goodhart, 375
 - Reports of the Steno Memorial Hospital and the Nordisk Insulin-laboratorium, Volume II, 1963, Gentofte, Denmark, 229-230
 - A Textbook of Medicine, by Russell L. Cecil and Robert F. Loeb, 166
- BOWMAN'S CAPSULE**
- and diabetic dogs, 704, 706
 - in prednisolone-treated rabbits, 596-598, 602
 - thickening
 - and glomerulosclerosis, 759, 761, 768
- BRAIN**
- and diabetes mellitus
 - pathologic changes, 424, 425
 - and hypoglycemia, 127
 - of infants of diabetic mothers, 436
 - and sulfonylurea therapy, *377
 - tissue
 - glucose utilization, *172
 - and vascular disease, 2
- BROCA'S FORMULA, 60**
- BROMSULPHTHALEIN, 253**
- BRONCHOPNEUMONIA, 158**
- BUTYLBIGUANIDE, 60**
- C**
- CAFFEINE**
- and obese hyperglycemic mice, *169
- CALCIUM**
- and insulin activity, 430-431
 - and ouabin, *534
- CALCIUM GLUCONATE**
- and hypoglycemia in rabbits, *462
- CALORIES**
- expenditure
 - new device for measuring, *814-815
 - increase
 - and hyperglyceridemia, *458
 - intake in juvenile diabetes study, 244, 245
 - and uremia, *169

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

- CAMP WIDJIWAGAN**, 676-677
- CANADA**
and diabetes, 214
- CARBOHYDRATES**
conversion and adipose tissue, 82
cytotoxicity, *47-48
in diet of juvenile diabetics, 240, 245
dietary, *179, 474
and clofibrate therapy, *453
in diabetes, 60
in free fatty acid study, 77
and electrocardiograms, *168
and enzyme activity, *236
and growth hormone, 44
and growth hormone secretion, 557
ingestion
and diabetes detection test, *454
loading
and diabetes detection method, 295-299
metabolism. *See* Metabolism, carbohydrate
and postgastrectomy hypoglycemia, 526
and premature infants, 127, 156
solution for glucose tolerance testing, 96-99
synthesis
and corticosteroids, *378
tolerance
and age, sex, and diet, 413-422
and amyloid deposits, *612
and blood glucose level, *315-316
in children of diabetic families, *438-439
and diazoxide and chlorothiazide, *439
and hyperthyroidism, 740-743
and hypoglycemia, *459-460
and oral hypoglycemic agents, *318
tolerance tests
and amino acid nitrogen alterations, *448
- CARBON DIOXIDE**
and glucose, 311
production
in leucocytes, 586-587
by perfused rat heart, *685
- CARBUTAMIDE**, 59-70
in diabetes study in India, 405
and hypoglycemia, 606-607
- CARCINOID SYNDROME**
and hypoglycemia and pancreas tumor, *53
- CARCINOMA**
bronchogenic, and insulin and glucagon, *53
of colon, 759
and cyclophosphamide treatment, *612
diabetic
glomerulosclerosis, 763
mortality, 221
and diabetics and nondiabetics, *608-609
hepatic, *234
islet cell
and Cushing's syndrome, *684
and diazoxide, *469, *610
pancreatic, *48, 226-227, *815
and diazoxide, *450
- CARDIOMEGALY**
and infants of diabetic mothers, 436
- CARDIOVASCULAR DISEASE. See also** Heart disease
and glomerulosclerosis, 759, 761, 763
and small-bowel ulcers, 228
- CARTILAGE**
powder and diabetic wounds, *170-171
- CASE REPORTS**
acute tubular necrosis and dialysis treatment, 36-37
attempted suicide with phenformin, 811
blood insulin levels in islet-cell tumor patients, *49
diabetes and gouty arthritis, *116
diabetes and hypophysectomy, 43
diabetes and pituitary insufficiency, *50
diabetic acidosis secondary to steroid therapy, *114
diabetic coma, *609
diabetic glomerulosclerosis and plasma proteins, 757-763
diabetic neuropathy, 3-8, *47
diabetic retinopathy and hemochromatosis, *682
diet and urate excretion, 739
ethanol metabolism in diabetic dogs, 15-17
exocrine pancreas and diabetes, *53
growth hormone survival, *50
hyperinsulinism and Cushing's syndrome, *684
hypoglycemia and dwarfism with growth hormone deficiency, *613
insulin antibodies without insulin treatment, 551
insulin and glucagon in hepatic metastasis, *53
insulin resistance, *612
insulin secreting pancreatic tumors, *115
islet-cell tumors, *49
lactose- or galactose-induced hypoglycemia, *681-682
misleading tolbutamide test, *816
nalidixic acid overdose, *683
nondiabetic ketosis in diabetic pregnancy, *464
obesity and fasting, *532
pancreas tumor hypoglycemia and carcinoid syndrome, *53
pancreatectomy, *683
pancreatic secretion in diabetes, *48
peptic ulcer with islet cell tumor, *116
post-pancreatectomy functioning, *613
reactive hypoglycemia and mild diabetes, *612
reversal of retinal vascular changes in diabetes, 121-122
studies of energy metabolism, *50
sulfonylureas during pregnancy, *51
sulfonylurea therapy study, 68
tolbutamide-induced hypoglycemia, *114
- CASE STUDY**
severe hypoglycemia after tolbutamide and carbutamide treatment, 606-607
- CATARACTS**
and diabetes, *231-232
in diabetic dogs, 705
and experimental sugar, radiation and metabolism, *611
in juvenile diabetes study, 265
- CATECHOLAMINES**
and alcohol, *233
and glucose, 78
hyperglycemia, *235
and hypoglycemia, 333
and lipolysis of triglyceride, 184
- CELL POISONS**
and glucose uptake, 128-131
- CELLS**
dehydration
and nonketoadidotic coma, 162
necrobiosis
in prednisolone-induced nephropathy in rabbits, 599
- CEREBRAL ACCIDENTS**
and diabetic mortality, 221
- CEREBRAL INFARCTS**, 759, 761
- CEREBRAL THROMBOSIS**
and diabetics and nondiabetics, 110
- CEREBROSPINAL FLUID**
in diabetic neuropathy, 5, 7, 429
in tubular necrosis case, 36
- CEREBROVASCULAR SYSTEM**
accidents
and diabetic neuropathy, 425
and mortality, 68
and nonketoadidotic coma, 162
amyloidosis, *612
disease
and diabetes, 425, 428
and tolbutamide, 654
- CESAREAN SECTION**, 256
and alloxan diabetic rats, 137-140
and diabetic pregnancy, 157, *379-380

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

CHARCOT'S JOINTS, 427

CHILDREN

- and abnormal insulin, 780-786
- blood sugar data, *460
- camping trips, 676-681
- and Dextrostix tests, *611
- diabetic
 - attitude toward diabetes, 106-109
 - of diabetic families
 - carbohydrate tolerance and tolbutamide response, *438-439
 - and diabetic neuropathy, 428
 - glucose and free fatty acid metabolism in obese adolescents, *746-747
- and glycogenesis, 337-338
- and growth hormone levels, 43
- and hypoglycemia, 348
 - with salicylate poisoning, *315
 - and tolbutamide tolerance, *315
- and iron in bones, 142
- and ketotic hypoglycemia, *315
- and microangiopathy mortalities, 308
- and neuropathy, 518-519
- and new glucose tolerance test, 96
- obese
 - and glucose and free fatty acid metabolism, *610
 - reversal of retinal vascular changes, 121-127
 - siblings of diabetics, *438

CHLOROPHENOXYISOBUTYRATE

and lipids, fat tolerance and uric acid, *814

CHLOROTHIAZIDE

and carbohydrate intolerance, *439

peripheral action, *609

CHLORPHENTERMINE

and obese diabetics, *451-452

CHLORPROPAMIDE, *51, *114

and blood glucose and plasma insulin, *463

and blood sugar, 650-656

in diabetes study in India, 405, 408

long-term therapy, *814

in serum and urine, 362-367

and severe hypoglycemia, 606

and urea synthesis and glyconeogenesis, 209-211

CHOLANGITIS

and pancreatotomy, *683

CHOLELITHIASIS, *465

and aged diabetics, *47

CHOLESTEROL

and arteries and insulin, *746

and atherosclerosis, 369

and diabetic neuropathy, 1

dietary, 332

and ethanol, *52, *171

and high fat diet, *464

- and ischemic heart disease, *234
- in juvenile diabetes study, 250
- lowering response
 - and clofibrate, *453
 - and mebanazine, *236
- and newborn of alloxan-diabetic rats, 724-728
- and pancreatotomy, *681
- and phenformin hydrochloride, *465
- and polyunsaturated fatty acids, 105
- and pregnancy, *609
- and sugar and starch ingestion, *378
- and weight gain, *314

CHOLINE

and hyperlipemia, 666-668

CHROMATO-ELECTROPHORESIS, *235

of insulin-I-131, 342

CHROMATOGRAPHY

and blood acetone determination, 663-665

and blood glucose separation, 730

and distribution of C-14 into fatty acids, *457

fluorescent insulin, *51

gas-liquid, 105

and glycogen metabolism, *749

and insulin

- antibodies, 397
- degradation, 90-91
- like activity, 809

of labeled insulin, *449

paper, 690

of radioactivity incorporation, 28

and separation of bound and free insulin, 392

urine, *456

and lactose-induced hypoglycemia, *682

CHROMALUM HEMATOXYLIN PHLOXINE, 328

CHROM-HEMATOXYLIN METHOD, 195

CHYLOMICRON

metabolism in adipose tissue, *535-536

CITRATE

and lipogenesis, *447

CLOFIBRATE

and diabetic hyperlipidemia, *452-453

COBALT CHLORIDE

and glucagon, *51, 368

COMA

and alcohol ingestion, 350

hypoglycemic, 606

and face color, 201

COMA, DIABETIC

and blood acetone chromatography, 663-665

- and diabetic neuropathy, 425, 428
- and face color, 201, 207
- hyperosmolar nonacidotic, *609
- India and West compared, 409
- without ketoacidosis, 162-165, 371
- and menarchial age, 788, 790
- and mortality, 221
- pre-, 121
- and sodium lactate treatment, *440

CONFERENCE ON DIABETIC VASCULAR PATHOLOGY, 110

CONVULSIONS

and hypoglycemia, *49

and nalidixic acid, *683

CORONARY DISEASE. See Heart disease

CORTICOSTEROIDS

and ACTH, 334

and diarrhea, 371

and human growth hormone, *315

and hydrocorticoids during fasting, *381

and liver carbohydrate synthesis, *378

and partial pancreatotomy, 593

CORTICOTROPHIN, *169

CORTISOL, *169

and alloxan, *235

and amino acid incorporation, *115

and carbohydrate metabolism, *113

and hyperlipemia and ketonemia, 33-35

and insulin, *169

-like activity, *52

and lipolysis and lipogenesis, 369

and pancreas, 194-200

CORTISONE

and alloxan diabetes, 792

and alloxan-diabetic rat fetuses, 727

and glomeruli in rabbits, 595

-glucose tolerance tests, *48, *170, *315, 371, *467

and hypophysectomy, 43, 659

and insulin

- requirement, *52
- resistance, *52

and islet cell tumors, *115

and lipemia, 604

and 5-nucleotidase and adenosine triphosphatase activities, *380

and tumor growth and glycosuria, 93

CORTISONE ACETATE, 93

CREATININE, 93

clearance and hyperuricemia, 739

and glucose oxidase, 224

and severe hypoglycemia, 606

CUSHING'S SYNDROME, *169, 736

and diabetes, 28

and hyperinsulinism, *684

and insulin resistance, 556

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

CYANOSIS, *611
and infants of diabetic mothers, 160

1-CYCLOHEXYL-3-UREA, *684

CYCLOPAL, 513

CYCLOPHOSPHAMIDE
and diabetes, *612

CYSTEINE
and insulin, *53, *114

D

DENMARK
and diabetes, 215

2-DEOXYGLUCOSE, 184
and serum insulin levels, *444

DESOXYCORTICOSTERONE
and hypophysectomized dogs, 659

DEXAMETHASONE, *169

DEXTROSE
and electrocardiographic changes, *168
toxicity, *48

DEXTROSTIX, *170, *232, *611, *817

DIABETES INSIPIDUS
and diabetes mellitus
heredity factors, *116
and hypoglycemia, *169

DIABETES MELLITUS
and acetate I-C-14 incorporation into
fatty acids, 709-715
and Achilles reflex, *380
and Addison's disease and myxedema,
*317
and adrenal function, *169
and adrenal steroids, 729-736
alloxan induced
and anaphylaxis and granuloma for-
mation, *116
and cartilage powder, *170-171
among American Indians, *439-450
and antibodies to insulin, 396-402
and aortic metabolism, 310
and asteroid hyalitis, *171-172
and atherosclerosis, 41
and beta-aminopropionitrile treatment
of lathyric rats, *613
and beta cell structure in rabbits, 792-
803
and blepharoptosis, *455-456
blood sugar control and M-value, *612
and blood sugar and exercise, *317
and blood vessel changes, 310
and bone metabolism, *455
and capillary changes, *469-470
and carbohydrate tolerance
in Tecumseh, Michigan, 413-422

and cataracts, *231-232, *611
in Chinese hamsters, *448-449
and chlorpropamide, 650-656
and citric acid cycle, 590
classifications, 60
control
and degenerative complications, 3,
4, 7
and environment, *469
and neuropathies, 518
and weight reduction, 2
convocation in Toronto, 37-43
and coronary heart disease, *117
and cyclophosphamide, *612
and degenerative lesions, 1, 2
detection, *461
and enzyme strip test, *452
and fasting plasma assays, *533
and fatty acid metabolism, 715
and glucose tolerance tests, *685
new mass screening method, 295-299
in pregnancy, *170
and reproducibility of glucose toler-
ance tests, 473-479
simplified Glucola screening test,
*453-454
and "stress" blood glucose level,
*462
in Sweden, *531, *534-535
and diabetes insipidus
heredity factors, *116
and diabetic foot, *172
diagnosis, 478-479, 519, 700
and blood saccharoids, 719
and glucose tolerance tests, *535,
583
incorrect, 606-607
and necrobiosis lipoidica, *314-315
oral sodium tolbutamide test, *451
and diet, *318, *463-464, *748, *816,
*817
adherence and artificial sweeteners,
*682
-induced in sand rat, *610
and lipids, *611
and digestive alterations, *465
and diguanides, *53
duration
and atrophic skin lesion, *817
and basement membrane thickness,
*47
and longevity, 40
and microangiopathy, *682
and motor-nerve function, *115
and neuropathy, 3, 6, 428
and oral therapy, 61-62, 64
and retinopathy, *379
early diagnosis, 1, *53, 481-487
and emotional stress, *467-468
and estrogen, *458
and ethanol or wine, 14-18, *52, *171
and ethyl-a-p-chlorophenoxy-isobuty-
rate, *467
etiology, *234, 550, 552
and environmental factors, 518
and exocrine pancreas, *53

and face color, 201-208
and family history study, *609
and fasting
serum insulin-like activity, *442
and fat and protein metabolism, 633,
662
and free fatty acids and glucose tol-
erance, 77-82
and free fatty acid metabolism, *232
and gastrointestinal tract, 371
and glomerulosclerosis, 755-770
and glucose
metabolism in leucocytes, 584-590
-6-phosphatase, 337
tolerance in old age, 581, 582
uptake of muscle, 716-718
and glycoproteins, *168
and gouty arthritis, *116
and growth hormone, 43-45, 308, 369,
556-558
and heredity, *170, *318, 371, *610
and hormones, 368
and hyperlipidemia, *452-453
and hypertension, *377, *748
and hyperthyroidism
and glucose tolerance, 740-743
and hypoglycemia, *314, *459-460
and hypothalamic lesions, *233
and impotence, 370
in India, 404-411
induced in rats, *52
and infection resistance, *114
and insulin, 12, *457, *460-461
antagonism, 369
antibody-induced, 369
-binding, 27-32, *235
degradation, 343
dependence, 552, *747
inhibition, *608
and insulin-like activity, 71-76,
*684-685
resistance, *440, *818
response to protein, *442
uptake by kidney tissue, 274-278
and iron in osteoid seams of bones,
142-145
and ischemic heart disease, *169
and ischemic leg ulcers, *318
juvenile
adjustment problems, 40-41, 260
and antibody titers, 28
attitudes, 106-109
blood sugar levels, *460
course with unmeasured diet, 240-
270
and diet-induced diabetic syndrome,
*441
educational attainments, 259-260
and ethanol, 353-354
glucose loading and insulin activity,
*49
and insulin abnormalities, 780-786
management, *317-318, *531
pancreas study, 619-632
and plasma insulin, 552-553
and sulfonylurea therapy, 64, 68

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-543	December, 755-824

SUBJECT INDEX 1965

- and synalbumin antagonist in sibilings, *438
- and urinary tract infections, *315
- and wilderness camping, 676-681
- ketosis-resistant, *814
- labile, 41, 279-288
- and lipid metabolism, *447
- and L-xylulose in serum, 311-312
- maternal
 - and congenital malformations, 160, 161, 260, 371, 429, 436, 482
 - and fetal beta cell granulation, 137-141
 - and management of infants, 435-437
 - and neonatal problems of infants, 157-161
 - and pancreas insulin content in infants and fetuses, 573-578
 - and serum proteins of infants, *438
 - and tolbutamide tolerance tests of newborn infants, *468
- maturity-onset
 - and angiopathy, 309-310
 - and bromsulphthalein, serum alkaline phosphatase, and thymol flocculation increases, 253
- death rate, 68
- determination in childhood, *438-439
- and glucose tolerance and serum insulin, *457-458
- and glucose tolerance tests, 77
- and high carbohydrate diet, *458
- and insulin-like activity study, 71
- and insulin response, 387, *442
- and neuropathy, *234
- and serum insulin, 26, 28, 309, *683
- and sulfonylurea therapy, 59, 64
- and menarchial age, 788-791
- and monamine-oxidase inhibitors, *236
- and multiple sclerosis, *464
- and myocardial infarction, 84-86
- and necrobiosis lipoidica, *234-235
- neonatal, *233
- and nephropathy, 310
- neurologic disorders, 370, 424-429, 516-520
- new programs for, *51
- nonketotic, 4, 7, 162-165
- and obesity, *748
- onset
 - and diabetic neuropathy, 518
 - and osteoporosis, *316
 - and pancreas beta-cell granulation, *444-445
 - and pancreatic isoantibodies, 226-227
 - and pancreatic secretion studies, *48
 - panel discussion in Great Britain, *48
 - and papillary necrosis, *167
 - pathophysiology, *815
 - and phagocytic activity of leukocytes, *114
 - and pituitary insufficiency, *50
 - and post-hypophysectomy care, *316-317
- potential, *466, 489-491
- and pregnancy, *51
- and premature coronary artery disease, *611
- prevention, 41, *815
- and programmed instruction, *316
- and pruritis, *168
- and pseudotabes syndrome, *47
- psychological factors, 106-109
- and pyruvate excretion, *231
- and race, *236
- and reactive hypoglycemia, *612
- research controversies, 549-568
- and retina
 - detachment, *446
 - vascular changes, 121-127
- and retinopathy and nephropathy in dogs, 700-707
- Sandmeyer
 - and glucose production, *746
 - and Schmidt's Syndrome, *48
 - and serum globulin system, *382
 - serum insulin activity, *453
 - and serum insulin-like activity, *382
 - sex differences, *454
 - and sex hormones, *452
 - and socio-economic problems, 40
 - spontaneous in mice, *747
 - stages, *815
 - "starvation," 555-556
 - and steroids, *381-382
 - and sulfonylureas, 59-70, 392-394, *463
- survey
 - of aged, *47
 - Oxford, Massachusetts, *461
 - of Pima Indians of Arizona, *439-450
 - of population groups, 40
 - 1964 world, 212-223
- susceptibility
 - and obesity, *612
- symptoms
 - and blood sugar levels, 3
 - and taste threshold, *536
 - thiazide-induced, 132-136
 - and thymic hormone, 325-331
 - and tolbutamide, *470, 650-656
- treatment
 - with chlorphentermine, *451-452
 - with sulfonylureas, 362-367, *377
- and triglycerides, 668
- and tuberculosis, 301
- and tumors, *608-609
- and ulcers, *684
- untreated
 - and insulin-like activity, 10, 805-810
 - and sulfation factor, *172
- and urinary tract infection, *818
- and urine
 - albumin, *234
 - bacteria, *533
- and vascular disease, 110-111, 307-308, *440
- and vascular lesions, *817
- and weight reduction, *52
- DIABETES, PANCREATIC
 - and ketonemia, 33-35
 - and steroid diabetes, 93-95
- DIABETES, STEROID
 - and pancreatic diabetes, 93-95
- DIABETOLOGIA, 812-813
- DIALYSIS
 - and acute tubular necrosis, 36-37
 - and conversion of complexed to free insulin, 388
 - and insulin binding, 568
 - of insulin and fluorescein isothiocyanate, 276
 - and serum protein fractionation, 71, 72
- DIARRHEA
 - and chlorphentermine, *451
 - and diabetes, 371, *465
 - and diabetic neuropathy, 5, 7, 267, 426, 428, 429, 516, 520
 - and hypoglycemia, *53
 - in juvenile diabetic, 121
- DIAZOXIDE, *115
 - diabetes
 - and insulin inhibition, *439
 - and hyperglycemia, *469, 591-594
 - and hypoglycemia, *610
- DICHLOROISOPROTERENOL
 - and lipid mobilization, *447
- DIET
 - and aged diabetics, *47
 - in alloxan diabetes and ketoacidosis study, 289, 290
 - of animals in insulin-inactivation studies, 88
 - atherogenic, 369
 - and blood glucose levels, 416-422
 - and blood lipids, *611
 - and blood sugar response to glucagon, *817
 - and carbohydrate contents of foods, *379
 - carbohydrate-free, *318
 - and chlorpropamide and tolbutamide study, 651
- CHO, 121
 - choline-deficient, 666-668
 - of chronic hypoxia subjects, 100
 - in cortisol study, 194
 - and diabetes, *318, *817
 - study in India, 405, 411
 - and diabetic retinopathy, 121-122
 - during diazoxide hyperglycemia study, *450
 - of dogs in tolbutamide study, 392
 - and ethanol and wine, *171
 - and exercise, *317
 - fatty acids, 395
 - in fibrocystic disease of pancreas, *117
 - and fructose intolerance, 336
 - fructose rich
 - and citrate-cleavage activity, *683

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-613
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

in galactosemia, 335
and glucose production, *746
in glucose tolerance test reproducibility study, 474
gluten-free
and diarrhea, 371
high-carbohydrate, 186
and ketosis, *464
and lipogenesis, *236
high fat
and diabetes, *463-464
and insulin requirements, 369
and vascular disease, 307
high protein
and insulin response, *442
and hormones
in gluconeogenesis, *445
and human depot fat, 105
and hyperglycemia and glycosuria, 43
and hyperglyceridemia, *458
and hyperuricemia, 739
and hypoglycemia, *610
-induced diabetes, *441, *610
-induced diabetic syndrome, *441
in induced pancreatitis in rats, 634
and insulin activity, 71, *114, *816
and intravenous glucagon response, 104
iron-enriched
and siderosis and hemochromatosis, 699, 708
and juvenile diabetes, 41, 107, 240-270, *317-318, *531, 679-680
ketogenic
and glucagon, 338
low carbohydrate
and artificial sweeteners, *682
-high fat, *52
and serum insulin, *748
low fat
and diabetic retinopathy, 44
high carbohydrates and retinopathy, *816
high protein, *168
low sodium
and hypophysectomy, *317
in myocardial infarction and carbohydrate metabolism study, 84
in new glucose tolerance test, 97
and obesity, *451
phenylalanine-deficient, 335
of pancreatectomized dogs, 33, 690, 730
of pancreatectomized rats, 93
and plasma insulin response, *453
of premature infants, 160
and Project Head Start, 723
pyridoxine deficient, *380
Rockland rat, 179
and serum cholesterol and liver lipids, *533
in study of free fatty acids during glucose tolerance tests, 77
in study of labile diabetes, 279-280
in study of thiazide and carbohydrate metabolism, 132

sugar and starch, *378
in sulfonyleurea therapy study, 60, 68
and suspected maternal diabetes, *170
and tissue response to insulin, 21
Torula yeast, *114
vitamin B₆ deficient-, 515
DIETHYLAMINOETHYL CELLULOSE, 71, 72
DIGUANIDES, *53
DIHYDROXYACETONE, *382
3,5-DIMETHYLPYRAZONE
and carbohydrate and fatty acid metabolism, 507-514
DIPHOSPHOPYRIDINE NUCLEOTIDE, 18
DIPHThERIA, 8, 723
DISULFRAM, *114
DPN. *See* Diphosphopyridine nucleotide
DRUGS
addiction and glucose tolerance, 477
adverse reactions reporting programs, 480
antihypertensive
and glucose tolerance, *377
benzothiadiazine
and carbohydrate metabolism, *612
and glucose oxidase test, 225
and nonketoadicotic coma, 162
and prediabetes, 593
prescription
and advertising, 506, 525
DUPUYTREN'S CONTRACTURE
and diabetes, 261
DWARFISM
and growth hormones, 562, *613
with hypoglycemia, *613

E

ELECTRICAL POTENTIAL
and sugar transfer, *47
ELECTROCARDIOGRAPHY, *168
and exercise, *317
in juvenile diabetes study, 241, 267
ELECTROPHORESIS
of fluorescent insulin, *51
of free and bound insulin, *608
of growth hormone, *610
and insulin binding, 564
of insulin-I-131 antibody complexes, *50-51
and insulin-like activity assay, 809
in juvenile diabetes study, 251
paper
and exercise, *317

of plasma proteins, 788
polyacrylamide gel, *50-51
serum fraction, 27-32, 72-73, 76
serum glycoproteins, *168
and serum insulin-like activity, 649
serum protein, *116
tumor glucagon, *53
ELECTROENCEPHALOGRAPHY
in juvenile diabetes study, 241, 259
ENCEPHALOPATHY, 424, 428
ENDOCRINE GLANDS
and carbohydrate metabolism, *452
disorders, *317, *818
and diabetes, 300-303
and insulin resistance, 432
and thymic hormone, 331
and infants of diabetic mothers, 371
and insulin-induced hypoglycemia, *169
polyendocrinopathy, *48
and vitamin B₆ deficiency, *380
ENTEROPATHY, DIABETIC, *455
ENZYMES
activity and glucose 6-P, *749
and carbohydrate metabolism, *683-684
conversion in liver, *233
and diabetes, 370, 373
and fatty acid synthesis, *232
and glucocorticoids, 484
and gluconeogenesis, 307
and lipogenesis, *236
and glucose metabolism, 355-359
and glycogen synthesis, 306, *533, 734-735
and glycolysis and tricarboxylic acid cycle, *377
hepatic and pancreatic, 146
and hypoglycemia, 333-338
and insulin, 87, 633, 662
and liver carbohydrate synthesis, *378
metabolism
and low pH levels, *113
pancreatic
and fibrocystic disease of pancreas, *117
and plasma arachidonic acid, *681

EPILEPSY
and diabetes, 259
and fructose intolerance, 337
EPINEPHRINE
and adipose tissue electrical potentials, 529-530
and arachidonic acid in pancreatectomized dogs, *681
and blood glucose, 156, *747
and 3,5-dimethylpyrazole, 508, 514
and fatty acid release and lipolysis, *231
and hyperglycemia, *235, 353
and hypoglycemia, 333-335, 338, 536

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

- and insulin secretion, *444
and lipid synthesis, and glucose and fatty acid metabolism, *446-447
and metabolism, 561, 562
in muscles, *378
in obese adolescents, *746-747
and nonketacidotic coma, 162
and obese adolescents, *610
and phosphorylase activity, *534
response in infants, *815
- ERYTHROCYTES**
and blood sugar concentration, 672
and galactosemia, 335
and glucose movement, *232-233
glucose-6-phosphate dehydrogenase deficiency, *315
- ESTROGENS**
and diabetes, 368, *452, *458
and partial pancreatectomy, 593
- ETHANOL**, 15
assay
Fisher method, 15
Harger dichromate method, 15
Somogyi method, 15
effect on lipids, ketones, and blood sugar, *52, *171
and glucose uptake, *172
and hypoglycemia, 350-360, *448
and iron, 144
and lipid metabolism, *533
metabolism, 14-18
precipitates, 26
- ETHYL-a-p-CHLOROPHENOXY-ISO-BUTYRATE**, *467
- EUROPE**
Sweden
diabetes detection in, *531
mass diabetes survey, *534-535
- EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES**, 812-813
- EXERCISE**
and blood sugar, *317, 419
and calorie expenditure
device for measuring, *814-815
and free fatty acids, *380, *611
and glucose utilization, 369
and juvenile diabetes, 677
and serum cholesterol and liver lipids, *533
- EYE**
blepharoptosis, and diabetes, *455-456
diabetic changes in, 41, 428
in juvenile diabetes, 241, 257
and microangiopathy, *47
and pituitary irradiation, 310
visual acuity and vascular anatomy, 126
- F**
- FAMILY HISTORY**, *116, 371
and carbohydrate tolerance and tolbutamide response of obese children, *438-439
and diabetes detection
in Sweden, *531
test, *454
of diabetics and nondiabetics, *609
and glucose tolerance tests, *318, 473, 477, 481, 482, 489
and hyperlipemia, 258
and hyperthyroidism and diabetes study, 741
and insulin
antagonism, *438
-like activity, *170
in juvenile diabetes study, 242
and marriage, 260
and multiple sclerosis, *464
and obesity, *612
in phenformin hydrochloride study, *465
and postgastrectomy hypoglycemia, 526
and prediabetes, 175
and red faces, 201, 204
and RH negative pregnant subjects, *460
and South African diabetics, *470
and study of menarchial age of diabetics, 788
and synalbumin antagonism, 566
- FATTY ACIDS**
and acetate I-C-14 incorporation, 709-715
and basement membrane thickening, 370
in depot fat
and diet, 395
and diabetes onset, 411
esterified
and alloxan diabetic rats, 180, 182, 184
and pancreatectomized dogs, *681
and triglyceride determination, 636
free
and adipose tissue, 181, 184
and amino acid nitrogen, *448
and blood sugar, 369
determination, *684
and diabetic acidosis, 370
and diazoxide, *610
and emotional stress, *467-468
and estrogen, *458
and ethanol, *52, *171
and exposure to cold, *379, *683
and glucose
ingestion, *748
and insulin in pregnancy, *113
tolerance tests, 77-82
utilization, *455
and growth hormone, 374
and hormone activity, 87
and hyperlipemia, *232
and insulin, 633
and insulin-induced hypoglycemia, *532
and ketones and glucose, 286, 287
and medium-chain triglycerides, *448
metabolism, *233, 559-562
and 3,5-dimethylpyrazole, 507-514
and insulin, *117
and obese adolescents, *610, *746-747
and myocardial infarction, 84-86
and pancreatitis, *462
and phenformin and tolbutamide, *456
and stress, 380
turnover rate, *232
utilization, *531
and glucose carbon incorporation, 26
-glucose cycle, *117
glucose metabolism, *171
of human depot fat, 105
in juvenile diabetes study, 251
and lipogenesis, *457
metabolism
and carbohydrate metabolism, *171
and glucose, *684
and hormones, *231
in rat intestine, *535
mobilization
and growth hormone, 368
and insulin antibodies, 493
nonesterified
Dole's method for determination, 33
and glucose utilization, 370
and growth hormone, 44, 368
in maternal and cord plasma, *613
in pancreatectomized and normal dogs, 33-35
and phenethylbiguanide study, *461
and pregnancy, *377
rapid turnover theory, *171
and thiazide therapy, 133, 135
in thyrotoxicosis, *50
oxidation rate, *50
polyunsaturated
and diabetes, *463-464
and serum lipids, 332
release
and adipose tissue, *231
and insulin, *447
and steroids, *382
synthesis, 306
and alloxan diabetes, *232
hormonal effects, *446-447
and insulin, *683-684, *749
and net gas exchange, *115
- FETUS**
abnormalities
and sulfonylureas, 435-436
of alloxan-diabetic rats, 724-728
beta cell granulation
and glucose, *444-445

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-543	December, 755-824

- emia,
287
erides,
507-
*610,
86
mide,
n, 26
*171
mal
461
- blood sugar levels, *235
and diabetic pregnancy, 372
and glucose and fructose metabolism,
*113
and hyperglycemia, 137-141
indications for early delivery, 158
and insulin, 573-578
and maternal diabetes, 44, 435
and maternal prediabetes, 175-176,
*485, *681
mortality, 261
and urinary estriol treatment, *682
and placental gradient, *172
plasma insulin and blood sugar, *381
- FIBRIN
and diabetic glomerulosclerosis, 756,
765
- FIBRINOGEN, 756, 767
- FIBRINOLYSIS
and phenformin, *532
- FLUORESCIN ISOTHIOCYANATE
and insulin, 274-278
- FOOD
intake, and methylprednisolone, 732
for juvenile diabetic campers, 679-680
- FORMOL-DIMEDONE, 180
- FRANCE
and diabetes, 214, 221
- FRUCTOSE
autoclaved, *48
and electrical potential studies, *47
and ethanol ingestion, 14, 359
and glucose tolerance tests, 96
intolerance, and enzyme defects, 333,
335-336
metabolism, *113, *446
tolerance
in infants, 156
and uremia, *169, *459
uptake, and insulin, *115
- FRUCTOSE-1-6-DIPHOSPHATE, 147
- FRUCTOSE-6-PHOSPHATE, *52
- FRUCTOSE-1-PHOSPHATE ALDO-
LASE, 336
- FRUCTOSURIA
and hereditary fructose intolerance,
335-336
- FURUNCULOSIS, 77

G

- GALACTOSE
and blood glucose levels, 156
and cataracts, *611
and electrical potential studies, *47
and glucose tolerance tests, 96, 335

- induced hypoglycemia, *681-682
and insulin-like activity, *444
- GALACTOSE-1-PHOSPHATE, 335
- GALACTOSE-6-PHOSPHATE, *52
- GALACTOSEMIA, 44, *681-682
and enzyme defects, 333, 335
- GAMMA GLOBULIN
insulin-like activity, 71-76
and serum assay of bound and free in-
sulin, 397
- GANGRENE, 516, *531, 761
of feet, *172
and mortality, 221
and neuropathy, 7, 426
- GASTRIC SECRETION
and insulin, *316
- GASTRIN, *316
- GASTROINTESTINAL TRACT, 295
bleeding, and nonketoacidotic coma,
162
and diabetes, 371, *465
disturbances
and diabetic neuropathy, 428
and sulfonylurea therapy, 67
and glucose, 193, 345
and insulin
hypoglycemia, *532
secretion, *167, *168
and pancreas, *48
and phenformin overdose, 811-812
in pregnancy, *683
proteinases, and insulin activity, 698
and pyrazole action, 514
surgery, and hyperinsulinism-hypogly-
cemia, 526-528
and tolbutamide, *814
- GENES
and abortions and stillbirths, 340, 367
and biochemical defect, 41
and diabetes, 43, 221, *234, 371, 519,
550, 610
juvenile, 780
potential, 491
and fatty acid metabolism, 709
and hyperthyroidism and diabetes, 743
and insulin antagonism, *438
and prediabetes, 481
and renal lesions, 550
and retinopathy, *379
- GERMANY
and diabetes, 214
- GLOMERULI
of prednisolone-fed rabbits, 600-602
- GLOMERULOSCLEROSIS, 310
and auto-immune reaction, 402
cause of, 110
and cortisone, 595

- and diabetic dogs, 706, 709-710
and electron microscopy, 310, 604
experimental diabetic, *377
and glomerulonephritis and systemic
lupus erythematosus, *441-
442
and insulin, 276, 278, 551
in juvenile diabetes study, 265-266
and prediabetes, 550
and renal lesions, 755-770
and retinal lesions, 517

- GLUCAGON, *50
and amino acid nitrogen, *447
and alcohol hypoglycemia, 351, 353
and blood glucose, 156
and bronchogenic metastases, *53
and cobaltous chloride, 51
and fasting, *816
and free fatty acids, 87
-free insulin, *169
and glucose, 368
and glucose anomers, *747
and hypertriglyceridemia, *611
and hypoglycemia, 333, 334
immunoassay, two-antibody system,
*450
-induced hyperglycemia, *444
and insulin, 368
and islet cell tumors, *115
and lipid synthesis and glucose metab-
olism, *446
and liver, *167
and phosphorylase activity, *534
and plasma arachidonic acid in pan-
createctomized dogs, *681
radioimmunoassay, *167
test, 100, 101-102

- GLUCOCORTICOIDS
and glucose tolerance test, 481, 484
and pancreatic islets, 194, 198

- GLUCOKINASE
and insulin, *468

- GLUCONEOGENESIS
and adrenal cortical hormones, *113
and adrenal steroids, 729-736
and alcohol ingestion, 350-360
and diet and hormones, *445
and enzymes, *236, 306
and hypoxia, 104
increase, 333
and stress, 518

- GLUCOSAMINE
and atherosclerosis, *380

- GLUCOSAMINE-6-PHOSPHATE, *52

- GLUCOSE
and amino acids, *235
and beta cell granulation, *444-445
breakdown to glycogen, and insulin,
*815
concentration in liver, *167

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58
February, 59-120
March, 121-174
April, 175-238

May, 239-324
June, 325-386
July, 387-472
August, 473-548

September, 549-618
October, 619-688
November, 689-754
December, 755-824

- cortisone tolerance tests, 481-487
- disposal
 - in elderly diabetics and nondiabetics, 579-582
 - and intestinal mucosal extract, *440-441
- and electrical potential studies, *47
- and ethanol metabolism rate, 14
- and fat metabolism, *235
- fatty acids
 - cycle, *117, 369
- and fatty acids
 - free, *534
 - metabolism, *684
 - release, *231
 - synthesis, *683-684
 - uptake, *171
- and hyperinsulinism, *49
- and hypoglycemia, 249, 344-346
- and infant acidosis, 160
- inhibitors, *51
- and insulin
 - dosage, 280-281
 - and free fatty acids in pregnancy, *113
 - in pregnancy, *381
 - response, *683
 - secretion, *444
- intolerance
 - azotemic, *459
 - and diabetic neuropathy, 428
- intravenous and oral, *168
- and islet cell secretion, 305
- kinetics, and diabetes, 373
- and lipogenesis, *447
- loading
 - and acromegaly, *167
 - and insulin-like activity, 10, 11, 12, 71, 72-76
 - and serum insulin assays, 27-32, *116
- in maternal and cord plasma, *613
- metabolism, *50, *236
 - and adrenal steroids, 729-736
 - and fatty acids, *171, 374
 - and glucose-6-phosphate, *468-469
 - and glycosides, *534
 - and growth hormone, *379
 - hormonal effects, *446-447
 - and insulin, *682, 689-695
 - and insulin antibodies, 369
 - of islet cell tumors, *49
 - in leucocytes of diabetics, 584-590
 - and liver, *466
 - and L-xylulose, 311
 - and nutrition, *746
 - in obese adolescents, *610, *746
 - in pregnancy, *609
 - in sheep fetus, *113
- movement
 - in erythrocytes, *232-233
- and newborn infants, 127, 156
- output and hypoglycemia, *114
- and palmitate, *171
- and pancreatic changes, 493-500
- and pancreatic diabetes, 93
- phosphorylation, 26, 306
- and plasma insulin, 778
- and plasma lipids, in pregnancy, *609
- and respiration, *685
- response in normals, *442
- and serum insulin, *470, *532-533
- and sulfonylureas, 209-211
- tasting tests and diabetes, *536
- and thiazides, *115
- tolerance
 - and age, sex and test conditions, 413-422
 - and antihypertensive drugs, *377
 - and atrophy, *454
 - and cortisol, 194
 - and diet, *611
 - in fasting diabetics and nondiabetics, *442
 - and growth hormone, *444, 557-559
 - and hyperthyroidism, 740-743
 - and insulin, *314
 - and L-leucine sensitivity, *47
 - and mebanazine, *236
 - and multiple sclerosis, *464
 - and myocardial infarction, 84-86
 - and obesity, *378, 553-556, 559
 - in old age, 579-583
 - and renal disease, 550
 - and serum insulin, *457-458
 - and triglyceride-induced hyperketonemia, *448
 - and uremia, *169
- tolerance tests, *52, 53, *316
 - and adrenal steroid therapy, *114
 - and asteroid hyalitis, *171-172
 - and atherosclerosis, *682
 - and blood saccharoid, 719-722
 - and chronic hypoxia, 100-104
 - compared, 481-487, *535
 - and coronary heart disease, *116-117
 - and diabetes detection, 202, *315, *462, *531, *685
 - and diabetes with endocrinopathies, 301
 - and diabetic heredity, *318
 - and diazoxide hyperglycemia study, 592-594
 - and erythrocyte deficiency, 315
 - and free fatty acids, 77-82
 - Hagedorn-Jensen, 209
 - and hematocrit analysis, 672-674
 - and hypertension, *749
 - in juvenile diabetes study, 242
 - new, 296, 297
 - new carbohydrate solution for, 96-99
 - and normals and potential diabetics, *466
 - and normal urine, *609
 - and obesity, *438-439, *612
 - oral
 - and oral sodium tolbutamide tests compared, *451
 - reproducibility study, 473-479
 - and RH negative pregnancy, *460
 - and Oxford, Mass., diabetes survey, *461
 - and phenethylbiguanide study, *461
 - and postgastrectomy patients, 526-528
 - in prediabetes, 175
 - prednisone, 489-491
 - in pregnancy, *170, 371
 - and premature artery disease, *611
 - rapid intravenous, *683
 - and reactive hypoglycemia with mild diabetes, *612
 - and thiazide therapy, 132-133
 - in thyrotoxicosis, *50
 - and tolbutamide tolerance tests, *536
 - triamcinolone-, 481-487
 - and xerostomia, *48
 - transformation to glycogen, *235
 - transport, 368
 - and adipose tissue electrical potential, 529
 - and insulin, *815
 - and polyphosphates, *749
 - and protein synthesis, 662
 - and true anaphylaxis and granuloma formation, *116
 - uptake
 - and albumin antagonism, *356-357
 - and anaerobiosis and cell poisons, 128-131
 - by fractured dog limbs, *383
 - and insulin, *117
 - and insulin inhibitors, *115
 - and ketosis-resistant diabetes, *814
 - and lactate production, 310
 - of muscle tissue in diabetics, 716-718
 - new test for, 186-193
 - rat hemidiaphragm, *438
 - and secretion, *167
 - urine tests, 59, 224-225
 - utilization, 8
 - and alcohol hypoglycemia, 350-360
 - by chick embryo heart homogenates, *746
 - and chlorothiazide therapy, *612
 - and exercise, 369
 - and fatty acids, 370
 - and insulin, 341-349, *455
 - and intestinal absorption, *314
 - and ischemic heart disease, *234
 - and morphine, *172
 - and plasma sugar determinations, 165-166
 - and thyroid enzymes, *377

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

and fructose, 336
incorporation
 and insulin, 19-26
 into lipids, *457
and insulin assays, 309
and insulin study of pancreatized
 dogs, 689-695
and liver glycogen synthesis in dogs,
 *531
metabolism
 and blood reticulocytes, *747
 and 3,5-dimethylpyrazole, 508
 and hormones, *231

GLUCOSE-U-C-14
 uptake, *443

GLUCOSE OXIDASE METHOD, 127,
 224-225

GLUCOSE-6-PHOSPHATASE, *115,
 *682
 and Embden-Meyerhof pathways, *446
 and hypoglycemia, 337
 pancreatic, 146-156

GLUCOSE-6-PHOSPHATE, *52, *682
 and glucokinase inhibition, 307
 and glucose metabolism, *468-469
 and glycogen synthesis, 735
 and liver enzyme activity, *233, *749

GLUCOSURIA
 in pregnancy, 482

GLUTAMATE
 and Krebs cycle, *748

GLUTAMIC-OXALACETIC TRANS-
 AMINASES, 637

GLUTAMIC-PYRUVIC TRANSAMINA-
 SES, 637

GLUTATHIONE, 133, 135, 136
 -insulin transhydrogenase, 369, *749

GLUCOCORTICOID
 and diabetes, 550, 556

GLYCEMIA
 and diabetic lesions, 550
 and myocardial infarction, 84, 85
 in pancreatized and normal dogs,
 34

GLYCERIDES
 and sugar and starch ingestion, *378

GLYCERIDE-GLYCEROL
 activity of plasma lipoprotein, *467
 formation, 184
 and hormones, *231

GLYCEROL
 and fat metabolism, *235
 and fat pads of diabetic rats, 180, 181,
 183, 184
 mobilization in diabetes, 77

GLYCEROPHOSPHATES, 147
 and alloxan diabetic rats, 183, 184, 185

GLYCINE
 incorporation into protein, *171

GLYCOGEN
 activity studies, *52
 and anaerobiosis, *749
 content
 and diabetes, *682
 of rat liver, heart, and muscle, *232
 conversion to lactate, *115
 determinations
 Good, Kramer and Somogyi, 209
 formation and glucose-6-phosphate,
 *468-469
 and glucagon, 102, 104
 glucose transformation to, *235
 and infants of diabetic mothers, 436
 in livers of Indian diabetics, 408
 metabolism and insulin, *233
 and muscle glycogenesis, *169
 in normal and diabetic nerve tissue,
 *447
 and obesity in infants of diabetic
 mothers, 724
 and ouabain, *534
 and palmitate, *171, *455
 in pancreas beta cells, *450
 of rat diaphragm and adipose tissue,
 19-26
 storage disease
 and enzyme defects, 104, 333-338
 synthesis, 306, 729, 734-735
 and albumin, *457
 and insulin, *531
 and metabolism, *533
 and puromycin and actinomycin D,
 *236

GLYCOGENESIS
 and enzyme defects, 333-338
 and hyperthyroidism, 743

GLYCOGENOLYSIS, *534
 and adrenalin, 345
 and ethanol ingestion, 355
 and hyperthyroidism, 743
 inhibition, *171
 and D-ribose, *685

GLYCOGENOLYTIC AGENTS
 and liver phosphorylase, *534

GLYCOGENOSIS
 and skeletal muscle, *169

GLYCOLYSIS
 and insulin, 369

GLYCOGENOGENESIS
 and chlorpropamide, 209-211

GLYCOPROTEINS
 and diabetes and atherosclerosis, *168
 and prediabetes, *448-449

GLYCOSURIA, 43, *236, 397
 in alloxan diabetic mice, 325
 and alloxanized rats, 181, 502
 and diabetes
 diagnosis, 527, 700
 severity, 60
 study in India, 407
 and diabetic lesions, 550
 and diet-induced diabetic syndrome,
 *441
 and family history study, *609
 and fasting blood sugar values, 3
 and glucocorticoids, 194, 481
 and glycoproteins in hamsters, *448-
 449
 and growth hormone, *444
 and hypoglycemia, *459-460
 incidence in British town, *53
 and insulin, *50, *449, *815
 and juvenile diabetes, 242, 246-247,
 *531
 and mass survey in Blekinge, Sweden,
 *535
 and myocardial infarction, 84, 85
 and nalidixic acid, *683
 and neonatal diabetes, *233
 and neuropathy, 1, 4, 518
 and oral hypoglycemia, 405
 and pancreatized dogs, 690
 in pancreatic and steroid diabetes, 93-
 95
 postprandial, *464
 and prediabetes, 175
 and prednisolone-fed rabbits, 595-596
 and pregnancy, *170
 and pyruvate levels, *231
 renal, and itching, *168
 and retinopathy, *379

GOLGI COMPLEX
 and cortisone-alloxan-treated rabbits,
 793, 794, 796, 802

GONADOTROPINS, *452, 562

GOUT
 and reducing diets, 739

GREAT BRITAIN
 diabetes in, *48, 214, 221
 survey in village, *53

GREECE
 and diabetes incidence, 215

GROWTH HORMONE
 and alloxan diabetes, *50
 antagonism, and dwarfism, 562
 assays, *610
 and beta cell changes, 373
 deficiency, and hypoglycemia and
 dwarfism, *613
 -dependent sulfation factor, *172
 and diabetes, 43-45, 308, 369, 373, 411
 and glucose metabolism, 193, 311,
 *379
 and hypoglycemia, 333, *610

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

and hypophysectomy, *171
 -induced diabetes
 and retinopathy, 705
 in infants, *378
 and insulin
 antagonism, 368
 secretion, *167, *444
 and lipogenesis, 369
 and lipolysis, 369
 measurement, *315
 and metabolism, *117, *231
 and obesity, 370
 and plasma free fatty acids, 556
 and prediabetes, 369-370
 radioimmunoassay, *167
 role, 374
 secretion, and diabetes, 550, 552, 556-558
 and serum insulin response, *683
 and sex, 370
 survival in plasma, *50
 and thymic activity, 331

H

HASSAL'S BODIES, 329, 331

HEART

carbohydrate and fatty acid metabolism, *171
 free fatty acid utilization and acetate, *531
 glucose utilization, *746
 glucose uptake, and adrenal steroids, 735
 glycogen
 and amyloglucosidase, *232
 perfused rat
 and anaerobiosis, 128
 carbon dioxide formation, *685
 and ouabain, *534
 sugar penetration and inhibitors, *48

HEART DISEASE

coronary
 and race, *236
 and diabetic mortality, 221
 and diabetic neuropathy, 1, 2
 and glucose tolerance tests, *116-117
 ischemic
 and glucose utilization, *234
 and study of diabetic women, *169
 in juvenile diabetes study, 266-267

HEMATOCRIT, 165-166

HEMOCHROMATOSIS, *818

and kidneys, 277
 and neuropathy, 8
 and pancreatic antibodies, 227
 and retinopathy, *682
 and serum L-xylulose, 312
 and siderosis, 699, 708

HEMORRHAGE

adrenal glands, *815

and diabetic retinopathy, 264
 in induced pancreatitis in rats, 636
 retinal, 517
 metasomatotropin-diabetic dog, *378
 subarachnoid, in tubular necrosis patient, 33

HENLE'S LOOPS

in prednisolone-induced nephropathy, 599

HEPARIN, 186-187, 192

and insulin-like activity, 805-810
 and plasma insulin activity, 387
 and radioimmunoassay of serum insulin, 772-778

HEPATOMEGALY, 253, *465

HEREDITY

and diabetes, 41, 43, *116, *234, *318, 370, *609
 and diabetic atherosclerosis, 307
 and facial redness in diabetes, 207
 and fibrocystic disease of pancreas, *117
 and insulinase inhibition, 786
 and iron in osteoid seams, 145
 and juvenile diabetics, 107
 and neuropathies, 516, 518-519
 and obesity, *314

HEXOKINASE, *115

HEXOSE

intestinal transfer and phlorrhizin, *51

HISTAMINE

and insulin-like activity, *443

HISTIDINE

and insulin, *818

HODGKIN'S DISEASE

and serum L-xylulose, 312

HORMONES

binding to plasma protein, 562-565
 and blood sugar, 333
 and diabetes, 222, *234
 and diet in gluconeogenesis, *445
 and hyperglycemia and hypoglycemia, *469
 and induced hyperglycemia in rabbits, 792
 and insulin inactivity, 87-92
 from islet cells, 305
 and metabolism, 368, *446-447
 and neuropathy, 429
 ovine prolactin
 and metabolism, *231
 pituitary gonadotrophin
 and diabetic impotence, 428
 in pregnancy
 and free fatty acid increase, *113
 secretin
 and glucose uptake, *167
 sexual
 and diabetes, *452, 501-505

testosterone

and mammary glands of alloxan-diabetic rats, 501-505
 thymic reticular, 331

HYALINE MEMBRANE DISEASE, 158, 159, 160, 435, 436, 577

HYDRAMNIOS, 261

HYDROCHLOROTHIAZIDE, *115, 132

HYDROCORTISONE, *49

and glucose metabolism, 729-736
 and infant hypoglycemia, *815

HYDROXYBUTYRATE, 498

17-HYDROXYCORTICOID, 132, 133, 135, *169

17-HYDROXYCORTICOSTEROID

and infants of diabetic mothers, 436

HYDROXYHEXAMIDE, *456

HYPERAZOTEMIA, *236

HYPERBILIRUBINEMIA

and infants of diabetic mothers, 158-159, 161, 436

HYPERCHLOREMIA, 162

HYPERCHOLESTEROLEMIA

and diabetic neuropathy, 3
 and glucose metabolism in leucocytes, 584-590
 and high cholesterol diets, *611
 and retinal vascular changes, 121, 126

HYPERCORTICALISM, 95

HYPERGLYCEMIA, 43, 397, 425, 429

and alloxanized rats, 180, 181
 and antihypertensive drugs, *377
 and antisera, *170
 and beta cell
 activity, 306
 damage, 199
 granulation, 137-141
 and caffeine, *169
 and COCL₂-injected rats, *51
 and diabetes diagnosis, 176, 202
 and Dextrostix tests, *817
 and diabetic neuropathy, 517-518
 and dialysis, 37
 and diazoxide, *450, *469, 591-594
 and diet-induced diabetic syndrome, *441
 and ethanol, 353
 glucagon-induced, *444
 and glucocorticoids, 194
 and glucose disposal rate in elderly nondiabetics, 581
 glucose and insulin antibody induced, 493-500
 and glycogenolytic agents, *534
 and glycosuria, *168
 and growth hormone, *50, 193, *378, *444

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58
 February, 59-120
 March, 121-174
 April, 175-238

May, 239-324
 June, 325-386
 July, 387-472
 August, 473-548

September, 549-618
 October, 619-688
 November, 689-754
 December, 755-824

- and guinea pig anti-bovine insulin serum, *49
hormone-induced in rabbits, 792
hydrocortisone-induced
and 3,5-dimethylpyrazole, 508, 509, 514
and hyperketonemia, *458
and hyperosmolar coma, 164
and hyperthyroidism, 743
and hypophysectomy, 556
and hypothalamic gold uptake, *378
and insulin, *815
antiserum, 370
intestinal, 696-698
-like activity, *685
secretion, 345
and islet-cell formation, 368
and juvenile diabetes study, 240, 242, 246, 247, 249
and ketoacidosis, 290
and liver glucose production, 736
and nalidixic acid, *683
and obesity, *610
and pancreas islet and beta cells, 578
and pancreatic insulin regulation, 309
and peptide, *445
and phenformin, *465-466
and potential diabetes, 491
and red faces, 201
and retinopathy, 550
and sulfonyleurea therapy, *463
and thiazide therapy, 133, 134, 135
and thymic changes, 329
and xerostomia, *48
- HYPERGLYCERIDEMIA**
and carbohydrate tolerance, *458
- HYPERINSULINEMIA**, *52, *816
and alloxanized rats, 291
and Cushing's syndrome, *684
and diabetic neuropathy, retinopathy, nephropathy, and premature vascular disease, *685
and hypoglycemia, *314, 338, 344-346, 526-528
and insulin sensitivity, 552, 553
and maturity onset diabetes, 343
in multiple sclerosis, *464
and obesity, 553-555
and pancreas alpha cells, 334
and pancreatitis, *462
and pregnancy, *749
and tolbutamide, leucine, and glucose, *49-50
- HYPERKETONEMIA**, *235, *458, *683
and ethanol and wine, *171
and guinea pig anti-bovine insulin serum, *49
triglyceride-induced
and glucose tolerance, *448
and urate excretion, 739, 787, 804
- HYPERLIPEMIA**
and choline deficiency, 666-668
- and clofibrate therapy, *452-453
and diet, 332
and diet-induced diabetic syndrome, *441
and ethyl-a-p-chlorophenoxy-isobutyrate, *467
and fatty acid metabolism, 713
and insulin, 33-35
and phenformin, *465-466
of pregnancy, *609
postprandial
and glucose utilization, *234
- HYPERNATREMIA**, 162, 164
- HYPERPHAGIA**
and hyperglycemia, *378
- HYPERPHOSPHATEMIA**, 162
- HYPERPLASIA**, *115
adrenal
and diabetes, *169
of blood vessels
and diabetic neuropathy, 426
islet cell, 641
and exocrine pancreatic tissue, 194-200
in fetuses and infants of diabetic mothers, 44, 573, 574, 577
- HYPERPROTEINEMIA**, 604
- HYPERTENSION**, *168, 201
and diabetes, 126
and glomerulosclerosis, 759
and glucose tolerance, *377
and ischemic leg ulcers, *318
in juvenile diabetes study, 265, 266-267
and menarchial age of diabetic women, 788, 789
and neuropathy, 425, 428
and potential diabetes, 489
and pregnancy, 577
renal arterial
and diabetes, *748-749
- HYPERTHYROIDISM**
and blood glucose test, 186-187
and glucose tolerance, 740-743
- HYPERTRIGLYCERIDEMIA**, 250, 251
and carbohydrate metabolism, *611
and chlorophenoxyisobutyrate and androstosterone, *814
- HYPERTROPHY**, *115
islet cell
in fetuses and infants of diabetic mothers, 573, 574, 577
- HYPERURICEMIA**
and diagnosing diabetes, *116
and fasting, 787, 804
and reducing diets, 739
and thiazide therapy, 135
- HYPOGLYCEMIA**, *168, 429
adrenocorticotrophic hormone-induced, *748
and alcoholism, *233, 350-360
and alloxan diabetes, *235
and amino acid nitrogen, *448
and birth weight, *535
and calcium and magnesium, *462
and carbohydrate tolerance, *459-460
and diabetes, *314
and diabetic neuropathy, 1, 2, 3, 4, *114, 428
and diazoxide, *450, *469, *610
and dichloroisoproterenol-treated rats, *447
and diguanides, *53
and dwarfism, *613
and enzymes, 333-338
and enzyme strip test, *452
and epinephrine, *235
and face color, 201
and free fatty acid levels, 78
and glucose tolerance testing, *52
and growth hormone, *315, 374, *378, 558
and hyperglycemia and glycosuria, *459-460
and hypothermia, *233-234
and infants, *468, *815
and insulin
activity, 431
insulin-induced
adrenocortical response, *169
and antisera, *170
and epinephrine, *536
and gastric secretions, *532
and growth hormone concentration, *50
and plasma free fatty acids, *532
and postgastrectomy, 526-528
and insulin
resistance, *377, *818
secretion, 341-348
therapy, 162
and islet cell tumors, *115
and juvenile diabetes study, 240, 245, 249-250, 259
and ketone bodies, *531
ketotic, *315
and labile diabetes, 287
lactose- or galactose-induced, *681-682
leucine, *439
and L-leucine, *47
and multiple sclerosis, *464
neonatal, 127, 156, 261
and neuropathy, *234
and newborn calves, *49
and pancreas tumor, *53
and pancreatectomy, *683
and pancreatic extracts, 389
and pancreatitis, *462
and phenformin, 812
postprandial and Regular Insulin, *316
and premature infants, *613
and Protamine Zinc Insulin, *534

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-549	December, 755-824

- and protein synthesis, 633
and pyridoxine-deficient diet, *380
and salicylate poisoning, *315
reactive, and mild diabetes, *612
and D-ribose, *685
and shock
 during sulfonyleurea therapy, *377
 and sugar determinations, 166
 and sulfated insulin, *440
 and thiazides, 132
 and thymic changes, 325, 328-331
 and tolbutamide, *114, 315, 606-607, *816
 and Wilm's tumor, *316
 and xerostomia, *48
- HYPOKALEMIA**
 and thiazide therapy, 135
- HYPONATREMIA**, 162
- HYPOPARATHYROIDISM**
 and infants of diabetic mothers, 436
- HYPOPHOSPHATEMIA**, *49
- HYPOPHYSEAL GLAND**
 and hypoglycemia, 334
- HYPOPHYSECTOMY**, 556, 557
 and adipose tissue metabolism, *171
 and diabetic retinopathy, 43
 and diazoxide, *469, 591, 592
 and growth hormone concentration, *50
 and insulin response, 368
 and insulin-like activity in dogs, 658-661
 and ketone bodies, 556
 and lipids and hormones, 33-35
 and retinopathy, 558
 and sodium and aldosterone metabolism control, *316-317
 and sulfation-factor, *172
- HYPOPHYSEO-ADRENAL FUNCTION**
 in diabetic angiopathy, *53
- HYPOPHYSECTOMY**
 and diabetes mellitus, *50
 diagnosis, *315
 and hypoglycemia, 348
 and irradiation in retinopathy, 308
- HYPOPROTEINEMIA**, 126
- HYPOTENSION**
 and diazoxide, *469
 and fasting for obesity, *532
 and hypophysectomy, *316-317
 orthostatic, 7
 responses to, 562
- HYPOTHALAMUS**
 and diabetes, *233, 425
 during hyperglycemia, *378
 and vitamin B₆ deficiency, *380
- HYPOTHERMIA**
 and hypoglycemia, *233-234
- HYPOTHYROIDISM**, 300, *455
 and hypothermia, *234
- HYPOTONIA**, *456
- HYPOXIA**
 and carbohydrate metabolism, 100-104
 and lactic acidosis, 162
 and phenformin, *464-465
- I**
- IMMUNOCHEMICAL METHOD**, 28, 31
- IMMUNOELECTROPHORESIS**, 27, 31, *170
 antisera, 755-756
 growth hormone, *610
 and pancreatic isoantibodies, 227
 and serum proteins, *438
- IMMUNOGLOBULIN**, 755, 756
- IMMUNOHISTOPATHOLOGY**
 of diabetic glomerulosclerosis, 755-770
- IMPOTENCE**
 and diabetes, 370
 and diabetic neuropathy, 5, 7, *47, 267, 427, 429, 520
- INDIANS**
 and diabetes mellitus, *236
- INFANTS**
 big, 28, 77
 and diabetic susceptibility, *612
 and hyperthyroidism and diabetes study, 741, 743
 and maternal diabetes, 481, 482, 577-578
 and maternal prediabetes, 550
 and prediabetic parents, 175-177
 congenital malformations, 160, 161
 and hypoglycemia, *815
 and maternal diabetes, 160, 161, 260, 371, 429, 436, 482
 and urinary estriol, *682
 and diabetic parents, 260
 fatty acid determination method, *684
 and fibrocystic disease of pancreas, *117
 and fructose intolerance, 336
 glycogenesis, 333, 337
 growth hormone metabolism and secretion, *378
 hyperglycemia, 137
 hypoglycemia, *115
 hypoglycemic
 and diabetic plasma injections, *613
 and maternal diabetes, *53, 157-161, 372, 435-437, 520, 724
 and maternal diabetes
 and allergic pancreatitis, 641
 and islet cell hyperplasia, 44
- neurologic abnormalities, 425, 429
and pancreas insulin content, 573-578
and serum proteins, *438
tolbutamide tolerance tests, *468
- neonatal
 and blood sugar, *815
 and diabetes, *233
 and hypoglycemia, 127, 156
premature, and hypoglycemia incidence, *613
with RH negative and diabetic mothers, *460
stillborn, and chromosome abnormalities, 340, 367
- INFECTIOUS**
 and juvenile diabetes, *317-318
- INSULIN**
 and acromegaly, *167
 activity
 augmentation, 10-13
 and calcium and magnesium, 430-431
 and diet and minerals, *114
 extrapancreatic regulation, 309
 and obesity and starvation, *748
 and adipose tissue, *454
 electrical potentials, *451, 529-530
 inactivation, 87-92
 and adipose tissue metabolism, 307
 and alcohol hypoglycemia, 351, 353-354
 and alloxan diabetic rat fetuses, 727
 and alloxanized pregnant rats, 137, 139
 and amino acid incorporation, *115
 antagonism, 82, 86, 369, 373, 610, 810
 and albumin, *456-457
 and chlorthalidone, 435
 in elderly nondiabetics, 581
 and glomerulosclerosis, 755, 756
 and glutathione-insulin transhydrogenase of liver, *749
 and growth hormone, 368
 and lesions, 518
 and siblings of diabetics, *438
 antibodies, *449, *747-748
 assay, *449
 and glomerulosclerosis, 551
 and insulin binding, 396-402
 in insulin-resistant diabetes, *52
 and pancreas studies, *449-450
 and anti-insulin serum, *49, 637, 638
 and arterial cholesterol uptake, *746
 assay
 Grodsky and Forsham immunochemical method, 28
 intraperitoneal, *443
 and resistance to insulinase, 783-786
 spectrophotometric, *468
 tumor slices, *49
 autoimmunity, 551-552
 and beta cell phosphatase activity, *168
 beta chain, and albumin, 568

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

- binding
and antibodies, *51, *531
and cationic exchange resins, *316
and fluorescein isothiocyanate, 51
and insulin antagonism, 563-568
and blood glucose
anomers, *747
regulation, 308
and blood, symposium, 308-309
"bound," activity, *443
bovine, 14, 15
absorption in newborn calf, *117
and antibodies, *170
and bronchogenic metastasis, *53
and carbohydrate metabolism, *233, 307, *380
cod and ox, 306
and citrate-cleavage activity, *683-684
concentration, in thyrotoxicosis, *50
crystalline, 565
beef, *449
and "bound," *443, *683
in diluted serum, 10, 11
and postprandial hyperlipemia, *234
crystalline zinc
and blood sugar study of children, *460
and protein incorporation, *167
deficiency
and epididymal adipose tissue, *382
and hormonal activity, 505
and retinopathy, *379
and diabetes control study, *469
and diabetes study in India, 405, 408
and diabetic angiopathies, 110
and diabetic lesions, 310, 551
and diazoxide hyperglycemia, *450
and diet, 121-122
dosage, 2
and aged diabetics, 47
in alloxan diabetes and ketoacidosis study, 290
and juvenile diabetic campers, 678
electrolytic reduction of disulfide bonds, *235
and emotional stress study, *467-468
and enzyme activity, 307, 633, 662
and ethanol metabolism rate, 14, 16, 17, 18
and exercise, *317
and fat metabolism, *235
and fatty acids, *232, 709-715
free, 77-82, *380, *447, *534, 559-561
and fluorescein isothiocyanate uptake in kidney tissue, 274-278
free and bound, 12, *608
functions, *815
and gastric secretion, *316
and glucagon, 368
glucagon-free, and amino acid nitrogen, *448
and glucokinase, 307, *468
and glucose, *168
disappearance rate, 156
and free fatty acids, *113
intolerance, *169
response in azotemia, *459
transport, 369
uptake, 128, 131
utilization, *455
and glyceride levels, *458
and glycogen synthesis, *236
and glycosuria control, *50
and growth hormone, 43, *50
and hepatic tissues, electrical potentials, *451
history, 37-40
and hyperthyroidism and diabetes study, 740
and hypoglycemia, *49, 162, *169, 333-334, *462, *532
and epinephrine, *536
and hypothermia, *234
lactose or galactose induced, *682
and oral administration, 696-698
immunoassay
and alloxan, 669-671
Berson and Yalow, *470
enzyme hydrolysis, *460-461
pancreatic and serum, 387-390
of prediabetics, 370
inactivation, and photo-oxidation study, *818
inhibition, and antagonism, *117
inhibitors, *115
albumin, *608
diazoxide, *439
insufficiency, and fatty acid synthesis, *749
and insulin-like activity, *684-685
intra-peritoneal action, 19-26
and juvenile diabetics, 41, 107, *317-318, 240, 245-246, 249, 780-786
and ketosis-resistant diabetes, *814
Lente, compared to NPH, *457
and lesions, 43
-like activity
in animals and man, *52
and anti-sera, 369-370
assays, 10, 27, *48, 78, 79, 387-390, *443, 580, 643-649, 713-714
and glucose and mannose, *444
and glucose response in normals, *442-443
and heparin, 805-810
and hypophysectomy and pancreatotomy in dogs, 658-661
and immunoreactive insulin in serum and lymph, *463
and juvenile diabetes, *49, 619, 630
in serum proteins, 71-76, *116
in urine, *681
-like thymic factor, 325-331, *447-448
and lipid formation, *457
and liver, *167
glucose balance, 307
glycogen synthesis in dog, *531
potassium uptake, 307
lyophilized gelatin, 10
metabolism, 84-86
of muscles, *378
in obese adolescents, *746-747
and pancreatitis, *462
studies, *117
and mitochondria phosphorylation, 516
and myeloschisis, *172
and N-acetyl-DL-homocysteine thiolactone, *236
and neonatal diabetes, *233
and nerve conduction, *232
and neuropathy, *234, *682
NPH
and blood sugar studies of children, *460
compared to Lente, *457
and pancreas tumor, *53
and pancreatectomy, 14, 16, 93, *683
and adrenal steroids, 730, 731, 732, 735
pancreatic, and spontaneous diabetes in mice, *747
and phenformin, *465
and phosphorylase activity, *534
and plasma lipids in pregnancy, *609
pork
and hypophysectomized dogs, 659
pork and beef
and antibody-binding capacity, *816
pork I-131, 772, 773
and pregnancy, 175
Protamine
and pancreatectomized dogs, 33-35
Protamine Zinc, *440
and alloxan diabetic rats, 179-184
and chickens, *534
and choline deficiency study, 666-667
and hypothalamic-obese rat, *233
and pancreatectomy, *613
and vitamin B₁₂ deficiency, 515
and protein
metabolism, 306
synthesis, *168-169, *533-534
and pyridine nucleotides, *446
and pyruvate levels, *231
radioimmunoassay, *167, *816
double antibody technique, 771-779
and glucose, tolbutamide, and L-leucine, *49-50
Rapitard and Actrapid, *685
Regular, 36, *316
and hypoglycemia, *459
and pancreatectomy, 33-35, *683
release
and basement membrane thickening, 110
and leucine, *439
requirements, 373
and high fat diet, 369
and hyperlabile diabetes, 279-288
resistance, 432-434
and acromegaly and Cushing's syndrome, 556
and adrenal steroids, *235, *818
and glucose uptake of muscle tissue, 716-718

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

to insulinase in juvenile diabetics, 780-786
 and 6-mercaptopurine, *612
 and peptide, *445
 and pregnancy, *377
 response
 adipose tissue, *454
 and glucose-6-phosphatase pathways, *446
 and hypertriglyceridemia, *611
 to ingested protein, *442
 role of, 8
 -secreting tumors, *115
 secretion
 and carbohydrate-restricted diet, *748
 endogenous, 12
 and glucose metabolism, 305, 689-695
 and growth hormone, *444
 in hypoglycemia, 341-348
 and insulin antibodies, 493-500
 in juvenile diabetes, 619
 and pancreas beta cells, *459
 and pancreas islet changes, 550, 552
 and regulation, *232
 study, *444
 sensitivity, *613
 and obesity, *378, *611
 and serum L-xylulose, 311
 and starvation, 556
 and steroids, *381-382
 and sugar inhibitors, *48
 sulfated, and insulin-resistant diabetes, *440
 and sulfhydryls, *114
 and sulfonylureas, 60, 63, 66-67, 103-104, *114, 392-394
 and tolbutamide, and blood glucose, *114
 tolerance
 and phenethylbiguanide, *461
 tests, *315
 and true anaphylaxis and granuloma formation, *116
 Ultralente, 36
 uptake
 and thiazides, *115
 and vitamin B₆ deficiency, 515
 and water uptake, *379
 Zinc, and photo-oxidation, *818

INSULIN I-125
 and antibodies to insulin, *449
 and insulin radioimmunological assay, *816

INSULIN I-131
 antibodies, *51
 and electrophoresis, *50-51
 and autoantibodies study, 397-402
 binding, 27-32, 564-566, 568
 immunochemical aspects, 309
 and insulin assays, 344-345
 purification and study, *381

and serum protein fractions, *534

INSULINASE
 and insulin breakdown in juvenile diabetics, 780-786

INSULINOMA
 diagnosis, *816

INTERNATIONAL DIABETES FEDERATION, FIFTH CONGRESS, 305-310, 368-373

INTESTINES
 and fatty acid metabolism, *535
 and glucose, *314, *440-441
 hexose and fluid transfer, *51
 insulin transport, *117, 696-698
 and leukemic mice, 325, 328
 sugar transfer, *47

IRON
 -binding capacity
 and menarchial age, 788, 790
 in bones of diabetics, 142-145, 375

ISLETS OF LANGERHANS
 in induced pancreatitis in rats, 635
 and insulin, 552
 in juvenile diabetes, 624-626, 629
 and leukemic mice, 327, 330
 and malnutrition, 411
 and severe hypoglycemia, 607, 608
 and sulfonylureas, 394

ISOANTIBODIES
 to human pancreas, 226-227

ISONIAZIDE, 4

ISOPROTERENOL, *534

ISRAEL
 diabetes incidence, 215
 and diabetics
 among arteriosclerotic Yemenites, 86
 and face color study, 201-208

J

JAPAN
 and diabetes incidence, 215

JAUNDICE
 and sulfonylurea therapy, 67

JERUSALEM
 face color and diabetes study, 102-108

JEWS
 and diabetes, 215
 and essential pentosuria, 311

K

KETOACIDOSIS, 43
 and alcohol hypoglycemia, 354
 and alloxan diabetes
 in rat, 289-294
 and atrophy, *454
 and diabetic pregnancy, 261
 and enzyme-strip test, *452
 and fluid loss, *318
 and growth hormone, 558
 and infection resistance, *114
 and insulin
 resistance, 432, *818
 secretion, 493
 and juvenile diabetics, 41, 107, 242, 247-249, 258
 and muscle metabolism, 82
 and plasma cortisol, 744-745
 and plasma insulin, 553
 and sodium lactate, *440
 and sulfonylurea therapy, 650, 656

KETOGENESIS
 and growth hormone, 368, 374

KETONEMIA
 and ethanol, *52
 and fasting for obesity, *532
 and insulin, *815
 and ketoacidosis criteria, 290
 and lipid infusion, 33-35

KETONES
 Acetest, 179
 and alloxanization, 180, 181, 184, 291
 and anti-insulin serum, *49
 Bessman's method for determination, 33
 and cold exposure, *683
 and ethanol ingestion, *52, *171
 and hypophysectomy, 556
 and insulin, *235, 280-281, 285-286
 and juvenile diabetes study, 247, 251
 and myocardial metabolism, *531
 in normal and hypophysectomized rats, 35
 and triglyceride-induced hyperketonemia, *448
 and urate excretion, 739
 in urine of juvenile diabetic, 121
 urine test for, 59

KETONURIA, 77, 370
 and alloxan-injected rats, 180, 183
 in diabetics in India, 407
 and insulin antibodies, *449
 and juvenile diabetes study, 240, 245, 247
 and ketone bodies, 286
 and menarchial age study, 788
 and pyruvate levels, *231
 and severity of diabetes, 60
 and steroids, *234

KETOSIS, *50, 370, 371, *609
 and adrenocorticotrophic hormone, *748

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

and alloxanized rats, 180, 181, 183
and blood sugar values, 3
in diabetes study in India, 405
and diabetic neuropathy, 429
and diet, 338
and fatty acid metabolism, 713
and growth hormone, 43, 556-557
and 17-hydroxycorticoids, 744-745
and hypoglycemia, *315
nondiabetic, and diabetic pregnancy,
*464
and plasma insulin, 552
-prone patients, 82
resistance in young diabetics, *814
and sodium lactate, *440

17-KETOSTEROIDS, 132, 133, 135

KIDNEY

and amino acids, 335
arterial hypertension, and diabetes,
*748-749
artificial, in acute tubular necrosis
case, 36-37
and atherogenic diet, 369
blood vessels, 426
damage and alloxanization, 291
in diabetics, 3, 8, 17, 41, *235-236,
702, 706
disease
and glucose tolerance, 550
and insulin uptake, 274-278
and juvenile diabetes study, 246
and prediabetes, 518
and prediabetic symptoms, 44
electronmicroscopy
and glomerulosclerosis, *377
function
and chlorpheniramine, *452
and diet, *816
glucose
excretion, 193
uptake, *172
glycosuria and itching, *168
and hormones, *231
in induced pancreatitis in rats, 639-
640
infections in juvenile diabetics, 256
insufficiency, and diabetic acidosis, 36-
37
and insulin-degrading enzymes, 87
Kolff Disposable Twin-Coil, 36
lesions, 550
diagnosis, 517
and plasma proteins, 755-770
and microangiopathy, *47
and mortality, 221
and neuropathies, 516
papillary necrosis, *167, *383
of prednisolone-treated rabbits, 595-
604
and severe hypoglycemia, 607-608
and sulfonyleureas, 59, 68, *377
and tolbutamide
excretion, *114
metabolism, *235

urate excretion in hyperketonemia,
739, 787, 804
KIMMELSTIEL-WILSON SYNDROME,
550
KREBS CYCLE, *447, *748
KREBS INTERMEDIATE METABO-
LITES
and vascular effects, *532
KREBS TRICARBOXYLIC ACID CY-
CLE, 747

L

LACTATE, 102

acidosis
and phenformin, 812
and cerebral metabolism, *748
formation from glycogen
and insulin, *233
and glucose uptake, *172, 310
-induced hypoglycemia, *681-682
metabolism
and diabetic acidosis, *440
and phenformin, *464-465
-pyruvate ratios, and lactic acidosis,
162

LEPROSY, 8

LESIONS

atheromatous, 369
atrophic skin, *817
and auto-immune mechanism, 518
and cartilage powder, *171
and diabetes, 43, *236, 550-551
and diabetic neuropathy, 1-8, 425, 426
enzymatic, and hypoglycemia, 333-338
eosinophile, in prednisolone-fed rab-
bits, 596
glomerular, 274, *377, 596-604
hypothalamic, *169, *233
ischemic, and diabetics and nondia-
betics, 110
Kimmelstiel-Wilson, 550
pancreatic
in anti-insulin serum-induced pan-
creatitis, 636-641
in juvenile diabetes, 629
placental, *817
renal
and plasma proteins, 755-770
vascular
and diabetes, *817
and diabetic neuropathy, 516
and glucose metabolism, 311
and insulin, 310
and potential diabetes, 491

LEUCINE, *49

and glucose oxidation, *49
and hyperinsulinism, *49-50
and hypoglycemia, 346-347
incorporation into protein, 306

and insulin release, 156, *439
and respiration, *685
sensitivity and glucose tolerance, *47

LEUCINE-I-C-14, *167
protein incorporation, *231, 305

LEUCOCYTES

and diabetes mellitus, *114
and diabetic neuropathy, 5
glucose metabolism, 584-590
in induced pancreatitis in rats, 635

LEUKEMIA

and insulin-like thymic factor, 325-
331, *447-448

LIPEMIA

and clofibrate, *453
and glucose utilization, *234
in pancreatectomized and normal dogs,
33-34
and tolbutamide, *232

LIPIDS

and alloxan diabetes, 181, 184
assay, Bragdon's, 33
and choline deficiency, 666
and clofibrate therapy, *452-453
and diabetic retinopathy, 44
and high fat diabetes diet, *464
in induced pancreatitis in rats, 639-
640
infusion in pancreatectomized dogs, 33-
35
and juvenile diabetes, 241, 250
and mebanazine, *236
metabolism, *50
and carbohydrate metabolism, 514
and ethanol, *536
and glucose uptake, 590
and insulin, *447
and serum and insulin, *457
mobilization, and insulin deficiency,
*447
and newborn of alloxan-diabetic rats,
724-728
in pancreatic tumor cells, *50
and phosphorus in pregnancy, *609
radioactivity
and Packard Tri-Carb Scintillation
Counter, 180
radioactivity incorporation, 709-715,
*747
and respiration, *685
and sugar and starch ingestion, *378
synthesis
and albumin, *356-357
and insulin, glucagon and epineph-
rine, *446-447
and leucocytes, 584

LIPOGENESIS

and adipose tissue, 82, *454
and enzyme metabolism, *236
and growth hormone, 368
and hormones, 369
and insulin, 8

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

LIPOLYSIS

- and diabetes, 633
- and epinephrine, *231
- and glucose production, 355
- and heredity, 370
- and hormones, 369
- and pituitary, 556-557
- and tolbutamide, *232

LIPOPROTEIN, *231

- and choline deficiency, 666
- and ischemic heart disease, *234
- lipase
 - and ethyl-a-p-chlorophenoxy-oxiso-
 - butyrate, *467
- pre-B, and diet, *458

LIPOATROPHIC DIABETES, 786

LIVER

- acetate metabolism and fat mobiliza-
- tion, *447
- acute hepatitis and blood glucose, 186,
- 191
- adenosine phosphates synthesis and
- alloxan diabetes, *684
- alcoholic damage and tolbutamide,
- *232
- and alcohol ingestion, 353, 355-360
- and alloxan diabetes, *232, 713
- anaerobic rat, and polyglucosides, *749
- in anti-insulin serum-induced pancrea-
- titis in rats, 639
- and "atypical" insulin, 649
- biopsy of Indian diabetics, 408
- carbohydrate
- and chronic hypoxia, 100
- cirrhosis, 221, 228
- citrate-cleavage enzyme, and carbohy-
- drate metabolism, *683-684
- and cortisol and triamcinolone, *113
- synthesis and puromycin aminonu-
- cleoside, *378
- and diabetic acidosis, 370
- of diabetic dogs, 17
- dihydroxyacetone metabolism, *382-383
- disease
 - and clofibrate, *453
 - and coma, 162
 - and hemochromatosis, 699, 708
 - and insulin-like activity, *441
 - and reduced hyperglycemic re-
 - sponse, 104
 - and tolbutamide and glucose toler-
 - ance tests, *536
 - and tolbutamide metabolism, *235
- DPN:DPNH ratio, 18
- electrical potentials, and insulin, *451
- enlargement and diabetes, 121
- enzymes
 - conversion, *233
 - and hypoglycemia, 333-338
- fatty acid synthesis, *749
- function
 - and chlorphentermine, *452

- in juvenile diabetes study, 241, 252-
 - 253
 - and glomerulosclerosis, 759
 - glucokinase
 - and insulin, *468
 - regulation, 306
 - gluconeogenesis, and adrenal steroids,
 - 729
 - glucose, 333-338
 - and adrenal steroids, 732-733
 - balance, and insulin, 307
 - extraction, 193
 - glycogen metabolism, *749
 - output and hypoglycemia, *114
 - storage, *314
 - uptake, *172
 - and glucose-6-phosphatase, 146
 - glucose-U-C-14 incorporation, 19, 20
 - glutamic-pyruvic transaminase and in-
 - sulin, 515
 - glutathione
 - and insulin inactivation, *816
 - insulin transhydrogenase, *749
 - glycogen
 - and amyloglucosidase, *232
 - and glucagon, *816-817
 - and gravity changes, *535
 - and insulin, *531
 - response to glucagon, 102, 104
 - and stress, *382
 - hemochromatosis
 - and serum L-xylulose, 312
 - homogenates
 - and glucose transformation, *235
 - and hyperbilirubinemia, 159
 - insufficiency, and mortality, 68
 - and insulin
 - binding, 31
 - degrading enzymes, 87, 91
 - and glucagon, *167
 - secretion, *168, 341-348
 - and leukemic mice, 325, 328
 - lipids
 - and alloxan diabetic rats, 180, 184
 - and diet and exercise, *533
 - synthesis, 666
 - metabolism, and glucose and fructose,
 - *466
 - perfused rat, *235
 - phosphorylase, and glycogenolytic
 - agents, *534
 - potassium uptake, 307
 - protein metabolism and insulin, 306
 - and sulfonylureas, 59, 60, *114
 - and thiazide therapy, 132
 - triglycerides, *458
 - urea synthesis and glyconeogenesis,
 - and chlorpropamide, 209-211
- # LUNGS
- and fibrocystic disease of pancreas,
 - *117
 - and infants of diabetic mothers, 158,
 - 160
 - and leukemic mice, 325, 328

LUPUS ERYTHEMATOSUS

- and glomerulonephritis and glomerulo-
- sclerosis, *441-442

L-XYLULOSE

- in sera of diabetics, 311-312

LYMPH

- insulin-like activity, *463

LYMPH NODE

- and leukemic mice, 325, 328

M

MAGNESIUM

- and insulin activity, 430-431

MAGNESIUM SULFATE

- and hypoglycemia in rabbits, *462

MALATE

- and lipogenesis, *447

MALNUTRITION

- and diabetic neuropathy, 516
- from diarrhea, 429
- and metabolism studies, *50

D-MANNITOL, *382, *532

MANNOHEPTULOSE, *236

- and glucose oxidation, *49

MANNOSE

- and glucose tolerance tests, 96
- and insulin
 - release, *232
 - secretion, *444
- uptake, and insulin, *115

MEBANAZINE, *236

MENTAL RETARDATION

- and galactosemia, 335

MENSTRUATION

- and glucose-1-C-14 oxidation, *50
- and juvenile diabetes, 255-256
- onset age
- and diabetes, 788-791

6-MERCAPTOPURINE

- and insulin resistance, *612

METABOLISM

- acetohexamide, *456
- of adipose tissue, 19, 77, *115, 179-185
- and hypophysectomy, *171
- and insulin, 307
- amino acid, and hyperketonemia, 804
- aortic, and diabetes, 310
- carbohydrate
 - and adrenal steroids, *113
 - and atrophy, *454
 - and benzothiadiazine drugs, *612
 - and chronic hypoxia, 100-104
 - comparison of mammals, *454
 - and diabetes, *170, 489-491

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58
February, 59-120
March, 121-174
April, 175-238

May, 239-324
June, 325-386
July, 387-472
August, 473-548

September, 549-618
October, 619-688
November, 689-754
December, 755-824

SUBJECT INDEX 1965

merulo-

62

0

9-185

, 804

*612

and 3,5-dimethylpyrazole, 507-514
 and dry mouth, *48
 and endocrine glands, *452
 and estrogen, *458
 and ethanol, 14
 and fatty acids, *171
 and fatty acid metabolism, *171
 and fat and insulin, *380
 and glyconeogenesis, 209-211
 and gravity changes, *535
 and growth hormones, *613
 and hormones, *231, 333
 and hyperglyceridemia, *458
 and hyperlipemia, *234
 and hypertriglyceridemia, *611
 and insulin, *233, 307
 and liver enzymes, *683-684
 and myocardial infarction, 84-86
 and neuropathy, *454
 and plasma sugar, 165
 and pregnancy, *113
 and radioimmunoassay, 771
 and sugar metabolism, *378
 and suspected diabetes, *170
 and thiazides, 132-136
 and thyroid therapy, *49
 and uremia, *169
 in vitamin B₆ deficiency, 515
 cerebral, *748
 chylomicrons and triglycerides, *535-536
 cortical bone, and diabetes, *455
 and diabetic neuropathy, 1-8, 516
 dihydroxyacetone, *382
 and early diabetes detection, 110
 enzymes
 and diabetic acidosis, *113
 enzymes, and lipogenesis and gluconeogenesis, *236
 and epinephrine, 561, 562
 ethanol, 14-18
 fat, 281, 395
 and growth hormone, 44
 and muscle and adipose tissue, 82
 fatty acid, *232, *747
 and carbohydrate and 3,5-dimethylpyrazole, 507-514
 and glucose, *684
 and insulin independent diabetes, 709-715
 in rat intestine, *535
 free fatty acid
 and exercise, *611
 free fatty acid and glucose
 in obese adolescents, *746-747
 and obesity, *748
 in frog muscle, *378
 fructose, and liver, 336
 glucose
 and ethanol, 350-360
 and free fatty acids, 559-562
 and fructose, *113
 and glucose-6-phosphate, *468-469
 and growth hormone, *379
 and insulin antibodies, 369
 and L-xylulose, 311

studies, *236
 and thiazides, *115
 and thymus gland, 325-331
 glucose C-14, *747
 growth hormone, 374
 and blood sugar, 43
 and hormones, *167, *231, 368
 after hypophysectomy, *316-317
 and idiopathic hemochromatosis, 699, 708
 in infants, *378
 and insulin and glucose C-14 incorporation, 19-26
 intestinal sugar transfer in rats, *47
 and Krebs intermediate metabolites, *532
 lactate
 and diabetic acidosis, *440
 and phenformin, *464-465
 lipid
 in fetuses of alloxan-diabetic rats, 724-728
 and insulin, *447
 and insulin and serum, *457
 liver, *466
 liver acetate
 and free fatty acids, *447
 and multiple sclerosis, *464
 myocardial, and ketone bodies, *531
 nucleic acid, and juvenile diabetes, 631
 and pancreatitis, *462
 of perfused rat heart, *685
 and prediabetes, 481
 protein and fatty acid and insulin, 633, 662
 pyruvate, *231, 369
 and diabetic neuropathies, 516
 and sex, nutrition, and body weight, *50
 and stress, *382
 studies, *117
 sugar and starch compared, *378
 sulfonyleurea, *382
 and tissues symposium, 306-307
 tolbutamide, *235
 uridine diphosphate glucose-glycogen glucosyltransferase from rat liver, *749

METALS

gold, hypothalamic uptake and hyperglycemia, *378
 iron in bones of diabetics, 142-145, 375
 poisoning, 8

METFORMIN

in diabetes study in India, 405

METHANOL, 20

METAPYRAPONE, *169

α-METHYLDOPA, *53

3-METHYLGLUCOSE, *47

α-METHYLGLUCOSIDE, *47

METHYLPREDNISOLONE-SUCCINATE

and glucose metabolism, 729-736

MICROANGIOPATHY, *234, 550

and facial redness, 207
 of human toes, *47
 and mortality, 308
 and necrobiosis lipoidica diabetorum, *314-315

MICROPHthalmia, *172

MICROSCOPY

of brain sections of diabetics, 425
 of cerebrovascular and pancreatic insular amyloid in old age, *612

of diabetic kidney tissue, 276

electron

and beta cells of diabetic rabbits, 792-803
 and capillary basement membrane, *234

and capillary lesions, 517
 and glomeruli of diabetic dogs, 700
 and glomerulosclerosis, 310, *441-442

of islet cell secretion, 305
 of kidneys, *377
 and microangiopathy, *47
 of pancreatic beta cells, 147-155, 497-499

of pancreatic tumors, *50
 of prednisolone-induced nephropathy, 595-604

kidney, 759-763

light, of pancreatic beta cells, 147
 of mammary glands of alloxan-diabetic rats, 502, 504, 505

of pancreatic tissue
 from juvenile diabetics, 620-629
 of rats, 635-641

skin

and red faces of diabetics, 204
 and thickened basement membranes, 110

MINERALS

calcium and magnesium, and hypoglycemia, *462
 and glucose transport, *749
 iron, and hemochromatosis and siderosis, 699, 708
 and serum insulin-like activity, *114

MINNESOTA MULTIPHASIC PERSONALITY INVENTORY, 107

MITOCHONDRIA, DIABETIC, 516

of cortisone-alloxanized rabbits, 794-795
 and glycolysis, *177

MONAMINE-OXIDASE INHIBITORS, *236

MONONEUROPATHY, 425, 427, 516

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58

February, 59-120

March, 121-174

April, 175-238

May, 239-324

June, 325-386

July, 387-472

August, 473-548

September, 549-618

October, 619-688

November, 689-754

December, 755-824

SUBJECT INDEX 1965

- MOROCOCHA**
carbohydrate metabolism study in, 100-104
- MORPHINE**
and glucose utilization, *172
- MORTALITY**
and alloxan-diabetic ewes, *235
and alloxanization, 290-291
of alloxanized rats, 180
causes in bone-study group, 142-143
and diabetes, 215-216, 221, 222, 489
and diabetic pregnancy, 371
and diet-induced diabetic syndrome, *441
and fasting in obesity, *532
fetal, *379-380, 435, *682
and fibrocystic disease of pancreas, *117
and glycogenesis, 337
of hypophysectomized dogs, 658, 661
infants of diabetic mothers, 159, 175, 177, 261, 435-437
of juvenile diabetics, 241, 242, 268-269, 619
and Kimmelstiel-Wilson syndrome, 550
and ligation of pancreatic duct, 194-195
and microangiopathy, 308
and nonketoacidotic coma, 162
and pancreatectomy, 93-95, 690
renal papillitis, 167
and severe hypoglycemia, 607, 608
and siderosis and hemochromatosis, 708
and sulfonyleureas, 59, 68, 654
- MUCOPOLYSACCHARIDES, 26**
metabolism, and insulin, 84
and muscle glycogenesis, *169
- MUCOPROTEINS**
and fibrocystic disease of pancreas, *117
- MULTIPLE SCLEROSIS**
and hyperinsulinism and edema, *464
- MUMPS**
and diabetes, 243
- MUSCLE**
and adipose tissue metabolism, 82, 86
aldolase, and fructosuria, 336
atrophy, 520
and neuropathy, 5
cells, and anaerobiosis and cell poisons, 128
disorders, and diabetes, 424, 425-426, 427
glucose uptake, *49
glucose uptake and adrenal steroids, 735
glycogen, and amyloglucosidase, *232
hexokinase regulation, 306
and insulin
-degrading enzymes, 87
and insulin-like activity assay, *48
and intraperitoneal insulin injections, 19, 20, 21
and protein metabolism, 306
metabolism, *378
- MYASTHENIA GRAVIS, 331**
- MYELOPATHY, 424, 427, 428, 520**
- MYELOSCHISES**
and insulin, *172
- MYOCARDIUM**
disease
and diabetic neuropathy, 1, 3
infarct
and carbohydrate metabolism, 84-86
and diabetic neuropathy, 518
and diabetics and nondiabetics, 110
and glomerulosclerosis, 759
and sulfonyleureas, 59, 68, 654
infarction
and glucose tolerance, *117
in juvenile diabetes study, 267
and nonketoacidotic coma, 162
and tolbutamide tolerance tests, *536
metabolism, and ketone bodies, *531
- MYOPATHY, 424**
- N**
- NADP-XYLITOL DEHYDROGENASE, 311**
- NARCOLEPTIC COMPLEX, *464**
- NECROBIOSIS LIPOIDICA**
and diabetic microangiopathy, *314-315
and ketonuria, *234
- NECROSIS, TUBULAR**
and dialysis, 36-37
- NEGROES**
and diabetes incidence, 215, 218
and erythrocyte deficiency, *315
- NEMBUTAL, 663, 690**
resistance, and tolbutamide, 392, 394
- NEPHROPATHY**
and diabetes, 310
etiology, 550-551
and heredity, 518
and hyperinsulinism, *685
prednisolone-induced, 595-604
and retinopathy in diabetic dogs, 700-707
- NEPHROPATHY, DIABETIC**
and hypertension, *749
in India, 408
and insulin dosage, 246
and mortality, 221
and neuropathy, 1, 3, 4, 7
- NEPHROTIC SYNDROME, 126**
- NERVOUS SYSTEM**
abnormalities in infant hypoglycemia, *815
and blood glucose levels, 127
damage, and hypoglycemia, 436
disorders and diabetes, 424-429
and experimental diabetes, *232
and insulin reactions, 249-250, *534
and lipid formation, *447
motor, and diabetes duration, *115
peripheral, insulin response, *682
and retrograde ejaculation, *455
- NEUROPATHY**
and achilles reflex, *380
and adrenal function, *169
definition, 424
and diabetes, *234
and hemochromatosis, *682
and multiple sclerosis, *464
- NEUROPATHY, DIABETIC, 424-429, 516-520, 759**
and abnormal taste threshold, *536
and atrophy, *454
and diabetes duration, 370
etiology, 110, 550-551
and hyperinsulinism, *685
and hypoglycemia, *114
and insulin metabolism, *682
in juvenile diabetes study, 267
nature of, 1-8
and pseudotabs syndrome, *47
and retrograde ejaculation, *455
treatment, 519
- NINHYDRIN, 90, 91**
- NITROGEN**
and adipose tissue, 183
metabolism
and protein metabolism, 209-211
- NITROGEN MUSTARD**
and islet cell tumors, *115
- NOREPINEPHRINE**
and adipose tissue electrical potential, 529-530
and nonketoacidotic coma, 162
- NORWAY**
diabetes in, 221
- 5-NUCLEOTIDASE**
and cortisone, *380
- NUTRITION**
and diabetes onset, 411
and glucose metabolism in dogs, *746
and insulin sensitivity of rat adipose tissue, *683
and liver disease, 699, 708
and metabolism studies, *50

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

and neuropathies, 516
and Project Head Start, 723

O

OBESITY, *380
and adipose tissue function, 82, 86
and aged diabetics, *47
and atherosclerosis, 307
and children of diabetic families,
*438-439
and diabetes, 221-222, *612
detection, *453, 473
diet-induced, *610
in India, 405, 406-407
and energy metabolism studies, *50
and fasting, *532
glucagon response, *816-817
and fatty acid
mobilization, *380
uptake, *171
and glucose
and free fatty acid metabolism, *610-
611, *746-747
tolerance, 559
and insulin sensitivity, *378
test study, 482
utilization, *467
and growth hormone, 370
and hyperglycemia, *168, *169
and hyperinsulinism, 553-555
and hyperuricemia, 787, 804
and hypothalamic lesions, *233
and infants of diabetic mothers, 724
and insulin activity, *748, 806
and menarchial age of diabetic wom-
en, 789-791
and neuropathy, 2, 4
and phenformin, *52
and serum insulin, 27, 28
-like activity, *442
response, *532, *683
and sulfation factor, *172
and sulfonylurea therapy, 59
and triglyceride levels, *314
and urine insulin-like activity, *681

OPHTHALMOPLEGIA
in diabetic neuropathy, 5

ORAL HYPOGLYCEMIC AGENTS. *See*
also Sulfonylureas
and aged diabetics, *47
and diabetes, 59-70, 77
and pregnancy, 435-436
study in India, 405, 408
3,5-dimethylpyrazole, 507-514
and emotional stress study, *467-468
and hyperthyroidism and diabetes
study, 740
and insulin-like activity, 809
and islet-cell formation, 369
and lactate metabolism, *464-465
new, *684

overdose, 811-812
and Regular Insulin, *316
and serum insulin-like activity, *318
and serum insulin levels, *444
and severe hypoglycemia, 606-607

OSTEITIS CONDENSANS ILIA, 261

OSTEOID SEAMS, 142-145

OSTEOMALACIA, 142, 145

OSTEOMYELITIS, 257

OSTEOPOROSIS
and diabetes, *316, *683

OUABIN
and metabolism of perfused rat heart,
*534

OVARIES
and leukemic mice, 325, 328
neoplasm, *114

OXALACETATE
and lipogenesis, *447

OXIDATION. *See also* Metabolism
of ethanol to acetaldehyde, 18
of tumors, *49

OXIDATIVE-PHOSPHORYLATION
and glucocorticoids, 484

OXYGEN
and carbohydrate metabolism, 100-104
and glucose uptake, *172
and new blood sugar test, *458
and premature infants, 160
uptake and fatty acid synthesis, *115

OXYTOCIN
and glucose metabolism, *379
and protein synthesis, *533-534
and urine volume, *464

P

**PACKARD TRI-CARB SCINTILLA-
TION COUNTER**, 180

PALMITATE
and glucose, *171
and insulin, *455
and respiration, *685

PALMITATE-I-C-14, *171
metabolism, *232
and 3,5-dimethylpyrazole, 508, 509,
511

PANCREAS
abdominal graft in dogs, 689-695
and glucose-6-phosphatase, 147
and hyperinsulinism, 334

alcoholic damage, and tolbutamide,
*232
in alloxan diabetic pregnant rats, 138-
141
alpha and beta cells
tumors compared, *50
alpha cells
distribution, *231
and autoantibodies to insulin, 396-402
beta cells
acid phosphatase and insulin secre-
tion, *168
and aging, 310
and alloxan, 180, 289, *532
degranulation, 493-500
and diet-induced diabetic syn-
drome, *441
in diabetic rabbits, 792-803
and glucose-6-phosphatase, 146-156
granulation, 137-141, *169, *444-
445
and growth hormone, 373
and insulin
response to sulfonylureas, 392-
394
secretion, *459
and leucine hypoglycemia, *439
and vitamin B₆, 515
blood vessels and diabetes, 426
carcinoma, hypoglycemia, and carci-
noid syndrome, *53
and cortisol, 194-200
of diabetic dogs, 17, 18
and diazoxide hyperglycemia, 591
exocrine function and diabetes, *53
fibrocystic disease, *117
glucagon levels and COCL₂, *51
and insulin
-antibody injected mice, *449-450
-binding, *316
in fetuses and infants of diabetic
mothers, 573-578
immunoassay, 387-390
and insulin, 552-553, 555
release, *232
-secretion capacity, 100
transfer, *52
islets
adenoma, *815
in alcohol hypoglycemia, 351
and alloxan, *383, 671
amyloidosis, *612
and auto-immune mechanism, 518
and chronic hypoxia, 103-104
and formation, 368
hyalinized, 110
and hypothalamic lesions, *233
and infants of diabetic mothers,
*468
and insulin secretion, *167, 550
insulinoma, 345-346
and leukemic mice, 325, 327-328
and neonatal diabetes, *233
quantitative studies, *380
and sulfonylureas, *114
symposium, 305-306

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58

February, 59-120

March, 121-174

April, 175-238

May, 239-324

June, 325-386

July, 387-472

August, 473-548

September, 549-618

October, 619-688

November, 689-754

December, 755-824

- tumors, *115, *747
and isoantibodies, 226-227
and malnutrition, 411
neoplasms in diabetics, *815
of postgastrectomy patients, 528
proteinases and oral insulin, 696
secretion studies in diabetics, *48
study of juvenile diabetes, 619-632
- PANCREATECTOMY**
and adrenal steroids, 729-736
and alloxan diabetes, 183, 184
and diazoxide, *469
hyperglycemia study, 591
and ethanol metabolism, 14, 16, 18
and insulin
degradation, 343-344
deprivation and restoration, 689-695
-like activity in dogs, 658-661
secreting tumors, *115
and ketoacidosis, 289
and ketonemia, 33-35
management, 14, *683
and plasma
arachidonic acid, *681
free fatty acids and lactic acid, *534
and retinopathy and nephropathy, 550-551
study of case, *613
and sulfonylureas, 103
in tumor growth and glycosuria studies, 93-95
- PANCREATIN, N.F., 14**
- PANCREATITIS**
allergic interstitial, 634-642
and diabetic dogs, 705-706
and diabetic neuropathy, 8
and insulin
degradation, 343
metabolism, *462
and isoantibodies, 226-227
and retinopathy and nephropathy, 551
and thiazide therapy, 135
- PARKINSON'S DISEASE, 427, 607**
- PENTOBARBITAL**
and glucose uptake, *172
- PENTOSE PHOSPHATE CYCLE, *172**
- PENTOSURIA**
essential, and glucose metabolism, 311-312
- PEPTIDES**
and hyperglycemia and insulin resistance, *445
insulin-inhibitory activity, 87-92
radioimmunoassay, *167
- PERIARTERITIS NODOSA, 8**
- PERITONEAL CAVITY**
and insulin injections, 19-26
- PERITONITIS, 36**
- PHENETHYLBIGUANIDE**
and glucose and insulin, *461
- PHENFORMIN**
in diabetes study in India, 405
and digestive alterations, *465
effects on blood lipids, *456
and glucose uptake, *318
and lactate metabolism in hypoxic rats, *464-465
and lactic acidosis, 162
overdose, 811-812
and rheumatoid arthritis, *532
and weight reduction, *52
- PHENFORMIN HYDROCHLORIDE**
and serum lipids, *465-466
- PHENOBARBITAL**
and serum L-xylulose level, 312
- PHENYLHYDRAZINE, 745**
- PHENYLEPHRINE**
and blepharoptosis, *455
- PHENYLKETONURIA, 44**
and epinephrine, 334
- PHLEBOTROMBOSIS**
and toxic intravenous fluids, *48
- PHLORETIN**
and insulin inhibiting, *115
and sugar inhibiting, *48
- PHLORHIZIN, *47, *48**
and insulin inhibiting, *115
and intestinal hexose and sugar transfer, *51
- PHOSPHATE**
and cell poisons, 131
and galactosemia, 335
and insulin, 289
- PHOSPHOENOLPYRUVATE CARBOXYKINASE, *236**
- PHOSPHOFRUCTOKINASE**
activity in muscle, *378
- 6-PHOSPHOGLUCONIC ACID, 147, 148**
- PHOSPHOLIPIDS**
and ethanol, *52, *171
and high fat diet, *464
in juvenile diabetes study, 251
and newborn of alloxan-diabetic rats, 724-728
and pancreatotomy, *681
- PHOSPHORUS, 102**
radioactive, and islet cell tumors, *117
serum inorganic, and glucose loading, *49
- PHOSPHORYLASE, 128, *533**
and alloxan diabetes, *684
conversion, *378
- of 2-deoxyglucose, 184
of glucose, 306, 310
and glycogen storage disease, 337-338
and hypoglycemia, 334
and insulin, 369
and muscle glycogenesis, *169
oxidative, 102
and pancreatic beta cell glucose-6-phosphatase, 146-156
and sugar transport, 368
- PIMA INDIANS**
and diabetes prevalence, *439-450
- PITUITARY GLAND**
ablation, 121, 308
bovine, peptide from, *445
and diabetes, 556
and diazoxide hyperglycemia, 591
function and diabetic retinopathy, 308
gonadotrophic functions and diabetes, 370
insufficiency and plasma cortisol level, *169
irradiation and retinopathy, 310
radiosurgery, 44
and vitamin B₆ deficiency, *380
- PLACENTA**
and atropine test, *747
in diabetes, *817
and fructose production, *113
and growth hormone, 44
hormones and free fatty acid increase, *113
immature, and diabetic pregnancy, 435
and plasma insulin and blood glucose transport, *172
- PLASMA**
albumin, and insulin, 369
alpha-amino nitrogen, and hormones, *231
amino acid during carbohydrate tolerance tests, *448
arachidonic acid, and pancreatotomy, *681
assays and diabetes detection, *533
cholesterol, arterial uptake and insulin, *746
bicarbonate, and nonketoacidotic coma, 162-164
cholesterol, and steroids, *382
cholesterol esters, 105
corticoids, and diabetic ketosis, 744-745
cortisol, *169
and diabetic angiopathy, *53
and insulin, *169
and obesity, *381
fatty acids, glucose and insulin, *50
fetal sheep
and fructose and glucose, *113
free fatty acids
and diazoxide hyperglycemia, *450
and ethanol, 352
and exercise, *611
and glucose tolerance tests, 77-82

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

- and growth hormone, 374, 556
and lactic acid, *534
and stress, *382
glucagon, and COCL₂, *52
glucose
and ethanol, 350-360
and metabolism, *50
and pancreatectomized dogs, 690-692, 694-695
and thyrotoxicosis, *50
glyceride, and insulin, *458
growth hormone survival, *50
hormone determinations, *167
hyperglycemic factor, *613
immunoreactive insulin, and infants of diabetic mothers, 436
inorganic phosphorus, and insulin resistance, *377
insulin
activity, *168, 387
and adrenalectomized rats, *748
and alloxanized rats, 669-671
and diet, *453
immunoassay, 552
and insulin secretion, 341-348
-like activity
and insulin binding, 564-565
and ketosis-resistant diabetes, *814
and obese ketotic diabetes, 552-555
and placenta, *172
and pregnancy, *749, *818
and sulfonylurea therapy, *463
and urine insulin-like activity, *681
ketones
and exposure to cold, *379
and urate clearance, 787, 804
lipids
and ethanol ingestion, *52, *171
and fatty acids, 395
and insulin and glucose in pregnancy, *609
proteins
and binding to hormones, 562-564
and cortisone-induced glomerular lesions, 604
and renal lesions, 755-770
steroids, 556
sugar determinations, 165-166
triglycerides, 666
and cholesterol in pregnancy, *609
and ethanol, *52
PNEUMONIA
in juvenile diabetics study, 257
POLYARTERITIS NODOSA, 274
POLYCYTHEMIA, 201
and plasma sugar, 165
POLYDIPSIA, 619
and diabetes diagnosis in dogs, 700
POLYGLUCOSIDES
in anaerobic rat liver, *749
POLYNEUROPATHY, 427
and carbohydrate metabolism, *113
complications, nondiabetic, 577
edema, 228
and effect of insulin and glucose on plasma lipids, *609
and glucose
infusions, *381
loading, 27
production in dogs, *746
tolerance, *458
tolerance test, 96, *170, 481-487, *683
and hyperglycemia, 137-141
and hyperthyroidism and diabetes study, 741
and insulin
inhibition, *608
resistance, *377
in juvenile diabetes study, 249, 260-261
and placental morphology, *817
and plasma
glucose and fatty acid, *613
insulin, *749, *818
and prediabetes, 175-177
RH negative, and glucose tolerance tests, *460
PREGNANCY, DIABETIC, 435-436, *681
and atropine test, *747
decline, 222
and insulin, 41, 630
management, 372, *379-380, *682
and neonatal problems, 157-161
and nondiabetic ketosis, *464
and sulfonylureas, *51
and tolbutamide, *381
PRISCOLINE, 427
PROCAINE, 186
PROGESTINS, *452
PROJECT HEAD START CHILD DEVELOPMENT CENTERS, 723
PROLACTINS
and glucose metabolism, *379
PROLINE, *115
PROSTATE GLANDS, *167, 256
PROTAMINE SULFATE
and protein synthesis, *534
PROTEINS
and adipose tissue electrical potential, 529
and basement membrane thickening, 110
beef hemoglobin, and insulin-like activity, *443
cerebrospinal fluid, and diabetic neuropathy, 429
of colostrum, *117
POLYPHOSPHATES
and glucose transport, *749
POLYSACCHARIDES
and glycogenoses, 337
POLYURIA, 619
and diabetes diagnosis in dogs, 700
in juvenile diabetes study, 245
POLYVINYL CHLORIDE, 76
PORTAL VEIN
and insulin secretion, 341
and medium chain triglyceride absorption, *448
POSTGASTRECTOMY SYNDROME
and blood glucose, 190-191
POTASSIUM, 102, 132, 136
chloride, *172, *609
cyanide reagent, 187
deficiency lesions, 604
ferricyanide
reagent, 187, 192
reduction method, 78
hydroxide, 20
metabolism, and insulin, *117
and thiazides, 228-229
and tissue electrical potential, 529
uptake of liver, 307
PRADER-WILLI SYNDROME, 786
PREDIABETES
and capillary basement membrane, *234
detection, 44, *438
and diazoxide treatment, 593
and growth hormone, 370
in hamsters, *448-449
and large birth weights, 518
and menarche, 788-791
and neuropathies, 1, 518
and nodular glomerulosclerosis, 550
and obesity, *380, *612
and pregnancy, 175-177, 436, *460, *681
and serum insulin
activity, *453
levels, 309
response, *532-533
symptoms, 44
tests, *52, 371-372, 481-487
and triglyceride infusion, *455
PREDNISOLONE
and adrenal steroid therapy, *818
and glucose tolerance test, *612
and hypoglycemic coma, 606
-induced nephropathy, 595-604
PREDNISONE
glucose tolerance test, 489-491
and insulin resistance, *612
PREGNANCY
and alloxan-diabetic rats, *235, 727

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

deficiency and diabetes, 411
and diabetic neuropathy, 5-8
dietary, 60
 and insulin response, *442
 and juvenile diabetics, 240
 and glomerulosclerosis, *442
 and glycine incorporation, *171
of granuloma tissue, and amino acid
 incorporation, *115
and growth hormone, 374, 557
insulin
 -binding, 27-32
and insulin
 -like activity, 387, 388
leucine-1-C-14 incorporation and hor-
 mones, *231
metabolism
 and insulin, 84
 and nitrogen metabolism, 209
radioimmunoassay, *167
synthesis, 306
 and carbohydrate-free diet, *318
 and ergastoplasm in rabbits, 802
 and insulin, *168-169, 633, 662
 and insulin or oxytocin, *533-534
urinary loss, 126

PROTEINURIA, *236
 and capillary basement membrane,
 *234
 and diabetic nephropathy, 2
 and glomerulosclerosis, 265
 in juvenile diabetic, 121, 126, *315
 and renal lesions, 517
 and urine sulfonyleureas, 366

PROTEOLYSIS
 and glucose production, 355

PRURITIS, 60, *168

PSEUDOTABES, 267, 425, 426

PSEUDOTABES SYNDROME, *47

PUBLIC HEALTH SERVICE, 478

PULMONARY SARCOIDOSIS, *114

PULMONARY TUBERCULOSIS
 and diabetic neuropathies, 4

PULSE WAVE VELOCITY
 and diabetes detection, 489-491

PURINES
 and blood sugar, *169

PUROMYCIN
 and carbohydrate synthesis, *378
 and glycogen synthesis, *236

PYLONEPHRITIS, 256
 and diabetic pregnancy, 261
 and renal vascular disease, *167

PYRIDINE NUCLEOTIDES
 glucose and fatty acid metabolism and
 hormones, *446-447

PYRIDOXINE, 515

PYRIMIDINES
 and blood sugar, *169

PYROGEN, *169

PYRUVATE, 102
 and cerebral metabolism, *748
 conversion to phosphoenolpyruvate,
 *236
 and diabetes, *231
 and ethanol, 357-360
 and fatty acid synthesis, *749
 and glucose metabolism, 587
 and lactate conversion, 162
 and lipogenesis, *447
 metabolism
 and diabetic neuropathy, 516
 and insulin, 369
 and muscle glycogenesis, *169
 and protein synthesis, *534

R

RACE
 and atherosclerosis, *470
 and sulfonyleurea study, 655

**REGISTRY OF TISSUE REACTIONS
 TO DRUGS**, 480

RENAL DIABETES
 and insulin uptake, 274-278

RESERPINE
 and free fatty acids, *532

**RESPIRATORY DISTRESS SYN-
 DROME**, 436
 and maternal diabetes, 158-159, 160

RETINA
 detached, and diabetes, *466
 hemorrhages, *168
 lesions, 550
 microaneurysms, 517
 photography of, 122-125
 vascular changes in diabetes, 3, 121-
 127

RETINOPATHY
 and adrenal function, *169
 and diabetic control, 267-268
 etiology, 110, 550-551
 and microaneurysms and exudates, 110

RETINOPATHY, DIABETIC, 759
 and anabolic steroids, *168
 and diabetic neuropathy, 1, 2, 3, 4, 7
 and diet, *816
 and experimental diabetic glomerulo-
 sclerosis, *377
 and erythrocytes, 8
 and hemochromatosis, *682
 and heredity, 518
 and hyperinsulinism, *685

and hypophysectomy, 43, 558
induced, *379
in juvenile diabetes study, 262-265
and menarchial age, 789-790
and nephropathy, 700-707
and pituitary
 function, 308
 irradiation, 310
and post-hypophysectomy care, *316-
 317
and prediabetes, 175
and reversal of vascular changes, 121-
 127
and salicylates, *462-463
and steroids, *382
treatment, 44
and vision, 310

RHEUMATISM, 2

RHEUMATOID ARTHRITIS
 with diabetes, and salicylate treat-
 ment, *462-463
 among Pima Indians, *439

D-RIBOSE
 and hypoglycemia, *685

RICKETS, 142

RNA
 and fatty acid synthesis, 662

ROENTGENOGRAPHY, 370

RUBEOSIS, 201-208

S

SALICYLATES
 and diabetic retinopathy, *462-463
 and hypoglycemia, *315
 and insulin inhibition, 130
 and nonketoacidotic coma, 162

SCHMIDT'S SYNDROME
 and diabetes mellitus, *48, 300-303

SCHIZOPHRENIA
 and insulin degradation, 342
 in juvenile diabetes study, 259

SECRETIN, *53

SEPHADEX, 28, *816

SEPHARDI
 and study of diabetes and face color,
 201-208

SEROTONIN
 and pancreas tumor, *53

SERUM
 albumin, and adipose water uptake,
 *379
 amylase, and antihypertensive drugs,
 *377
 anti-insulin, *449

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58
February, 59-120
March, 121-174
April, 175-238

May, 239-324
June, 325-386
July, 387-472
August, 473-548

September, 549-618
October, 619-688
November, 689-754
December, 755-824

SUBJECT INDEX 1965

and acute insulin deficiency, *49
and alloxan diabetic rats, 180, 183, 184
avian, *170
and beta cell degranulation, 305, 493-500
and free and bound insulin, *608
guinea pig, 14, 15, 17, 18
and hypophysectomized dogs, 659-661
and induced allergic interstitial pancreatitis, 634-642
and insulin, 780-786
beta-glucuronidase, and atherosclerosis, *682
bilirubin, and infants of diabetic mothers, 161
carbon dioxide
in juvenile diabetes, 242, 249
and ketoacidosis criteria, 290
cholesterol, 761
and atherogenic diet, 369
and chlorophenoxyisobutyrate and androsterone, *814
and diet and exercise, *533
and hyperthyroidism study, 741
and phenformin and tolbutamide, *456
determinations in thiazide study, 132-136
diastase, and diabetes, *53
ethanol concentration, 15
free fatty acids
in insulin-induced hypoglycemia, *536
and myocardial infarction, 84-86
and growth-hormone-dependent sulfation factor, *172
-induced papillary necrosis, *383
inorganic phosphorus response, *49
insulin
activity
and diet, *816
in normals and diabetics, *453
and adipose tissue, *48
antagonism, 12
and antibodies to insulin, 397-402
assays, *683
-binding antibodies, 279
-binding properties, 27-32
and carbohydrate-restricted diets, *748
and cholesterol in pregnancy, *609
and glucose, *683
and glucose loading, *49
and glucose and tolbutamide, *470
and glucose tolerance, *442, *457-458
immunoassay, double antibody technique, 771-779
immunochemical assay, 27
-like activity, 10-13, *52, 78, 79, *116, 132, 133, *170, 309, *382, *442, 643-649
compared with immunoreactive insulin, *463

and diet, *114, *441
and intestinal glucose absorption, *314
and hypoglycemic agents, *318
in hypophysectomized and depancreatized dogs, 658-661
and insulin resistance, 432-434
and intestinal mucosal extract, *440-441
and tolbutamide, *381
in newborn calf, *117
and postgastrectomy patients, 526-528
and potential diabetes, *466
response
and mild diabetes with hypoglycemia, *612
and prediabetes, *532-533
isoantibodies, 226
lactate, and muscle glycogenosis, *169
lipids
and chlorophenoxyisobutyrate and androsterone, *814
and diet, 332
formation, *457
and phenformin hydrochloride, *465-466
and skinfold thickness, and blood sugar, *314
L-xylulose, 311-312
and phagocytic activity of leukocytes, *114
phosphorus
and chlorothiazide, *609
potassium, 761
and antihypertensive drugs, *377
protein
-bound iodine, 740
in diabetic hamsters, *448-449
electrophoresis, *168
globulin fraction, 12
and immunoelectrophoretic method, 27
and infants of diabetic mothers, 371, *438
insulin
-like activity, 71-76, *382
separation, 780
and insulin I-131, *534
in juvenile diabetes, 251-252
pyruvate, and muscle glycogenosis, *169
sickness, 8
sodium
and nonketoacidotic coma, 162, 164
sulfonylureas, 362-367
triglycerides
and clofibrate, *452
and high fat diet, *464
urate, and hyperketonemia, 739
uric acid
and antihypertensive drugs, *377
and chlorophenoxyisobutyrate and androsterone, *814
and social class, 804

SEX

of animals in insulin-inactivation studies, 88
and bone study of diabetics, 142
and blood sugar levels, 247, 416-422
and cholesterol, *453
and degenerative complications in diabetes, 261
and diabetes, 216, 219, 222, *454
incidence, 406, 409, *454
juvenile, 241
and diabetic acidosis, 248
and fasting serum L-xylulose, 311
and glycosuria, 246
and growth hormone levels, 370
and infections in juvenile diabetics, 256-257
and insulin dosage, 246
and ketonuria, 247
and lipid concentrations, 250
and liver enlargement, 252-253
and metabolism, *50
and neuropathy, 428, 520
in pancreatic antibodies study, 226
and serum protein levels, 252
and skin disorders in juvenile diabetes, 257
and sulfonylureas, 63, 64
and triglyceride level, 251
and urine
bacteria, *533
glucose, *746

SHOCK, 201

hypoglycemic, 95
and fasting blood sugar values, 3
and sulfonylureas, *377
therapy, and insulin, 342

SKIN

allergies in sulfonylurea therapy, 59, 60, 67
changes
and diabetic neuropathy, 427
color, and diabetes, 201-208
and diabetic neuropathy, 516, 517
disorders in juvenile diabetes study, 257
-fold
technique, and diabetes detection, *461
thickness, serum lipids and blood sugar, *314
infections, and diabetes, 256
lesion, atrophic circumscribed, *817
and necrobiosis lipoidica, *234-235
and sulfonylureas, 654

SODIUM

acetoacetate, and urate excretion, 787, 804
arsenite, and insulin inhibition, 130
beta-hydroxybutyrate
and hyperuricemia, 739
and urate excretion, 787, 804
bicarbonate, 37
and diabetic acidosis therapy, *113
carbonate, 187

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58

February, 59-120

March, 121-174

April, 175-238

May, 239-324

June, 325-386

July, 387-472

August, 473-548

September, 549-618

October, 619-688

November, 689-754

December, 755-824

SUBJECT INDEX 1965

- chloride, 72, 187
and ethanol, 15
and insulin-protein separation, 388
- cyanide
and insulin inhibition, 130
- lactate, 37
and plasma free fatty acids, *534
- metabolism, *316-317
- and nonketoadidotic coma, 162, 164
- pentobarbital, 32
- sulfite, and enzyme conversion, *233
- SOMATOTROPIN, *378**
- SORBITOL**
and ethanol, 359
- SOUTH AFRICANS, *469-470**
- SPINAL CORD**
lesions, and diabetic amyotrophy, 520
syndromes, and diabetic neuropathy, 425, 427
- SPINAL ROOTS**
and diabetic neuropathy, 425, 427
- SPLANCHNIC NERVES**
and hypoglycemic convulsions, *49
- SPLEEN**
and leukemic mice, 325, 328
- STAPHYLOCOCCAL ENTERITIS, 36**
- STARVATION**
"accelerated"
in pregnancy, *113
and diabetes, *815
and growth hormone, 559
onset, 411
symptoms, 555-556
and glucagon response, *816-817
and growth hormone, 559
and hyperketonemia, 739
and insulin, 21, 25
activity, *748
dosage, *117
and reduced hyperglycemic response, 104
and urine insulin-like activity, *681
- STATISTICS**
abnormal insulin in juvenile diabetes, 781-785
abortions and chromosome defects, 340
Addison's disease, diabetes, and other endocrinopathies, 301, 303
adipose tissue carbohydrate metabolism and insulin response, *454
adrenal steroids and glucose kinetics, 731-734
age at menarche of juvenile diabetes, 255
albumin antagonism to insulin, *456-457
alloxan diabetic and normal rats, 182, 183
anaerobiosis and cell poisons, effect of on glucose uptake, 129-130
antibodies to insulin, 398-401
associated conditions at diabetes diagnosis, 243
attitudes of juvenile diabetics, 106-108
augmentation of insulin-like activity, 11, 12, 13
birth weights of infants with prediabetic parents, 176-177
blepharoptosis in diabetics, *455-456
blood glucose, 188-192
in elderly, 580
and hypnotically-induced emotional stress, *467-468
and insulin dosage, 284
and intestinal insulin administration in rabbits, 697-698
and ketoacidosis, 291
and plasma insulin, 554, 555
in premature infants, 127, 156
blood plasma, red cell sugars, and hematocrits, 165-166
blood saccharoid content in neuropsychiatric patients, 720-722
blood sugar
in juvenile diabetes study, 247
tests in leukemic mice, 326
body and gland weights of alloxan-diabetic rats given testosterone, 503
C-14 incorporation into fatty acids by blood, 710-714
cataracts and diabetes, *231
census of patients in juvenile diabetes study, 241-242
chlorpropamide and glucose and nitrogen metabolism, 210
clinic visits of juvenile diabetics, 243
cortisol, effects of on pancreas, 196-198
Dextrostix method, *381
diabetes
in Blekinge, Sweden, *534-535
carbohydrate tolerance, age, sex, and test conditions, 413-422
in Chinese hamster, 371
detection campaign in Sweden, *531
detection method, *461
and early or late menarchial onset, 788-791
and facial redness, 202, 203, 207, 208
incidence in British village, *53
in India, 405-410
diabetic program for aged, *47
diazoxide
-hyperglycemia study, 592, 593
and insulin inhibition, *439
diet and human depot fat, 105
digestive alterations in diabetes, *465
3,5-dimethylpyrazole and metabolism, 509-514
double antibody radioimmunoassay of insulin, 772-777
educational attainments of juvenile diabetics, 259
epinephrine in insulin-induced hypoglycemia, 334
ethanol metabolism, 15-17
exocrine pancreas in diabetes, *53
experimental alcohol hypoglycemia, 350-360
external pancreatic secretion and diabetes, *48
free fatty acid and glucose tolerance, 78-81
glucose
metabolism in leucocytes, 586-589
tolerance in hyperthyroidism, 742
tolerance tests, 97-99, 100-104
*116-117, *466-467, 481-487, 691-694, *438-439
glucose C-14 incorporation, 22-25
glucose-6-phosphatase activity in glycogen storage disease, 337
glycosuria, effect of tumors on, 93-95
gouty arthritis and diabetes, *116
glycosuria incidence in juvenile diabetics, 246
growth hormone metabolism and secretion in infants, *378
hemoglobin levels in juvenile diabetes study, 255
heparin and insulin-like activity, 806-809
hyperglycemia and beta granulation, 137-141
hyperosmolar coma and plasma bicarbonate levels, 163-164
immunoassay of glucagon, *450
inactivation of insulin by adipose tissue, 88-91
incubation media and methods in glucose uptake studies, 128-129
infants of diabetic mothers, 157-161
infections in juvenile diabetics, 256
insulin
activity and calcium and magnesium, 430-431
and blood glucose and alloxan, 670, 671
concentration in hypoglycemia, 348
dosage, 245-246, 282, 283
and (rat) hepatic glucokinase, *468
immunoassays, 330, 388-390
-like activity, 72-75, *463, 646-648
resistance, *818
response to protein, *442
iron in osteoid seams of bones from diabetics, 144
ischemic heart disease in diabetic women, *169
isoantibodies to human pancreas, 226-227
juvenile diabetes diet, 244, 255
ketoacidosis in juvenile diabetes study, 247-249
ketonuria in juvenile diabetes study, 247
labile diabetes study, 280

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

lactate metabolism and phenformin, *464-465
 lipids in newborn of alloxan-diabetic rats, 725-727
 liver function in juvenile diabetics, 253
 mass screening method for diabetes, 298, 299
 microangiopathy in toes, *47
 mortality, 68-69, 180, 268, 291
 motor-nerve function and duration of diabetes, *115
 myocardial infarction and carbohydrate metabolism study, 84-85
 neuropathy, 2, 3, 427, 518
 occupational achievements of juvenile diabetics, 260
 oral sodium tolbutamide test for diabetes, *451
 pancreas
 insulin content in fetuses and infants, 574-575
 tissue of juvenile diabetics, 620-628
 pancreatic lesions in rats, 637, 638
 phenethylbiguanide and glucose tolerance, *461
 phenformin and weight reduction, *52
 plasma lipids in juvenile diabetics, 250, 251
 pregnancy, diabetic, 371, *379-380
 pulse wave velocity in potential diabetics, 490-491
 retinopathy and diabetic control, 264, 268
 Schmidt's syndrome with diabetes, 302
 serum insulin
 -binding, 28-31
 and glucose tolerance, *457-458
 serum proteins
 in juvenile diabetics, 252
 and urine sulfonylureas, 362-367
 stillbirth rate in prediabetic women, 177
 "stress" postprandial blood sugar and diabetes detection, *462
 sulfated insulin study, *440
 sulfonylureas, 59, *114, *382, 652-656
 symptoms prior to diagnosis of juvenile diabetes, 241
 thiazide therapy, 133-136
 triamcinolone-glucose tolerance test, 482-487
 uptake of labeled insulin by kidney tissue, 275
 urine and blood pyruvate, *231
 urinary ketone bodies, serum ketone bodies, and serum free fatty acids and insulin dosage, 285
 vapor phase chromatography and acetone concentration, 664-665
 vascular complications in juvenile diabetes study, 262
 weight and height of juvenile diabetics, 254-255

world survey of diabetes mellitus, 212, 223
STERILITY
 and retrograde ejaculation, *455
STEROIDS
 adrenal
 and carbohydrate metabolism, *113
 and glucose metabolism, 729-736
 and insulin resistance, *235, *818
 anabolic
 and diabetes instability, *381-382
 and diabetic retinopathy, *168
 binding, 563
 and diabetic acidosis, *114
 and glucose-6-phosphatase, 337-338
 and growth hormone secretion, *315
 and ketonuria, *234
 and ketosis, 744-745
 and nephropathy in rabbits, 595-604
 and pancreas, 194-200
 and pancreatic diabetes, 95
 and tolbutamide, 132, *233
STILLBIRTHS
 and sulfonylurea drugs, *51
STRESS
 blood glucose level, and diabetes detection, *462
 and diabetes, 106, 107
 emotional, and blood glucose levels, *467-468
 and free fatty acid mobilization, *380
 and hypercorticalism, 95
 and juvenile diabetes, 243, 258-259, *317
 and metabolism, *382
STUDENT'S *t* TEST, 209
ST-WAVES
 in diabetic neuropathy, 2
SUCCINATE
 and lipogenesis, *447
SUCROSE
 metabolism, and carbohydrate metabolism, *378
SULFATION FACTOR, *172
SULFHYDRYLS
 and insulin, *114
SULFONYLUREAS, 103, *612
SULFONYLUREAS. See also Oral hypoglycemic agents
 and alcohol, *114
 and blood glucose and plasma insulin, *463
 and blood sugar, 650-656
 and digestive alterations, *465
 evaluation, 39-40
 and glucose output, 209-211

retention, *114
 and hypoglycemia, *114, 346-347
 and hypoglycemic shock, *377
 and insulin response, 392-394
 and juvenile diabetes, *531, 553
 and ketosis-resistant diabetes, *814
 and leucine hypoglycemia, *439
 and metabolism, *382
 and pancreas beta cells in rabbits, 800
 and pregnancy, *51
 in serum and urine, 362-367
 and therapy of Bertram, Bendtfeldt and Otto, 59
SULFUR, RADIOACTIVE, *172
SURGERY
 adrenalectomy, 308
 amputation, 7, *172, 427, 429
 cataracts, *231-232
 and diabetic neuropathy onset, 518
 gastrectomy, *116, 526-528
 and ischemic leg ulcers, *318
 islet tissue transplantation, 41-42
 and lesions, *684
 mastoidectomy, 257
 pancreas
 autograft in dogs, 689-695
 resectioning, *115
 pancreatic tumors, *117
 pituitary gland, 44
 spinal transection and evisceration of rats, 508
 venous system, *116
SWEDEN
 diabetes in, 214-215
 and juvenile diabetics treated with unmeasured diet, 244
SYNALBUMIN
 insulin antagonism, *438, 566, *749, *815
SYPHILIS
 and neuropathy, 2, 4, *47

T

TABES DORSALIS, 520
TEMPERATURE
 and blood glucose levels, 419
 and infants of diabetic mothers, 436
 and insulin inactivating, 88-89
 low
 and ketones and fatty acids, *379, *683
TES-TAPE, 281
TESTOSTERONE
 and alloxan diabetic rats, 501-505
 and protein incorporation, *167
THALAMUS
 and diabetes, 425

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58
 February, 59-120
 March, 121-174
 April, 175-238

May, 239-324
 June, 325-386
 July, 387-472
 August, 473-548

September, 549-618
 October, 619-688
 November, 689-754
 December, 755-824

SUBJECT INDEX 1965

- THIAZIDES**
and carbohydrate intolerance, 132-136
and glucose uptake, *115
and small-bowel ulcers, 228-229
- THROMBOPHLEBITIS**, 227
- THROMBOSIS**
mesenteric, and nonketoacidotic coma, 162
- THYMUS**
of alloxan diabetic rats, 502
in diabetic pregnancy, 371
glucose uptake, and adrenal steroids, 735
insulin-like factor, *447-448
and leukemia, 325-331
- THYROID**, 43
and adrenal insufficiency, *48, 300-303
desiccated, and carbohydrate metabolism, *49
disorders and diabetes, 261
- THYROXIN**
antagonists, 562, 564
and insulin requirement, *50
- TISSUE**
adipose
activity and insulin, *683
assay of insulin and insulin-like activity, *48
carbohydrate metabolism and insulin responsiveness, *454
and chylomicrons and triglyceride metabolism, *535-536
and fatty acids
free, 559
release and lipolysis, *231
stability, 395
synthesis, *447, *749
and glucose
metabolism, 369, *379
uptake, *49, 77-82, *443
uptake and adrenal steroids, 735
uptake and thiazides, *115
glucose C-14 incorporation, 19-26
and glucuronic acid pathway, 311
glycogen synthesis, *533
and hypophysectomy, *171
and insulin, *379
bioassay, *441
effect on electrical potentials, *451
deficient, *382
inactivation, 87-92
-like activity
and 3,5-dimethylpyrazole, 508-509, 510
-like activity assay, 71-76, 643-649
uptake and myocardial infarction, 84-86
and malnutrition, 411
metabolism, *115, *117, 179-185,
*233, 307
and obesity, *314
and plasma insulin activity, 387
protein synthesis, *533-534
pyridine nucleotides, glucose and fatty acid metabolism, and hormones, *446-447
in AKR mouse, 325-331
and alloxan action, *532
capillary basement membranes, *234, *235-236
circulation, and diabetes, 373
electrical potential and insulin, 529-530
epididymal fat
and alloxan diabetic rat studies, 180
and glucose-I-C-14 metabolism, *681
and glucose uptake and cell poisons, 128-131
and insulin, 669
-like activity, *49, 72, *116, *170, 387, 658, 659, 805-810
and lipid formation, *457
and serum insulin-like activity, 132
fatty acid uptake, *171
fibrin and fibrinogen detection, 756
glomerular, and renal lesions, 517
glucose
uptake and phenformin, *318
utilization, *314
granuloma, and amino acid incorporation, *115
hyaline membrane, 158, 159
hypoxia, 162
iron, 142
kidney
and immunohistopathological study of glomerulosclerosis, 755-770
and insulin uptake, 274-278
metabolism
and hormone immunoassays, *167
symposium, 306-307
mouse diaphragm
and insulin and palmitate, *455
serum insulin assay, *453
muscle
and glucose uptake, 716-718
and glycogenesis, *169
metabolism studies, *117
pancreatic
and alloxan, *383
and cortisol, 194-200
transplanted to eye, 306
rat diaphragm
and albumin and insulin antagonism, *456-457
and glucose C-14 incorporation, 19-26
and glucose-6-phosphatase, *446
and glucose uptake and ketosis-resistant diabetes, *814
and insulin
inhibition, *608
-like activity, 74, 78, 805-810
and serum insulin-like activity, 387
rat epididymal fat
and glucose tolerance, 580
and insulin and palmitate, *455
rat hemidiaphragm
assays, 566, 567-568
glucose uptake, *438, 778
and cell poisons, 128-131
retinal and renal, of diabetic dogs, 702-704
vascular wall, and insulin, 84
- TOLBUTAMIDE**, 18, *49, *51, *234, 397
and alcohol, *114
and alcoholism, *233
and blood lipids, *456
and blood sugar, 650-656
comparison with new hypoglycemic agent, *684
in diabetes study in India, 405, 408
and exercise, *317
and gastric secretion, *814
and glucose and leucine-H-3 incorporation into protein, 305
and hyperinsulinism, *49-50
and hypertriglyceridemia, *611
and hypoglycemia, *114, 347, 606-607, 697-698
and insulin
and blood glucose, *114
conversion, 387
release, 156, *232, 392-394
response, 309
and islet cell secretion, 305
and lipemia, *232
metabolism, and kidney and liver disease, *235
and monamine-oxidase inhibitors, *236
and neuropathy, *234
in oral hypoglycemic study, 59-70
oral sodium, and diabetes diagnostic test, *451
and phenformin, *465
response
and erythrocyte deficiency, *315
in mild and severe diabetic hamsters, *449
and obese children of diabetics, *438-439
and serum insulin
levels, *470
-like activity, *381
in serum and urine, 362-367
test, 100, 101, *816
 dangers, 607
and triamcinolone-glucose tolerance tests compared, 481-487
and thiazide therapy, 132, 134
tolerance
and hypoglycemic children, *315
tolerance test
and glucose tolerance test, *536
in infants of diabetic mothers, *468
- TRIAMCINOLONE**
and carbohydrate metabolism, *113
-glucose tolerance test, 481-487

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

TRIAMCINOLONE ACETONIDE, *234

TRIGLYCERIDES, 184
and diabetes, 44, 666
and ethanol and dry wine, *171
and ethyl-a-p-chlorophenoxy-isobutyrate study, *467
and free fatty acids, 77, 87
and hyperlipemia, *232
and ischemic heart disease, *234
in juvenile diabetes study, 251
metabolism, *233
in adipose tissue, *535-536
and insulin, *233
and weight gain, *314

TRIGLYCERIDE GLYCEROL
and palmitate, *455

TRYPSIN, *53
and diagnosing fibrocystic disease, *117

TUBERCULOSIS
adrenal, 301
and diabetes mellitus, 301
and juvenile diabetes, 257

TUMORS. *See also* specific types
in diabetics and nondiabetics, *608-609

and hypoglycemia, 330, 347-348
islet cell, *53
blood insulin level studies, *49-50
clinical and biochemical studies, *49
and glucose tolerance, 346, 347
and insulin secretion, *115
and peptic ulcer, *116
and spontaneous diabetes in mice, *747
ulcerogenic, *117
and neuropathy, *47
ovarian, *114
pancreatic
electron microscopy, *50
in pancreatic and steroid diabetes, 93-95
Wilms' and hypoglycemia, *316

T-WAVES
in diabetic neuropathy, 2

TWINS
and diabetes and hyperthyroidism, 743
and hypoglycemia, 338, *535
and organ transplantation, 41
and skeletal muscle glycogenesis, *169

TYRODE SOLUTION, 209, 210, 211

TYROSINE
and insulin degradation, 91

U

ULCER
duodenal
and tolbutamide, *814

in glomerulosclerosis patient, 761
leg, *115-116
ischemic, *318
neuropathic
and diabetes, *684
of lower extremities, 427
neurotrophic
and diabetic neuropathy, 520
peptic
and pancreatic islet cell tumor, *116
small-bowel, and thiazides, 228-229

ULTRACENTRIFUGATION
in autoantibodies to insulin study, 399, 401
in insulin-binding studies, 27-32, 566

UNITED STATES
and diabetes, 213-214, 221

UNITED STATES PUBLIC HEALTH
SERVICE
1964-65 interviews with diabetics, *51

UREA
synthesis and chlorpropamide, 209-211

UREMIA
and fructose and glucose tolerance, *169
and nonketoacidotic coma, 162

URIDINE DIPHOSPHOGLUCOSE-
TRANSGLUCOSYLASE,
*533

URINARY TRACT
infection, and diabetes, *315, *818

URINE
acetone, and dietary carbohydrate, 474
albumin, *234
bacteria in diabetic and nondiabetic patients, *533
corticoids, *169
estriol, and diabetic pregnancy, 371, 435, *682
fructose, *113
glucose, *746
in alloxan diabetic mice, 325
in alloxan diabetic rats, 502
and creatinine and uric acid of pancreatized rats, 93
and emotional stress, *467-468
and insulin dosage, 285-286
and ketone bodies, 179
and labile diabetes study, 281-283, 287
and nitrogen and choline, 667
and sulfated insulin, *440
tests, 290, *609, *816
gonadotrophins, *236
growth hormone determinations, 43
17-hydroxycorticoids and 17-ketosteroids, 132, 133
5-hydroxyindolacetic acid, *53
insulin-like activity, and obesity, *681
of juvenile diabetic, 121

ketone bodies, 285-286, 287
in lactose- or galactose-induced hypoglycemia, *682
metabolites of acetohexamide, *456
3-methoxy-4-hydroxy-mandelic acid, 78
nitrogen, *459
17-OHCS excretion and diabetic angiopathy, *53
and phenformin overdose, 811
pituitary gonadotrophin, and diabetic neuropathy, 427-428
plasma acetone, 162
polypeptide, *445
protein, and pancreatotomy, *613
pyruvate, *231
steroids, 556
and tolbutamide, *233
sugar
and diabetes control study, *469
and diabetes detection, *461
of guinea pigs in cortisol study, 195-196
in juvenile diabetes study, 246
and nonacidotic coma, *609
sulfonyleureas, 362-367
tests
Benedict's method, 224
Combistix, 224
copper reduction, 224
enzyme impregnated paper, *53
for glucose, ketone bodies, and albumin, 59
glucose oxidase, false negative reactions in, *224-225
and insulin study, *457
and juvenile diabetics, 107, 108, 241, *315, 678
in prednisolone-fed rabbits, 595
for sugar, 41
in tubular necrosis case, 36
urate
and hyperketonemia, 739, 787, 804
uric acid, 93, 132, 224
L-xylulose and hereditary pentosuria, 311

V

VASCULAR DISEASE
and chlorpropamide, *814
and diabetes, 47, 110-111, 157, 162
juvenile, 241, 262
among diabetic Pima Indians, *440
and hyperinsulinism, *685
mortality, 268-269
and neurologic classification, 425
and neuropathy, 1-8
occlusive
and diabetic neuropathy, 426
and preclinical diabetes, *611
and prediabetes, 44
renal, *167
symposium, 307-308

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

SUBJECT INDEX 1965

VASCULAR SYSTEM

- and diabetes, 516, *531, 489-491, 549-552
- diabetic changes, and red face, 207
- and diabetic deaths, 221
- and headaches, and multiple sclerosis, *464
- and Krebs' intermediate metabolites, *532
- lesions
 - and diabetes, *817
 - and diabetic neuropathy, 516
- surgery, *116

VEINS

- portal-peripheral
- and serum insulin concentration, *444

VITAMINS

- B-complex
 - and diabetic neuropathy, 516, 519
- B₆ deficiency
 - and carbohydrate and fat metabolism, *380
 - and insulin, 515
- deficiency
 - and diabetic neuropathy, 2, 4, 8, 516
 - and fibrocystic disease of pancreas, *117
- K, and premature infants, 160
- and pancreatectomy, *683
- and rickets, 142

VOMITING, *168

- and diazoxide, *610
- and glucose tolerance tests, 96, 296
- and hypoglycemia, 249
- and juvenile diabetes, 121, *317-318
- and phenformin overdose, 811

W

WALKER CARCINOMA, 256, 93

WEIGHT. *See also* Obesity

- of adrenal glands during cortisol treatment, 197

- and alloxan diabetes, 179, *235
- of animals in insulin-inactivation studies, 88
- and bicarbonate deficit calculations, *113
- at birth
 - and hypoglycemia, 333, *535
 - of infants of diabetic mothers, 175-177, 371, 436, *468
- and blood saccharoid content, 721, 722
- and diabetes control study, *469
- of diabetics in India, 406-407, 410
- of diabetic infants, *233
- of dogs in tolbutamide study, 392
- gain, and triglycerides, *314
- and glucose tolerance test study, 474, 475, 477
- of guinea pigs during cortisol study, 194, 195, 196
- and insulin
 - distribution, 342
 - dosage, 291
- and insulin-like activity study, 71
- in juvenile diabetes study, 245, 255
- and ketoacidosis, 293
- loss
 - and alloxanization, 180, 291
 - and chlorpheniramine, *451
 - and diabetes control, 2
 - and diabetic neuropathy, 427, 516
 - and hyperketonemia, 739
 - and hyperthyroidism, 740
 - and juvenile diabetes onset, 619
 - and ketosis, 787, 804
 - and phenformin, *52
 - and serum insulin levels, *748
 - and sulfonylureas, *114
- and metabolism, *50
- of newborn of alloxan-diabetic rats, 724, 725-728
- of pancreas in juvenile diabetes, 632
- of partially pancreatectomized rats, 93
- and phenformin hydrochloride study, *465
- and phenformin and tolbutamide treatment compared, *456
- and prediabetes, 518
- of premature infants, 127, 159, 160

of rats

- in chlorpropamide study, 209
- in hyperglycemia study, 137
- and sulfonylureas, 59, 61, 64, 68, 366-655
- and thiazide therapy, 132
- and triamcinolone-glucose tolerance test study, 482

WEST BERLIN

- study of oral hypoglycemic agents, 50-70

WORLD HEALTH ORGANIZATION 216

WORLD SURVEY OF DIABETES, 212-223

X

XANTHOSIS

- and juvenile diabetes, 258

XEROSTOMIA

- and carbohydrate metabolism, *48

XYLOCAINE, 186

XYLOSE

- and cataracts, *611

Y

YALOW AND BERSON IMMUNOASSAY, 771

YEMENITES

- diabetes and arteriosclerosis, 86

YTTRIUM, RADIOACTIVE, 44, 308

Z

ZINC GLUCAGON

- and hypoglycemia, 334

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

AUTHOR INDEX 1965

In this index are the names of authors of articles that have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1965. Entries marked with an asterisk (*) indicate authors of material that appeared in the Abstracts only. The Subject Index appears on page 1.

A

Abbott, M. M., *47
 Abdine, F. H., *316
 Abdul-Haj, S. K., *314-315
 Abdulhayoglu, Sefik, *167
 Abelson, Denis M., *317
 Abraham, S., *377
 Adams, Levi C., *447, *682
 Adamson, Lucille, *448
 Addis, G. J., *113
 Ahrén, Kurt, 501-506
 Ahuja, M. M. S., *814
 Albrink, Margaret J., *314
 Alden, James S., *609
 Alexander, D. Pauline, *113
 Allen, William E., 392-395, *439
 Allweiss, David M., *453
 Alm, G., *231
 Almonte, Alicia A., *451
 Alp, Haluk, *316, *608
 Alpert, Norman R., *749
 Altszuler, N., *531
 Anderson, Elmer A., *317
 Anderson, G. V., *460
 Anderson, J., *231
 Anderson, John, 362-367
 Anderson, John B., 350-361
 Angervall, Lennart, 501-506, 724-728
 Antoniadis, Harry N., *443, *608, *683
 Appleman, David H., *47
 Arai, Y., *167-168
 Aranda, Barbeito A., *452
 Arenas, Jorge Cinco, *817
 Arky, Ronald A., 350-361, *448
 Arnold, Craig R., *47
 Amott, James H., *440
 Arnould, Yvette, *314
 Aronson, Betty E., *608-609
 Aronson, Stanley M., *608-609
 Arquilla, Edward R., *449
 Arvill, Anders, 501-506
 Ashmore, James, 179-185, *447, *749
 Awai, Kozi, 709-715, *747
 Aylett, Pamela, *814
 Azerad, E., *235-236
 Azuela, Jose Chaves, *817
 Azuma, Tohru, *113

B

Back, Kurt W., *380
 Bailey, C. Cabell, *531

Bailey, Richard E., *816
 Ball, Eric G., *115, *233
 Balodimos, Marios C., *451
 Balter, Abraham M., 719-723
 Bamforth, J., *316
 Banson, B. B., *47
 Barden, Herbert, 146-156
 Barnard, Donald M., *314
 Barron, Edward J., *440
 Barry, R. J. C., *47
 Barsky, R. F., *234
 Bassenge, E., *531
 Bauer, Hans G., *377
 Bauer, Marjorie Frantz, *314-315
 Bayley, T. J., *613
 Beardwood, Donald M., *466-467, *609
 Beardwood, Joseph T., Jr., *609
 Beck, J. C., *231, *440-441
 Becker, Frank O., *47
 Beigelman, Paul M., *451, 529-530
 Bell, Louisea, *453
 Belleau, Roger, *451
 Bellens, Roger, *314
 Benjamin, W., *232
 Benner, Ernest J., *814
 Bennett, Ivan L., Jr., *48, 300-304
 Bennett, Peter H., *439-440
 Berger, Sheldon, *442, *453
 Berkow, Joseph W., 700-708
 Berkowitz, Donald, *814
 Bernard, A. G., *609
 Bernhard, Hella, 59-70
 Berry, Roger J., *47-48
 Berson, Solomon A., *167, 341-349, 549-572
 Best, Charles H., 493-500, 666-668
 Bethune, Robert W. M., *663-665
 Bewsher, P. D., *447
 Beyer, Jurgen, 658-662
 Bianchi, Albert, *684
 Bihler, I., *48
 Bing, R. J., *531
 Bird, R., *232
 Bishop, J. S., 531
 Bissel, Grosvenor, 650-657
 Bjerknes, C., *531
 Björntorp, Per, *231, 724-728
 Bledsoe, Turner, *48
 Bleicher, Sheldon J., *113, 350-361
 Blereau, Robert P., *114
 Block, Melvin A., *172
 Bloodworth, J. M. B., Jr., *377, *379, *441-442
 Bloom, Walter Lyon, *814-815
 Blum, Stuart F., *816-817

Blümchen, G., *531
 Bogdonoff, Morton D., *380
 Bolinger, Robert E., *232, *681
 Bolton, R., *684
 Bondy, Philip K., *317
 Bonessi, J. V., *49
 Bongiovanni, Alfred M., *613
 Boonij, H. L., *749
 Borman, Aleck, *684
 Borondy, Paul E., *382, *612
 Boronow, Richard C., *681
 Boshell, Buris R., 132-136, *608
 Bouthilet, R., *534
 Boyle, Constance, *446-447
 Brandt, Lars, *531
 Brecher, George, *378
 Brechner, Verne L., 663-665
 Bregant, Robert, 186-193
 Brennan, Mildred T., 392-395
 Brien, T. C., *815-816
 Britton, H. C., *113
 Broadhead, Charles L., *233
 Bronstein, Seymour B., *451-452
 Brooks, Frank P., *532
 Brown, Harold, *233
 Brown, J., 224-225, *442, *748
 Brown, Joseph D., *231
 Brown, Joseph P., *114
 Brown, P. E., *53
 Brown, Robert W., *681
 Brummer, Benta, *378
 Bullock, Weldon K., *314
 Burch, Thomas A., *439-440
 Burkholder, Peter M., 755-770
 Burnham, Clinton, 473-480
 Burns, Thomas W., 186
 Burt, Richard L., *377, *388, *609
 Bybee, J. D., *114
 Byrne, John J., *462
 Byron, J., *460-461

C

Cahill, George F., Jr., *48, *443, *445-446, *463, *747, *815
 Caird, F. I., *231-232
 Calame, Simone S., *167
 Calderon, Rolando, 100-105
 Camerini-Dávalos, Rafael A., *318, *466-467, *815
 Cameron, J. Stewart, *167
 Campagnoli, Mario, *452
 Campbell, James, *444
 Canfield, Craig J., *747

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

Caren, Raymond, *681
 Carliner, Nathan H., *377
 Carpenter, Charles C. J., *48, 300-304
 Cary, Eliza, *170
 Cashaw, Jesse, *233
 Cavert, H. M., *48
 Cederquist, Dena, *533
 Cesari, E., *167
 Chai, P. Y., 27-32
 Chaikoff, I. L., 377
 Chazan, Joseph A., 132-136
 Cheldelin, Vernon H., *746
 Cheraskin, E., *48
 Chester, Edward M., *459-460
 Chetty, M. P., *531
 Chey, Woo Yoon, *48
 Chlouverakis, C., *234
 Choufoer, J. C., *53
 Christensen, S., *746
 Christopher, Terrence C., 96-99
 Chryssochoos, Themistocles J., *452
 Cintra, Ulhoa A. B., *461
 Clark, James, *47
 Clark, William C., 14-18
 Cochran, Burt, Jr., *452-453
 Coffey, R. G., *746
 Cohen, Aharon M., 84-86
 Cohen, Alex K., 350-361
 Cohen, Geoffrey F., *815
 Cohen, Simon L., *232
 Cohn, Clarence, *453
 Cohn, Keith, *454
 Colby, Anthony Owen, 424-429, 516-525
 Colle, Eleanor, *315
 Colwell, Arthur R., Jr., 110-111, *114
 Colwell, Arthur R., Sr., *442
 Colwell, John A., *170
 Compt, C. M., *231
 Conard, Victor, *314
 Cone, Lawrence, 325-332, *447-448
 Conn, Jerome W., 10-13, *49-50, 71-76, *170, *382, *439, *442-443, *445
 Conrad, Marcel E., *747
 Cooke, A. M., *51
 Cooperstein, S. J., *383, *531-532
 Coore, H. G., *232
 Copp, E. F. F., *468-469
 Corbo, Lucille, *681
 Cornblath, Marvin, *377-378, *535, *613, *815
 Cortazar, Jaime, *465
 Cotton, Ernest K., *315
 Coulson, Walter, *383
 Cowan, J. S., 689-695, *746
 Cox, James, 700-708
 Crampton, Joseph H., *463-464
 Crane, C. W., *613
 Crevasse, Lamar E., *685
 Crofford, Oscar B., *378
 Crombie, D. L., *609
 Cronkite, Eugene P., *378
 Crooks, Hulda, *379
 Csapó, G., *53
 Cubberly, Peter T., *532
 Culp, Hilman W., *456
 Cunningham, George C., Jr., *315
 Cunningham, N. F., *49

Cunningham, Richard W., *818
 Cuthbertson, W. F. J., *232

D

Danforth, William H., *378
 Dangel, Mary Z., *610-611
 Dannenburg, Warren N., *609
 Danowski, T. S., *49, 162
 Daugela, Mary Z., *746-747
 Daughaday, William H., *377
 Davidson, John K., *453, 493-500
 Davidson, Mayer B., *456-457
 Davis, Charles B., *451
 Davis, Charles K., Jr., *378
 Davis, David M., 106-109
 Davis, Miles, *377, *536
 Davis, Richard A., *532
 Dawke, H., *49
 Dawson, A., *381
 de Bodo, R. C., *531
 del Castillo, E. J., 33-35
 De Moor, Pieter, 788-791
 Dennis, Brown W., *453-454
 DePew, L. L., 71-76
 De Pratti, Victor J., 311-313
 Devlin, James G., *815-816
 Di Girolamo, Mario, 87-92, *454
 Dikstein, S., *47
 Dilley, Ralph B., *115
 Dillon, Richard S., 672-674
 Dinwoodie, A. J., *169
 Ditschuneit, Hans, 658-662
 Dobson, Harold L., 489-492, 811-812
 Doisy, Richard J., *114, 579-583, *816
 Dollery, C. T., 121-127
 Drapkin, Arnold, *454
 Dray, Jan, *463
 Driscoll, Shirley G., 573-578
 Drorbaugh, James E., 157-161
 Drummey, Gladys D., *536
 Drummond, Keith R., 676-681
 Duhring, John L., *682
 Dulin, William E., *448-449, 507-515
 Dunn, A., *531
 Dupre, J., *167, *440-441
 Dürr, F., *609

E

Edelman, P. Michael, *378
 Edwards, A. V., *49
 Efron, Herman Y., 719-723
 Ehrlich, Robert M., *438
 Eichhorn, John H., *115
 Eisenstein, Albert B., *113, *378
 Eisentraut, Anna M., *51, *53
 Elevitich, Franklin R., *51
 Eliasson, Sven G., *232
 Ellenberg, Max, *454-455
 Elliot, Daniel W., *50
 Elliot, Robert R., 780-787
 Ellis, Joyce, *172, *749, *818
 Elrick, H., *167-168
 Engerman, R. L., *379

Enquist, Irving F., 170-171
 Entmacher, Paul S., 212-223
 Epstein, Frederick H., 413-423
 Ernest, Ingrid, *816
 Ernesti, Manfred, *610
 Etzwiler, Donnell, *315, 676-681
 Evans, Philip R., *681-682

F

Fabrykant, Maximilian, *168
 Fahlberg, Vera I., *315
 Fajans, Stefan S., *49-50, *439
 Falk, Sigmund, *451-452
 Faloon, William W., *816-817
 Farkas, Carol Spindell, *682
 Farrant, P. C., 274-278
 Fearnly, C. R., *532
 Felber, J. P., *455
 Fellner, Freda G., *438-439
 Field, James B., *49, *115, *233-234, *446-447
 Field, Richard A., *447, *462-463, *682
 Fillisti, L. P., *747
 Fine, J., *746, *816
 Finn, Jack, *449
 Fischer, R. B., *48
 Fisher, Gail F., 473-480
 Fitzgerald, M. G., *51, 175-178, *609
 Fleming, I. D., *232
 Floyd, John C., Jr., *49-50, *439
 Fonkalsrud, Eric W., *115
 Forbath, Nicholas F., 729-739
 Forbes, Audrey E., *377, *535
 Forbes, Clare E., *682
 Ford, Charles R., *232
 Ford, Henry C., *816
 Forist, Arlington A., *382
 Forsham, Peter H., *444, *532-533, *683
 Foster, Angela E., 350-361
 Francis, Thomas, Jr., 413-423
 Franckson, J. R. Marcel, *314
 Frankl, William S., *168
 Frantz, Andrew G., *315
 Frazer, Russell, *52, *442, *748
 Freinkel, Norbert, *113, 350-361, *462
 French, J. M., *613
 French, Samuel W., *383
 Frerichs, Heiko, *115
 Frey, Harald M., *50
 Fridland, A., *235
 Friedmann, Bernice, *445
 Froberg, Sven, *532
 Fröhlich, Edward D., *532
 Frohman, Lawrence A., *816
 Frost, H. M., *316, *455
 Fujita, Kay, 224-225
 Futterweit, Walter, *455-456

G

Galli, M. E., 33-35
 Galloway, John A., *456
 Galton, D. J., *682
 Goadby, H. K., *316-317
 Garcia, Luis A., 87-92

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58

May, 239-324

September, 549-618

February, 59-120

June, 325-386

October, 619-688

March, 121-174

July, 387-472

November, 689-754

April, 175-238

August, 473-548

December, 755-824

Garland, P. B., *533
 Gastineau, Clifford F., 279-288, *381-382
 Gebbie, T., *232
 Geddes, L. A., 489-492
 Geerling, Herbert, 658-662
 Gelfand, Maxwell L., *168
 Gelborn, A., *232
 Genuth, Saul, *816
 Gepts, Willy, 619-633
 Gerritsen, George C., *448-449, 507-515
 Gershberg, H., *456, *458
 Gershoff, Stanley N., *380, *443, *608, *683
 Gerstein, Mordecai M., 579-583
 Gilboa, Ygal, *460-461, *610
 Ginsberg, Jean, *609
 Giordano, J. C., *452
 Gitelson, Simon, 201-208
 Glick, Seymour M., *50, *167
 Gliemann, Jorgen, 643-649
 Goetz, Frederick C., *172, 226-228, *749, *818
 Goldberg, Marshall, *50
 Gonda, A., *231
 Goodman, Edward H., Jr., *445
 Goodman, H. Maurice, *379
 Goodner, Charles J., *456-457
 Goodrick, William I. M., *116
 Gordon, A., *817
 Gordon, Edgar S., *50
 Gorlin, Richard, *611
 Graber, Alan L., *450
 Graham, Charles A., *609
 Grasso, Sebastiano G., *444
 Gray, James, 489-492
 Greenberg, Beryl Z., *172, *749, *818
 Greenberg, Ernest, 43-45
 Greene, John W., Jr., *682
 Gregersen, G., *115
 Gregor, Wesley H., *170
 Greider, Marie H., *50
 Grodsky, Gerold M., 27-32, *51, 396-403, *444, *532-533, *611, *683
 Cudbjarnason, S., *531
 Guest, George M., 239-273
 Gundersen, Kare, *470, 805-810
 Gunn, G. C., 489-492
 Gunning, Barbara, *52, *171
 Gutman, Alisa, 77-83, *533

H

Hackel, D. B., *610
 Hadden, David R., *610
 Hagenfeldt, Lars, *682
 Haines, D. S. Milton, 666-668
 Haines, Howard, *610
 Haines, Robert J., 14-18
 Hainline, Adrian, Jr., *315-316
 Haist, R. E., 305-310, 368-373, *453, 493-500
 Halasy, M., *169
 Hales, C. N., *50, *381, *533
 Hall, W. E., *535
 Hamid, M. A., *231

Hamwi, George J., *381, 744-745
 Han, Yvonne, *458
 Hansen, Ruth Osterby, *533
 Hanson, Peter G., *379, *682-683
 Hardinge, Mervyn G., *379
 Harlan, William R., *536-537
 Harley, J. M. G., *379-380
 Harnos, G., *169
 Haro, Expedito N., *816-817
 Harris, E. J., *232-233
 Harvey, A. McGehee, *48, 300-304
 Hashim, Sami A., *380, *448
 Haunz, E. A., *457
 Hausberger, B. C., *233
 Hausberger, Franz X., *233
 Hayner, Norman S., 413-423
 Hazelwood, Robert L., *50
 Hazlett, Barbara, *453
 Heald, Felix P., *610-611, *746-747
 Hecht, A., *456
 Hegsted, D. Mark, *380
 Heideman, M. Lawrence, Jr., *50-51
 Heikinheimo, Rauno, 606-608
 Hellerström, Claes, *168, *380
 Hellier, F. F., *168
 Hellman, Bo, *168, *231, *380
 Hellman, L. M., *747
 Helmreich, Ernest, *378
 Henke, Wilbert J., *53
 Hennes, Allen R., *457, 709-715, *747
 Hennigar, Gordon R., *380
 Herman, Michael V., *611
 Herman, Robert H., *747
 Herman, Yaye F., *747
 Herrera, M. Guillermo, *171
 Herskovits, Theodore T., *818
 Hetenyi, Geza, Jr., 729-739
 Hill, John B., *747
 Hills, Peter R., *47-48
 Himel, H. A., *47
 Hindle, W., *316-317
 Hinks, N. T., *235
 Hirsch, Paul, *314-315
 Hitman, Donald, *317
 Hizukuri, Susumu, *233
 Hlad, C. J., Jr., *167-168
 Hocking, Elizabeth D., *532
 Hogg, James F., *382-383
 Hoisington, Sylvia, *450
 Holcomb, Blair, *814
 Holland, William M., *457-458
 Hollander, C. F., *53
 Holmgren, Luther E., *115-116
 Honick, Mary D., *116
 Hood, Thomas C., *380
 Hood, Tony E., 186-193
 Horwitz, Francis, *316
 House, E. L., 325-332
 House, Lawrence, *447-448
 Houssay, B. A., 33-35
 Hubbell, John P., Jr., 157-161
 Huber, Agnes M., *380, *443, *608, *683
 Huizenga, Kenneth A., *116
 Hulpieu, Harold R., 14-18
 Hulse, M., *456, *458

Hutchinson, Mary, *231-232
 Hyams, D. E., *50

I

Ikeda, Masakazu, *685
 Illingworth, Barbara, 333-340
 Inge-Bert, Täljedal, *168
 Ingle, Dwight J., 93-95
 Irwin, Glenn W., *457-458
 Ishmael, William K., *116
 Islam, Mohammed A., *683
 Issekutz, B., Jr., *534, *611
 Isselbacher, Kurt J., *536
 Izzo, Joseph L., *450

J

Jackson, Robert L., 437
 James, V. H. T., *169
 Jamplis, Robert W., *117
 Javier, Z. C., *456, *458
 Jensen, J., *746
 Jersild, M., *612, *685
 Jett, Marian, 740-744
 Johnson, May, *318
 Johnson, Perry B., *533
 Johnson, Robert E., *379, *682-683
 Jones, C. S., *168
 Jones, E. E., *747
 Jones, Evelyn M., *533
 Jordan, Paul H., Jr., *316
 Joshi, Prakash C., *451
 Jungas, Robert L., *233

K

Kadish, Arnold Henry, *458
 Kahil, M. E., *233
 Káldor, Antal, 209
 Kane, John P., *611
 Kaplinski, Naomi Wertheimer, 201
 Kar, Bimal C., 404-412
 Karam, John H., 27-32, *444, *532-533, *683
 Karchmer, Samuel, *817
 Kasi, A. M., *233
 Katsoyannis, P. G., *168-169
 Katz, Harvey P., *380
 Katz, Hyman M., 650-657
 Kaufman, Mildred, *51, *316, *817
 Kaye, Robert, *613
 Kedes, Laurence H., *233-234
 Keen, Harry, *170, *234
 Kelin, M., 142-145, *316
 Keller, Dan F., *315-316
 Kennedy, A. C., *169
 Kent, Gerald T., 295-299
 Kerkof, P. R., *377
 Kessler, Margaret, 239-273
 Kim, Jae Nam, 137-141
 King, Edward J., *684
 King, Judith, *749
 Kinsell, Laurance W., *52, *171, *458
 Kirk, Robert F., *683
 Kirsh, Marvin M., *439

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

AUTHOR INDEX 1965

Kjelsberg, Marcus O., 413-423
 Klein, Robert F., *380
 Kleist, Thomas J., 387-391
 Klinenberg, James R., *48
 Klink, D. D., *459
 Knight, William A., *53
 Knizley, Homer, *685
 Knopf, Ralph F., *49-50, *439
 Knowles, Harvey C., Jr., 165-166, 239-273, 740-744
 Koch, E., *683
 Koike, T., *534
 Kolff, Willem J., 36-37
 Kopelovich, L., *377
 Kormacker, Melodee S., *683-684
 Krah, M. E., *533-534
 Kraus, Shirley D., *116
 Kreines, Kenneth, 740-744
 Kreisberg, Robert A., *534
 Krosnick, Arthur, *380-381
 Kruger, Fred A., *381, 744-745
 Krut, L. H., *234
 Kuftinec, Dubravko M., *169
 Kunitake, G. M., 224-225
 Kurucz, A., *612
 Kurucz, J., *612
 Kuzuya, Takeshi, *612
 Kyle, G. Clayton, *682

L

Lacy, Paul E., *47, 634-642
 Lampe, Joan, 239-273
 Landon, J., *169
 Landau, Bernard R., *442, *446
 Lardy, Henry A., *236
 Larner, Joseph, *52, *233
 Lasagna, Louis, *536
 Lauener, Roland W., *47
 Lauris, Vilma, 19-26, *48, *445-446
 Lazarow, Arnold, *383, *444-445, *531-532, 669-671
 Lazarus, Sydney S., 146, *459, 792-804
 Leake, Norman H., *380
 Lebovitz, Harcid E., *816
 LeCompte, Philip M., *460-461
 Lee, James H., *683
 Lee, R. Hewlett, *117
 Legg, Susan, *232
 Lehoczy, T., *169, 716-718
 Leibel, B. S., *47
 Lentle, B. C., *169
 Leonards, Jack R., 96, 295-299
 Lepkovsky, S., *534
 Lerman, Sidney, *611
 Lerner, Leonard J., *684
 Levine, Rachmiel, *234, *447-448
 Levine, Robert A., *534
 Lewis, G. W., *234
 Liebow, Irving M., *169
 Like, A. A., *441, *747
 Liljedahl, Sten-Otto, *532
 Lin, Boniface J., 805-810
 Linner, Erik, *816
 Linton, A. L., *169

Lippiello, Lee, *438-439
 Little, J. Alick, *440, *535
 Livingston, Linda, *378
 Llerena, Alberto L., 100
 Lochner, J. de V., *51, *53
 Lockwood, Dean H., *534, *747-748
 Logothetopoulos, John, *449-450, 493-500
 Longcope, Christopher, *611
 Lonergan, E. T., *50
 Longmire, William P., Jr., *115
 Lostroh, Ardis J., *167
 Louis, L. H., *445
 Loutfi, A. H., *316
 Love, Thomas A., *748
 Lowell, A., *613
 Lowenstein, J. M., *683-684
 Lubetzki, J., *235-236
 Lucas, Charles, 10-13, *382, *442-443
 Luft, R., *167
 Luke, R. G., *169
 Lukens, F. D., *316
 Lukert, Barbara P., *681
 Lyngsoe, Jens, *116

M

MacGregor, Malcolm, *611
 Mackay, N., *817
 Mackenzie, Malcolm S., *459-460
 Madison, James F., *234-235
 Magyar, I., 716-718
 Mainguet, Paul, *314
 Malins, J. M., *51, 175
 Malkin, Martin F., 87-92
 Mandell, Stanley, *115
 Maqueo, Manuel, *817
 Marble, Alexander, *167, *318, *466-467, *609, *818
 Marcus, Gabor, *235
 Mari, S., *456
 Marks, Herbert H., 212-223
 Marks, Vincent, *381, *684
 Markson, C. A., *47
 Marler, Eric, *460
 Marmor, Bruce M., 579-583
 Marshall, Frederick J., *456
 Martin, Dan A., *469
 Martin, Julio M., *438
 Martin, Sister M. John, *533
 Martinson, Alf, 724-728
 Márton, I., 716-718
 Maruhama, Yoshisuke, *611
 Matos, Otsenre E., *685
 Matthews, J., *47
 Matz, Robert, *454
 Maumenee, A. E., 700-708
 Mayer, Jean, *169
 Mayer, L. A., *468-469
 Maynard, Donald E., *381, 744-745
 Mazza, R., *231
 McCullagh, Perry E., 36-37, 96
 McDonald, Glen W., 473-480
 McElin, Thomas W., *681
 McGarry, E. E., *231
 McMahon, Robert E., *456

Meade, Robert C., 387-391, *459, 526-528
 Medina, Ambrosio M., 676-681
 Medley, D. R. K., *612
 Meigs, J. Wister, *314
 Melin, Hans, *817
 Mendelson, Jack H., *536
 Merimee, Thomas J., *381, *534, *612
 Mestman, J. H., *460
 Miki, E., *441
 Miller, H. I., *534, *611
 Miller, Max, *439-440, *464-465, *466
 Mills, I. H., *316-317
 Mills, S. C., *235
 Milner, R. D. C., *381
 Minick, M. C., *445
 Mirsky, Stanley, *455-456, *465-466
 Mistry, S. D., *236
 Mitchell, M. L., *460-461, *610
 Molnar, George D., *235, 279-288, *381-382
 Monroe, Mary Lou, *681
 Montgomery, D. A. D., *379-380
 Montoyo, Henry J., *533
 Moody, A. J., *455
 Morard, J.-C., *235-236
 Morgan, Carl R., *457-458, 669-671
 Morgen, R. O., *231
 Morley, Nina H., 666-668
 Morris, B., *684
 Morris, J. H., *232
 Moses, C., *49
 Mosonyi, L., *116
 Moutsos, Spero E., *748-749
 Moxness, Karen E., 279-288, *381-382
 Mueller, Peter S., *610-611, *746-747
 Munck, O., *612, *685
 Munke, Arne, *534-535
 Munroe, John F., 584-590

N

Nabarro, J. D. N., 162-165
 Nabwangu, M. J., *469
 Nadon, Grant W., *535
 Nakamoto, Satoru, 36-37
 Nakamura, R. M., 224-225
 Navarrete, Victoriano N., 481-488
 Nelhaus, Gerhard, *613
 Neilson, J. McE., *817
 Nelson, Eino, *235
 Nelson, George H., *613
 Nelson, Jerald C., *461
 Newburgh, R. W., *746
 Newey, H., *51
 Newill, Vaun A., *169
 Nielsen, Robert L., *463-464
 Nigam, V. N., *235
 Ninomiya, Rikuo, 729-739
 Nixon, D. A., *113
 Nordern, Ake, *531
 Northcutt, Robert C., *48
 Northrop, Gretajo, *235
 Norton, Margaret, *453
 Novak, Milan, *684
 Nydick, Martin, *612

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

AUTHOR INDEX 1965

459, 526 Nye, E. R., *116-117

O

Oakley, N. W., 121-127
Oberdisse, K., *49
Oberlander, Lawrence, *170-171
O'Brien, Donough, 780-787
Odell, William D., *613
Ogilvie, Robertson F., 595-605
Oji, Nobuyoshi, *467
Okun, Ronald, *377
Ooms, Henri, *449
Oro, Lars, *532
Oseasohn, Robert, *169
O'Sullivan, John B., *113, *461
O'Sullivan, Michael O., *535
Owen, John A., Jr., *453
Owens, James N., Jr., *116
Oyama, Jiro, *382, *535

P

Palumbo, Pasquale J., *235
Pansky, B., 325-332, *447-448
Parker, John W., *51
Parker, Mary L., *377-378
Parks, R. E., Jr., *235
Parrish, J. A., *818
Partamian, Jean O., *443
Partridge, John W., *814
Patel, D. P., *52
Patel, Roda K., *613
Patterson, D. S. P., *49
Patterson, Roy, *170
Pattishall, Evan G., 106-109
Patz, Arnall, 700-708
Paul, P., *534, *611
Paulsen, Elsa P., *438-439, *468
Pavlatos, Fotios Ch., *532-533, *611, *683
Payne, Richard W., *116
Pengelly, C. R., *612
Pereira, Virgilio Gonçalves, *461
Perez-Stable, Eliseo, 748-749
Pettersson, Kerstin, *236
Petzoldt, Rudiger, 658-662
Pfeiffer, Ernst F., 658-662
Phair, John P., *317
Picchioni, Janice A., *613
Pierce, A. E., *117
Pines, Kermit L., *454
Pirart, Jean, 1-9
Pirie, Antoinette, *231-232
Pi-sunyer, F. Xavier, *462
Piszkiewicz, D., *468-469
Planchart, Alfredo, 430-431, *462
Platt, William T., *382, *535
Pogátsa, Gábor, 209-211
Poliakoff, Harry, *462
Polsky, Louis S., *170
Polster, Sheldon A., *532
Pomeranze, Julius, *684
Pometta, Daniel, *318
Porte, Daniel, Jr., *450

Pote, William W. H., Jr., *317
Poucher, Russell L., *452-453
Powell, Elinor D. U., *462-463
Power, Lawrence, 10-13, 71-76, *170, *382
Prahl, James W., 289-294, *440
Pray, Laurance C., *117
Press, Leon, *452
Prout, Thaddeus E., *381, *534, *610, *747-748
Pyke, D. A., *51

Q

Querido, A., *53
Quintana, Rodrigo, *316

R

Raben, M. S., 374, *610
Rabinowitz, David, *117
Rabkin, Mitchell T., *315
Rachmeller, Betty, *453
Rafaelsen, Ole J., 19-26
Randle, P. J., *232, *533
Rapp, Waldean G., *684
Rappaport, A. M., 689-695
Rasio, Eugenio, *463
Rastogi, Krishna Sudha, *444
Read, Charles H., *317-318
Reaven, Gerald M., *318, *463, *684-685
Recant, Lillian, *316, *608
Rees, J. Russell, *167
Reeves, Robert L., *463-464
Reid, J. D., *232
Reid, R. L., *235
Reilly, E. B., 224-225
Reisner, Solomon H., *377-378, *535, *613, *815
Renner, Ruth, *318
Rennie, I. D. B., *170
Renold, Albert E., 19-26, *171
Reyes-Leal, Bernardo, 71-76, *170
Richardson, B. D., *236
Rietti, C. T., 33-35
Ringsdorf, W. M., Jr., *48
Risbrook, Arthur, *462
Risdall, P. C., *117
Robert, Cavett McN., Jr., *532
Roberts, H. J., *52, *464
Robinson, Ronald, *611
Rodahl, K., *534, *611
Rodbell, Martin, *535-536
Rogers, D. E., *114
Roginsky, Martin, *462
Roldán, A., 33-35
Rona, Mira, *378
Roncone, Angela, *450
Rony, Hugo R., *464
Rosell-Perez, M., *52
Rosenberg, Abner S., *168
Rosevear, John W., 279-288, *381-382
Roth, Donald A., *459, 526-528
Roth, Jesse, *50, *167
Roy, Claude C., 780-787
Rubenstein, A., *469-470
Rubinstein, D., *231
Rudman, Daniel, 87-92, *454
Rudnick, P. A., *748
Ruggles, Thomas, *464-465
Rull, Juan, *439, *442-443
Russell, R. Patterson, *377
Russell, Richard O., *818

S

Sabo, Jack, *170-171
Sabour, Mohammed S., 595-605
Sacks, Jacob, *684
Sacks, William, *748
Sailer, F.-X., *683
Sakata, Kazuki, *685
Salans, Lester B., *318, *684-685
Samaan, Naguib, *52, *442, *748
Samarco, P., *235-236
Samols, Ellis, *612, *684
Sanchez-Medina, Mario, *465
Sandler, Richard, *171
Sanford, P. A., *51
Saravis, Calvin A., *608
Sarver, M. E., *49
Schachner, Stephen H., *381, 744-745
Schaefer, Louis E., *465
Schapiro, Robert H., *536
Scheig, Robert L., *536
Schelling, Jean-Louis, *377, *536
Schertsen, Bengt, *531
Schichiri, Motoaki, *466
Schless, Guy Lacy, *171
Schlichtkrull, J., *612, *685
Schlierf, Guenter, *52, *171, *458
Schlosser, G. H., *451
Schmidt-Nelson, Kurt, *610
Schnatz, J. David, *382
Schoeffling, Karl, 658-662
Schollmeyer, P., *531
Schulman, Charles L., *532
Schwartz, Irving L., *378
Schwartz, Melvin J., *455-456, *465-466
Schwartz, Philip, *612
Schwartz, Theodore B., *47
Scow, Robert O., *535-536
Seftel, H. C., *469-470
Segal, Barry M., *117
Seibles, Thomas S., *818
Seltzer, Holbrook S., 392-395, *439
Sether, Lowell A., *613
Seto, Dudley, 36-37
Severson, Arlen R., *613
Shafir, Eleazar, 77-84, *533
Shabbender, S., *316
Shapiro, Alvin P., *748-749
Shaw, B., *117
Shay, Harry, *48
Shedden, W. I. H., 274-278
Sheldon, Joanna, 362-367
Shepard, Claudine, *382
Shipp, Joseph C., 106-109, *171, 584-590, *685, *818
Short, A. L., 128-131

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

- Shrago, Earl, *236
 Shreeve, Walton W., *467
 Shuman, Charles R., *48
 Shuman, John, 10-13
 Siemers, Dorothy E., 676-681
 Silbert, Cynthia K., 350-361
 Silverberg, Steven G., *48
 Simon, G., *169
 Simone, Rosemary, *448
 Simons, E. L., *233
 Simpson-Morgan, M. W., *684
 Sims, Ethan A. H., *446
 Singer, David L., 350-361
 Sirek, Anna, *438, 658-662
 Sirek, Otakar V., *438, 658-662
 Sirota, David K., *454
 Skillman, Thomas G., 239-273
 Skom, Joseph H., *466
 Slone, Dennis, *48, *771-779
 Slonevsky, Lillian, *438
 Sloviter, Henry A., *685
 Smith, David L., *382
 Smith, J. Lawton, *171-172
 Smith, Kaighn, *682
 Smolens, Joseph, *613
 Smyth, D. H., *47, *51
 Sniffen, Ronald C., *115
 Soeldner, J. Stuart, *48, 432-435, *441, *463, *466-467, 771-779
 Solomon, Neil, *48, 300-304
 Southon, Ann, *170
 Sovik, O., *236
 Spellacy, William N., *172, *749, *818
 Sprague, Randall G., 37-43
 Spritz, Norton, *467
 Sreedharan, Thekkeyil, *683
 Staquet, M. J., *469, 591-594
 Starkman, S. P., *47
 Steele, R., *531
 Steenrod, William J., Jr., 289-294, *440
 Stein, H. A., *47
 Steinberg, Arthur G., *439-440
 Steiner, Donald F., *749
 Steinke, Jurgen, *48, 432-435, *441, 573-578, *747
 Sterne, J., *53
 Stevens, Ronald, *232
 Stiglitz, Robert A., 387-391
 Stimmler, L., *167-168
 Stone, Daniel B., *114, *231, *318
 Stoner, Linda, 362-367
 Stowers, J. M., *52
 Streeten, David H. P., 579-583
 Styron, Charles W., *460
 Sukowski, Ernest J., *749
 Summerskill, William H. J., *116
 Sussman, Karl E., *467-468, *748
 Swarner, Julia B., *379
 Sweeney, Martin J., *749
 Svanborg, Alvar, *816
 Szücs, S., *53
- T**
 Takahashi, H., *455
 Takemori, A. E., *172
- Täljedal, Inge-Bert, *380
 Tarrant, M. E., 179-185, *447
 Tarver, H., *236
 Tashjian, Andrew J., *467
 Taton, Jan, *318
 Tauxe, W. Newton, *235
 Taylor, K. W., *748
 Teagan, Susan J., *382-383
 Tetreault, Leon, *536
 Thomas, J. P., *169
 Thomas, William C., Jr., 375
 Thompson, Howard K., Jr., 460
 Thompson, William P., *461
 Thomson, W. S. T., *113
 Thurnau, Gary, 226-228
 Timmer, Richard F., *748
 Titus, Charles, *467-468
 Tocus, E. C., 696-699
 Tomizawa, Henry H., *749
 Tonelli, G., 696-699
 Torres, Isabel H., 481-488
 Touchstone, Joseph C., *682
 Tovey, J. E., *685
 Tranquada, Robert E., *460
 Travis, Randall H., *459-460
 Trayner, I., *748
 Trayner, R., *442
 Treister, Michael, *464-465
 Trillwood, Wilfred, *47-48
 Tripathy, Bibhuti B., 404-412
 Troyer, William G., *380
 Tryding, Nils, *531
 Tsao, Makepeace U., *382-383
 Tyangkul, Phienvit, *448
- U**
 Ulstrom, Robert A., *315
 Unger, Roger H., *51, *53
 Uzawa, Haruo, *52, *170
- V**
 Vacca, Joseph B., *53
 Vallbona, C., 489-492
 van der Heul, R. O., *53
 van der Sluys Veer, J., *53
 van Dongen, Robert, *172
 Van Huss, Wayne D., *533
 Van Itallie, Theodore B., *380
 Van Peenan, Hubert J., 186-193
 van Rijssel, T. G., *53
 Van Steveninck, J., *749
 Varandani, P. T., *749
 Vecchio, Thomas J., *382
 Verhaegen, Herman, 788-791
 Verhaegen-Declercq, Marie Louise, 788-791
 Viktora, J., 591-594
 Villanueva, A. R., 142-145
 Villavicencio, E., 226-228
 Virupaksha, T. K., *236
 Volk, Bruno W., 792-804
 Voll, Artur, *536
 Vranic, Mladen, 194-200, 689-695, *746
- W**
 Waburton, Richard, *383
 Wahlberg, Fredrik, *682
 Wajchenberg, Bernardo Léo, *461
 Walker, Alexander R. P., *236
 Walker, Joan B., *53, *533
 Wall, Mary, *609
 Wallace, John M., *536-537
 Watkins, Dudley, *383
 Watson, K. C., *531
 Weber, Herbert, *454-455
 Wegienka, Laurence C., *444
 Weil, Leopold, *818
 Weingarten, Clifford M., *114
 Weinhouse, Sidney, *445
 Weisenfeld, Shirley, *452
 Weismann, Rodger E., *318
 Welch, J. D., *113
 Weller, John M., *612
 Wellman, Klaus W., *459, 792-804
 Wells, Lemen J., *444-445
 Wendt, V. E., *531
 Whaley, William H., *613
 White, W. L., Jr., *48
 Whitehouse, Fred W., *172, *455
 Whitfield, A. G. W., *613
 Whitney, J. E., 128-131
 Wick, A. N., *468-469
 Wickstrom, Lennart, *236
 Wieland, Ralph G., *381, 744-745
 Wilber, John F., *613
 Wilbur, Blake C., *117
 Williams, A. H., *51
 Williams, Franklin T., *469
 Williams, Robert H., *382, *450, *461, *612
 Williamson, John R., *534
 Winegrad, Albert L., 311-313
 Wiggard, Joseph P., *383
 Wolf, Herman, *452-453
 Wolff, F. W., *469, 591-594
 Wray, James B., *383
 Wrenshall, G. A., 689-695, *746
 Wright, E. M., *47
 Wright, F. E., 128-131
 Wright, Peter H., *49, *449, 634-642
 Wybregt, Susan H., *613
 Wynn, V., *169
- Y**
 Yabo, R., 591-594
 Yalow, Rosalyn S., *167, 341-349, 507-572
 Yde, Hans, *172
 Yeager, Vernon L., *613
 Young, Jerry W., *236
 Young, R. B., *613
 Younger, Lee, *749
 Youngquist, Ronald, 676-681
- Z**
 Zalme, Elizabeth, 165-166
 Zierler, Kenneth L., *117
 Zuspan, Frederick P., *613

DIABETES: VOLUME 14 (1965) PAGE NUMBERS BY ISSUE

January, 1-58	May, 239-324	September, 549-618
February, 59-120	June, 325-386	October, 619-688
March, 121-174	July, 387-472	November, 689-754
April, 175-238	August, 473-548	December, 755-824

°461
6

4

2-804

*455

-745

450, *41

6

44-642

349, 50